



HEALTH ANNUAL STATEMENT

FOR THE YEAR ENDED DECEMBER 31, 2024
OF THE CONDITION AND AFFAIRS OF THE

Wellmark, Inc.

NAIC Group Code 0770 0770 NAIC Company Code 88848 Employer's ID Number 42-0318333
(Current) (Prior)

Organized under the Laws of Iowa, State of Domicile or Port of Entry IA

Country of Domicile United States of America

Licensed as business type: Life, Accident & Health

Is HMO Federally Qualified? Yes [] No []

Incorporated/Organized 09/19/1939 Commenced Business 10/01/1939

Statutory Home Office 1331 Grand Avenue, Des Moines, IA, US 50309-2901
(Street and Number) (City or Town, State, Country and Zip Code)

Main Administrative Office 1331 Grand Avenue
(Street and Number)
Des Moines, IA, US 50309-2901, 515-376-4500
(City or Town, State, Country and Zip Code) (Area Code) (Telephone Number)

Mail Address 1331 Grand Avenue, Des Moines, IA, US 50309-2901
(Street and Number or P.O. Box) (City or Town, State, Country and Zip Code)

Primary Location of Books and Records 1331 Grand Avenue
(Street and Number)
Des Moines, IA, US 50309-2901, 515-376-4500
(City or Town, State, Country and Zip Code) (Area Code) (Telephone Number)

Internet Website Address www.wellmark.com

Statutory Statement Contact Ashley Ariel Arellano, 515-376-6307
(Name) (Area Code) (Telephone Number)
arellanoaa@wellmark.com, 515-376-9054
(E-mail Address) (FAX Number)

OFFICERS

President & CEO Cory Randall Harris EVP, CFO & Treasurer David Seth Brown
Secretary Scott Andrew Sundstrom

OTHER

Marcelle Jo Chickering John Thomas Clendenin G. Paul Eddy
Paul Joshua Hlivko # Laura Jean Jackson Christa Daneen Kuennen
Jared Blayne Landin Sean Joseph McTaggart Naim Anwar Munir MD

DIRECTORS OR TRUSTEES

Richard Phillip DeBartolo # Cory Randall Harris Daryl Keith Henze - Chairman
William Curt Hunter Douglas Dwight Laird Harlan John Langstraat
Paul Edward Larson Angeline Marie Lavin Renee Vachelle Schaaf #
Timothy John Theriault David Arthur Vaudt Therese Michele Vaughan

State of Iowa SS
County of Polk

The officers of this reporting entity being duly sworn, each depose and say that they are the described officers of said reporting entity, and that on the reporting period stated above, all of the herein described assets were the absolute property of the said reporting entity, free and clear from any liens or claims thereon, except as herein stated, and that this statement, together with related exhibits, schedules and explanations therein contained, annexed or referred to, is a full and true statement of all the assets and liabilities and of the condition and affairs of the said reporting entity as of the reporting period stated above, and of its income and deductions therefrom for the period ended, and have been completed in accordance with the NAIC Annual Statement Instructions and Accounting Practices and Procedures manual except to the extent that: (1) state law may differ; or, (2) that state rules or regulations require differences in reporting not related to accounting practices and procedures, according to the best of their information, knowledge and belief, respectively. Furthermore, the scope of this attestation by the described officers also includes the related corresponding electronic filing with the NAIC, when required, that is an exact copy (except for formatting differences due to electronic filing) of the enclosed statement. The electronic filing may be requested by various regulators in lieu of or in addition to the enclosed statement.

Cory Randall Harris
President & CEO

Scott Andrew Sundstrom
Secretary

David Seth Brown
EVP, CFO & Treasurer

Subscribed and sworn to before me this _____ day of _____

- a. Is this an original filing? Yes [X] No []
b. If no,
1. State the amendment number.....
2. Date filed
3. Number of pages attached.....

ANNUAL STATEMENT FOR THE YEAR 2024 OF THE Wellmark, Inc.

ASSETS

	Current Year			Prior Year
	1 Assets	2 Nonadmitted Assets	3 Net Admitted Assets (Cols. 1 - 2)	4 Net Admitted Assets
1. Bonds (Schedule D)	1,065,432,620	0	1,065,432,620	1,046,468,772
2. Stocks (Schedule D):				
2.1 Preferred stocks	2,592,741	552,485	2,040,256	1,721,443
2.2 Common stocks	1,538,351,518	50,274,178	1,488,077,340	1,413,067,061
3. Mortgage loans on real estate (Schedule B):				
3.1 First liens	0	0	0	0
3.2 Other than first liens.....	0	0	0	0
4. Real estate (Schedule A):				
4.1 Properties occupied by the company (less \$0 encumbrances)	122,608,054	23,608,054	99,000,000	99,000,000
4.2 Properties held for the production of income (less \$0 encumbrances)	0	0	0	0
4.3 Properties held for sale (less \$0 encumbrances)	0	0	0	0
5. Cash (\$327,849,435 , Schedule E - Part 1), cash equivalents (\$29,100,393 , Schedule E - Part 2) and short-term investments (\$0 , Schedule DA)	356,949,828	0	356,949,828	508,858,472
6. Contract loans, (including \$0 premium notes)	0	0	0	0
7. Derivatives (Schedule DB)	0	0	0	0
8. Other invested assets (Schedule BA)	483,495,283	15,848,554	467,646,729	313,083,377
9. Receivables for securities	2,230,730	0	2,230,730	8,733,811
10. Securities lending reinvested collateral assets (Schedule DL)	0	0	0	0
11. Aggregate write-ins for invested assets	0	0	0	0
12. Subtotals, cash and invested assets (Lines 1 to 11)	3,571,660,774	90,283,271	3,481,377,503	3,390,932,936
13. Title plants less \$0 charged off (for Title insurers only)	0	0	0	0
14. Investment income due and accrued	9,161,773	0	9,161,773	9,277,577
15. Premiums and considerations:				
15.1 Uncollected premiums and agents' balances in the course of collection	61,636,696	0	61,636,696	91,104,216
15.2 Deferred premiums, agents' balances and installments booked but deferred and not yet due (including \$0 earned but unbilled premiums)	0	0	0	0
15.3 Accrued retrospective premiums (\$12,153,599) and contracts subject to redetermination (\$26,619,900)	38,773,499	0	38,773,499	24,209,828
16. Reinsurance:				
16.1 Amounts recoverable from reinsurers	0	0	0	0
16.2 Funds held by or deposited with reinsured companies	0	0	0	0
16.3 Other amounts receivable under reinsurance contracts	0	0	0	0
17. Amounts receivable relating to uninsured plans	210,074,063	15,942,020	194,132,043	215,075,468
18.1 Current federal and foreign income tax recoverable and interest thereon	26,528,093	0	26,528,093	27,232,408
18.2 Net deferred tax asset	66,293,000	5,641,000	60,652,000	55,930,000
19. Guaranty funds receivable or on deposit	1,731,817	0	1,731,817	5,072,274
20. Electronic data processing equipment and software	4,980,895	4,702,778	278,117	681,331
21. Furniture and equipment, including health care delivery assets (\$0)	30,009,210	30,009,210	0	0
22. Net adjustment in assets and liabilities due to foreign exchange rates	0	0	0	0
23. Receivables from parent, subsidiaries and affiliates	37,588,407	12,971,828	24,616,579	12,310,568
24. Health care (\$76,719,200) and other amounts receivable	152,984,642	54,650,144	98,334,498	74,665,195
25. Aggregate write-ins for other-than-invested assets	49,124,856	48,654,617	470,239	512,270
26. Total assets excluding Separate Accounts, Segregated Accounts and Protected Cell Accounts (Lines 12 to 25)	4,260,547,725	262,854,868	3,997,692,857	3,907,004,071
27. From Separate Accounts, Segregated Accounts and Protected Cell Accounts	0	0	0	0
28. Total (Lines 26 and 27)	4,260,547,725	262,854,868	3,997,692,857	3,907,004,071
DETAILS OF WRITE-INS				
1101.				
1102.				
1103.				
1198. Summary of remaining write-ins for Line 11 from overflow page	0	0	0	0
1199. Totals (Lines 1101 through 1103 plus 1198)(Line 11 above)	0	0	0	0
2501. Prepaid Premium Tax Assets	12,298,421	12,298,421	0	0
2502. Prepaid Pension Costs	20,795,651	20,795,651	0	0
2503. Other Prepaid Expenses	14,231,963	14,231,963	0	0
2598. Summary of remaining write-ins for Line 25 from overflow page	1,798,821	1,328,582	470,239	512,270
2599. Totals (Lines 2501 through 2503 plus 2598)(Line 25 above)	49,124,856	48,654,617	470,239	512,270

LIABILITIES, CAPITAL AND SURPLUS

	Current Year			Prior Year
	1 Covered	2 Uncovered	3 Total	4 Total
1. Claims unpaid (less \$0 reinsurance ceded)	255,675,060	0	255,675,060	236,281,742
2. Accrued medical incentive pool and bonus amounts	1,895,331	0	1,895,331	3,410,000
3. Unpaid claims adjustment expenses.....	4,317,926	0	4,317,926	4,058,760
4. Aggregate health policy reserves, including the liability of \$0 for medical loss ratio rebate per the Public Health Service Act	46,966,191	0	46,966,191	64,509,978
5. Aggregate life policy reserves.....	0	0	0	0
6. Property/casualty unearned premium reserves.....	0	0	0	0
7. Aggregate health claim reserves.....	0	0	0	0
8. Premiums received in advance.....	98,433,423	0	98,433,423	91,548,951
9. General expenses due or accrued.....	230,896,297	0	230,896,297	198,719,885
10.1 Current federal and foreign income tax payable and interest thereon (including \$0 on realized capital gains (losses)) ..	1,127,066	0	1,127,066	0
10.2 Net deferred tax liability.....	0	0	0	0
11. Ceded reinsurance premiums payable.....	0	0	0	0
12. Amounts withheld or retained for the account of others.....	7,329,102	0	7,329,102	6,118,820
13. Remittances and items not allocated.....	138,268,918	0	138,268,918	192,297,292
14. Borrowed money (including \$0 current) and interest thereon \$0 (including \$0 current).....	0	0	0	0
15. Amounts due to parent, subsidiaries and affiliates.....	14,526,841	0	14,526,841	114,722,610
16. Derivatives.....	0	0	0	0
17. Payable for securities.....	623,433	0	623,433	91,510,740
18. Payable for securities lending	0	0	0	0
19. Funds held under reinsurance treaties (with \$0 authorized reinsurers, \$0 unauthorized reinsurers and \$0 certified reinsurers).....	0	0	0	0
20. Reinsurance in unauthorized and certified (\$0) companies	0	0	0	0
21. Net adjustments in assets and liabilities due to foreign exchange rates	0	0	0	0
22. Liability for amounts held under uninsured plans.....	71,161,679	0	71,161,679	107,204,954
23. Aggregate write-ins for other liabilities (including \$ 142,168,189 current).....	206,360,598	0	206,360,598	156,085,654
24. Total liabilities (Lines 1 to 23).....	1,077,581,865	0	1,077,581,865	1,266,469,386
25. Aggregate write-ins for special surplus funds.....	XXX	XXX	0	0
26. Common capital stock.....	XXX	XXX	0	0
27. Preferred capital stock.....	XXX	XXX	0	0
28. Gross paid in and contributed surplus.....	XXX	XXX	0	0
29. Surplus notes.....	XXX	XXX	0	0
30. Aggregate write-ins for other-than-special surplus funds.....	XXX	XXX	0	0
31. Unassigned funds (surplus).....	XXX	XXX	2,920,110,992	2,640,534,685
32. Less treasury stock, at cost:				
32.10 shares common (value included in Line 26 \$0).....	XXX	XXX	0	0
32.20 shares preferred (value included in Line 27 \$0).....	XXX	XXX	0	0
33. Total capital and surplus (Lines 25 to 31 minus Line 32).....	XXX	XXX	2,920,110,992	2,640,534,685
34. Total liabilities, capital and surplus (Lines 24 and 33)	XXX	XXX	3,997,692,857	3,907,004,071
DETAILS OF WRITE-INS				
2301. Other Liabilities	58,159,725	0	58,159,725	8,896,335
2302. Health Assessments	6,940,000	0	6,940,000	9,190,000
2303. Payments in Process	138,455,667	0	138,455,667	134,981,025
2398. Summary of remaining write-ins for Line 23 from overflow page	2,805,206	0	2,805,206	3,018,294
2399. Totals (Lines 2301 through 2303 plus 2398)(Line 23 above)	206,360,598	0	206,360,598	156,085,654
2501.	XXX	XXX		
2502.	XXX	XXX		
2503.	XXX	XXX		
2598. Summary of remaining write-ins for Line 25 from overflow page	XXX	XXX	0	0
2599. Totals (Lines 2501 through 2503 plus 2598)(Line 25 above)	XXX	XXX	0	0
3001.	XXX	XXX		
3002.	XXX	XXX		
3003.	XXX	XXX		
3098. Summary of remaining write-ins for Line 30 from overflow page	XXX	XXX	0	0
3099. Totals (Lines 3001 through 3003 plus 3098)(Line 30 above)	XXX	XXX	0	0

STATEMENT OF REVENUE AND EXPENSES

	Current Year		Prior Year
	1 Uncovered	2 Total	3 Total
1. Member Months.....	XXX	13,177,714	13,565,905
2. Net premium income (including \$0 non-health premium income)	XXX	2,704,620,889	2,615,179,412
3. Change in unearned premium reserves and reserve for rate credits	XXX	17,784,788	6,650,684
4. Fee-for-service (net of \$0 medical expenses)	XXX	0	0
5. Risk revenue	XXX	0	0
6. Aggregate write-ins for other health care related revenues	XXX	0	0
7. Aggregate write-ins for other non-health revenues	XXX	0	0
8. Total revenues (Lines 2 to 7)	XXX	2,722,405,677	2,621,830,096
Hospital and Medical:			
9. Hospital/medical benefits	0	1,513,459,244	1,446,352,894
10. Other professional services	0	298,620,326	278,739,254
11. Outside referrals	0	93,008,087	82,010,668
12. Emergency room and out-of-area	0	106,464,576	99,276,071
13. Prescription drugs	0	340,594,338	329,894,368
14. Aggregate write-ins for other hospital and medical.....	0	0	0
15. Incentive pool, withhold adjustments and bonus amounts	0	8,230,868	12,498,726
16. Subtotal (Lines 9 to 15)	0	2,360,377,439	2,248,771,981
Less:			
17. Net reinsurance recoveries	0	0	0
18. Total hospital and medical (Lines 16 minus 17)	0	2,360,377,439	2,248,771,981
19. Non-health claims (net)	0	0	0
20. Claims adjustment expenses, including \$ 18,689,820 cost containment expenses	0	86,597,546	86,294,705
21. General administrative expenses	0	229,764,035	200,118,325
22. Increase in reserves for life and accident and health contracts (including \$0 increase in reserves for life only)	0	0	0
23. Total underwriting deductions (Lines 18 through 22).....	0	2,676,739,020	2,535,185,011
24. Net underwriting gain or (loss) (Lines 8 minus 23)	XXX	45,666,657	86,645,085
25. Net investment income earned (Exhibit of Net Investment Income, Line 17)	0	198,567,109	192,450,559
26. Net realized capital gains (losses) less capital gains tax of \$ 1,353,000	0	7,748,550	6,254,039
27. Net investment gains (losses) (Lines 25 plus 26)	0	206,315,659	198,704,598
28. Net gain or (loss) from agents' or premium balances charged off [(amount recovered \$0) (amount charged off \$0)]	0	0	0
29. Aggregate write-ins for other income or expenses	0	(19,142,070)	(1,980,543)
30. Net income or (loss) after capital gains tax and before all other federal income taxes (Lines 24 plus 27 plus 28 plus 29)	XXX	232,840,246	283,369,140
31. Federal and foreign income taxes incurred	XXX	51,821,000	66,836,000
32. Net income (loss) (Lines 30 minus 31)	XXX	181,019,246	216,533,140
DETAILS OF WRITE-INS			
0601.	XXX		
0602.	XXX		
0603.	XXX		
0698. Summary of remaining write-ins for Line 6 from overflow page	XXX	0	0
0699. Totals (Lines 0601 through 0603 plus 0698)(Line 6 above)	XXX	0	0
0701.	XXX		
0702.	XXX		
0703.	XXX		
0798. Summary of remaining write-ins for Line 7 from overflow page	XXX	0	0
0799. Totals (Lines 0701 through 0703 plus 0798)(Line 7 above)	XXX	0	0
1401.			
1402.			
1403.			
1498. Summary of remaining write-ins for Line 14 from overflow page	0	0	0
1499. Totals (Lines 1401 through 1403 plus 1498)(Line 14 above)	0	0	0
2901. Other Expense	0	(19,142,070)	(1,980,543)
2902.			
2903.			
2998. Summary of remaining write-ins for Line 29 from overflow page	0	0	0
2999. Totals (Lines 2901 through 2903 plus 2998)(Line 29 above)	0	(19,142,070)	(1,980,543)

STATEMENT OF REVENUE AND EXPENSES (Continued)

	1 Current Year	2 Prior Year
CAPITAL AND SURPLUS ACCOUNT		
33. Capital and surplus prior reporting year.....	2,640,534,685	2,280,781,796
34. Net income or (loss) from Line 32	181,019,246	216,533,140
35. Change in valuation basis of aggregate policy and claim reserves	0	0
36. Change in net unrealized capital gains (losses) less capital gains tax of \$ 10,043,000	68,469,925	95,539,888
37. Change in net unrealized foreign exchange capital gain or (loss)	(6,948,915)	8,022,074
38. Change in net deferred income tax	12,082,000	24,834,000
39. Change in nonadmitted assets	12,295,243	(2,807,178)
40. Change in unauthorized and certified reinsurance	0	0
41. Change in treasury stock	0	0
42. Change in surplus notes	0	0
43. Cumulative effect of changes in accounting principles.....	0	0
44. Capital Changes:		
44.1 Paid in	0	0
44.2 Transferred from surplus (Stock Dividend).....	0	0
44.3 Transferred to surplus.....	0	0
45. Surplus adjustments:		
45.1 Paid in	0	0
45.2 Transferred to capital (Stock Dividend)	0	0
45.3 Transferred from capital	0	0
46. Dividends to stockholders	0	0
47. Aggregate write-ins for gains or (losses) in surplus	12,658,808	17,630,965
48. Net change in capital and surplus (Lines 34 to 47)	279,576,307	359,752,889
49. Capital and surplus end of reporting period (Line 33 plus 48)	2,920,110,992	2,640,534,685
DETAILS OF WRITE-INS		
4701. Change in Pension and Other Postemployment Benefit Obligation, Net of Tax	12,658,808	17,630,965
4702.		
4703.		
4798. Summary of remaining write-ins for Line 47 from overflow page	0	0
4799. Totals (Lines 4701 through 4703 plus 4798)(Line 47 above)	12,658,808	17,630,965

ANNUAL STATEMENT FOR THE YEAR 2024 OF THE Wellmark, Inc.

CASH FLOW

	1	2
	Current Year	Prior Year
Cash from Operations		
1. Premiums collected net of reinsurance	2,726,650,210	2,608,844,764
2. Net investment income	117,917,887	109,529,600
3. Miscellaneous income	0	0
4. Total (Lines 1 through 3)	2,844,568,097	2,718,374,364
5. Benefit and loss related payments	2,369,544,384	2,241,993,680
6. Net transfers to Separate Accounts, Segregated Accounts and Protected Cell Accounts	0	0
7. Commissions, expenses paid and aggregate write-ins for deductions	267,148,760	339,948,917
8. Dividends paid to policyholders	0	0
9. Federal and foreign income taxes paid (recovered) net of \$ 1,353,000 tax on capital gains (losses)	51,342,619	63,799,754
10. Total (Lines 5 through 9)	2,688,035,763	2,645,742,351
11. Net cash from operations (Line 4 minus Line 10)	156,532,334	72,632,013
Cash from Investments		
12. Proceeds from investments sold, matured or repaid:		
12.1 Bonds	1,820,962,659	1,156,389,278
12.2 Stocks	180,924,377	231,582,477
12.3 Mortgage loans	0	0
12.4 Real estate	0	0
12.5 Other invested assets	844,089	3,524,205
12.6 Net gains or (losses) on cash, cash equivalents and short-term investments	1,099	(45,169)
12.7 Miscellaneous proceeds	6,503,081	41,149,739
12.8 Total investment proceeds (Lines 12.1 to 12.7)	2,009,235,305	1,432,600,530
13. Cost of investments acquired (long-term only):		
13.1 Bonds	1,847,595,564	1,360,147,016
13.2 Stocks	146,283,539	169,926,099
13.3 Mortgage loans	0	0
13.4 Real estate	2,635,238	1,005,856
13.5 Other invested assets	179,170,800	80,324,000
13.6 Miscellaneous applications	91,140,299	8,270,242
13.7 Total investments acquired (Lines 13.1 to 13.6)	2,266,825,440	1,619,673,213
14. Net increase/(decrease) in contract loans and premium notes	0	0
15. Net cash from investments (Line 12.8 minus Line 13.7 minus Line 14)	(257,590,135)	(187,072,683)
Cash from Financing and Miscellaneous Sources		
16. Cash provided (applied):		
16.1 Surplus notes, capital notes	0	0
16.2 Capital and paid in surplus, less treasury stock	0	0
16.3 Borrowed funds	0	0
16.4 Net deposits on deposit-type contracts and other insurance liabilities	0	0
16.5 Dividends to stockholders	0	0
16.6 Other cash provided (applied)	(50,850,843)	298,271,979
17. Net cash from financing and miscellaneous sources (Lines 16.1 to 16.4 minus Line 16.5 plus Line 16.6)	(50,850,843)	298,271,979
RECONCILIATION OF CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS		
18. Net change in cash, cash equivalents and short-term investments (Line 11, plus Lines 15 and 17)	(151,908,644)	183,831,309
19. Cash, cash equivalents and short-term investments:		
19.1 Beginning of year	508,858,472	325,027,163
19.2 End of year (Line 18 plus Line 19.1)	356,949,828	508,858,472
Note: Supplemental disclosures of cash flow information for non-cash transactions:		
20.0001. Noncash dividend from subsidiary	89,000,000	89,500,000

ANNUAL STATEMENT FOR THE YEAR 2024 OF THE Wellmark, Inc.

ANALYSIS OF OPERATIONS BY LINES OF BUSINESS

	1 Total	Comprehensive (Hospital & Medical)		4 Medicare Supplement	5 Vision Only	6 Dental Only	7 Federal Employees Health Benefits Plan	8 Title XVIII Medicare	9 Title XIX Medicaid	10 Credit A&H	11 Disability Income	12 Long-Term Care	13 Other Health	14 Other Non-Health
		2 Individual	3 Group											
1. Net premium income	2,704,620,889	82,257,478	1,375,435,361	478,459,699	1,249,845	38,384,314	336,728,549	0	0	0	0	0	392,105,643	0
2. Change in unearned premium reserves and reserve for rate credit	17,784,788	90,552	555,892	(17,681)	0	6,696	17,149,329	0	0	0	0	0	0	0
3. Fee-for-service (net of \$ medical expenses)	0	0	0	0	0	0	0	0	0	0	0	0	0	XXX
4. Risk revenue	0	0	0	0	0	0	0	0	0	0	0	0	0	XXX
5. Aggregate write-ins for other health care related revenues	0	0	0	0	0	0	0	0	0	0	0	0	0	XXX
6. Aggregate write-ins for other non-health care related revenues	0	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	0
7. Total revenues (Lines 1 to 6)	2,722,405,677	82,348,030	1,375,991,253	478,442,018	1,249,845	38,391,010	353,877,878	0	0	0	0	0	392,105,643	0
8. Hospital/medical benefits	1,513,459,244	45,036,791	762,686,437	318,727,467	0	0	170,638,875	0	0	0	0	0	216,369,674	XXX
9. Other professional services	298,620,326	7,914,415	134,028,579	56,010,685	1,005,464	31,651,312	29,986,748	0	0	0	0	0	38,023,123	XXX
10. Outside referrals	93,008,087	2,767,690	46,870,114	19,587,070	0	0	10,486,437	0	0	0	0	0	13,296,776	XXX
11. Emergency room and out-of-area	106,464,576	3,168,122	53,651,321	22,420,944	0	0	12,003,624	0	0	0	0	0	15,220,565	XXX
12. Prescription drugs	340,594,338	8,614,902	180,144,272	1,136	0	0	97,944,170	0	0	0	0	0	53,889,858	XXX
13. Aggregate write-ins for other hospital and medical incentive pool, withhold adjustments and bonus amounts	8,230,868	457,346	7,773,522	0	0	0	0	0	0	0	0	0	0	XXX
15. Subtotal (Lines 8 to 14)	2,360,377,439	67,959,266	1,185,154,245	416,747,302	1,005,464	31,651,312	321,059,854	0	0	0	0	0	336,799,996	XXX
16. Net reinsurance recoveries	0	0	0	0	0	0	0	0	0	0	0	0	0	XXX
17. Total medical and hospital (Lines 15 minus 16)	2,360,377,439	67,959,266	1,185,154,245	416,747,302	1,005,464	31,651,312	321,059,854	0	0	0	0	0	336,799,996	XXX
18. Non-health claims (net)	0	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	0
19. Claims adjustment expenses including \$ 18,689,820 cost containment expenses	86,597,546	1,342,768	31,398,603	14,858,470	117,539	1,595,519	22,295,760	0	0	0	0	0	14,988,887	0
20. General administrative expenses	229,764,035	5,713,983	99,580,180	63,236,178	12,271	4,510,431	8,481,887	0	0	0	0	0	48,229,105	0
21. Increase in reserves for accident and health contracts	0	0	0	0	0	0	0	0	0	0	0	0	0	XXX
22. Increase in reserves for life contracts	0	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	0
23. Total underwriting deductions (Lines 17 to 22)	2,676,739,020	75,016,017	1,316,133,028	494,841,950	1,135,274	37,757,262	351,837,501	0	0	0	0	0	400,017,988	0
24. Net underwriting gain or (loss) (Line 7 minus Line 23)	45,666,657	7,332,013	59,858,225	(16,399,932)	114,571	633,748	2,040,377	0	0	0	0	0	(7,912,345)	0
DETAILS OF WRITE-INS														
0501.														XXX
0502.														XXX
0503.														XXX
0598. Summary of remaining write-ins for Line 5 from overflow page	0	0	0	0	0	0	0	0	0	0	0	0	0	XXX
0599. Totals (Lines 0501 through 0503 plus 0598) (Line 5 above)	0	0	0	0	0	0	0	0	0	0	0	0	0	XXX
0601.		XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX
0602.		XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX
0603.		XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX
0698. Summary of remaining write-ins for Line 6 from overflow page	0	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	0
0699. Totals (Lines 0601 through 0603 plus 0698) (Line 6 above)	0	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	0
1301.														XXX
1302.														XXX
1303.														XXX
1398. Summary of remaining write-ins for Line 13 from overflow page	0	0	0	0	0	0	0	0	0	0	0	0	0	XXX
1399. Totals (Lines 1301 through 1303 plus 1398) (Line 13 above)	0	0	0	0	0	0	0	0	0	0	0	0	0	XXX

ANNUAL STATEMENT FOR THE YEAR 2024 OF THE Wellmark, Inc.

UNDERWRITING AND INVESTMENT EXHIBIT

PART 1 - PREMIUMS

Line of Business	1 Direct Business	2 Reinsurance Assumed	3 Reinsurance Ceded	4 Net Premium Income (Cols. 1 + 2 - 3)
1. Comprehensive (hospital and medical) individual	82,257,478	0	0	82,257,478
2. Comprehensive (hospital and medical) group	1,375,435,361	0	0	1,375,435,361
3. Medicare Supplement	478,459,699	0	0	478,459,699
4. Vision only	1,249,845	0	0	1,249,845
5. Dental only	38,384,314	0	0	38,384,314
6. Federal Employees Health Benefits Plan	336,728,549	0	0	336,728,549
7. Title XVIII - Medicare	0	0	0	0
8. Title XIX - Medicaid	0	0	0	0
9. Credit A&H	0	0	0	0
10. Disability Income	0	0	0	0
11. Long-Term Care	0	0	0	0
12. Other health	392,105,643	0	0	392,105,643
13. Health subtotal (Lines 1 through 12)	2,704,620,889	0	0	2,704,620,889
14. Life	0	0	0	0
15. Property/casualty	0	0	0	0
16. Totals (Lines 13 to 15)	2,704,620,889	0	0	2,704,620,889

ANNUAL STATEMENT FOR THE YEAR 2024 OF THE Wellmark, Inc.
UNDERWRITING AND INVESTMENT EXHIBIT
PART 2 - CLAIMS INCURRED DURING THE YEAR

	1 Total	Comprehensive (Hospital & Medical)		4 Medicare Supplement	5 Vision Only	6 Dental Only	7 Federal Employees Health Benefits Plan	8 Title XVIII Medicare	9 Title XIX Medicaid	10 Credit A&H	11 Disability Income	12 Long-Term Care	13 Other Health	14 Other Non-Health
		2 Individual	3 Group											
1. Payments during the year:														
1.1 Direct	2,359,798,847	71,050,582	1,185,626,280	410,426,801	994,300	31,331,242	319,651,925	0	0	0	0	0	340,717,717	0
1.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1.3 Reinsurance ceded	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1.4 Net	2,359,798,847	71,050,582	1,185,626,280	410,426,801	994,300	31,331,242	319,651,925	0	0	0	0	0	340,717,717	0
2. Paid medical incentive pools and bonuses	9,745,537	614,305	9,131,232	0	0	0	0	0	0	0	0	0	0	0
3. Claim liability December 31, current year from Part 2A:														
3.1 Direct	255,675,060	8,213,000	125,478,752	66,915,000	40,665	1,890,443	25,388,000	0	0	0	0	0	27,749,200	0
3.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0	0	0	0	0
3.3 Reinsurance ceded	0	0	0	0	0	0	0	0	0	0	0	0	0	0
3.4 Net	255,675,060	8,213,000	125,478,752	66,915,000	40,665	1,890,443	25,388,000	0	0	0	0	0	27,749,200	0
4. Claim reserve December 31, current year from Part 2D:														
4.1 Direct	0	0	0	0	0	0	0	0	0	0	0	0	0	0
4.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0	0	0	0	0
4.3 Reinsurance ceded	0	0	0	0	0	0	0	0	0	0	0	0	0	0
4.4 Net	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5. Accrued medical incentive pools and bonuses, current year	1,895,331	100,837	1,794,494	0	0	0	0	0	0	0	0	0	0	0
6. Net health care receivables (a)	27,045,594	3,961,662	16,588,797	1,424,499	0	0	(65,929)	0	0	0	0	0	5,136,565	0
7. Amounts recoverable from reinsurers December 31, current year	0	0	0	0	0	0	0	0	0	0	0	0	0	0
8. Claim liability December 31, prior year from Part 2A:														
8.1 Direct	236,281,742	7,800,000	117,135,512	59,170,000	29,501	1,570,373	24,046,000	0	0	0	0	0	26,530,356	0
8.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0	0	0	0	0
8.3 Reinsurance ceded	0	0	0	0	0	0	0	0	0	0	0	0	0	0
8.4 Net	236,281,742	7,800,000	117,135,512	59,170,000	29,501	1,570,373	24,046,000	0	0	0	0	0	26,530,356	0
9. Claim reserve December 31, prior year from Part 2D:														
9.1 Direct	0	0	0	0	0	0	0	0	0	0	0	0	0	0
9.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0	0	0	0	0
9.3 Reinsurance ceded	0	0	0	0	0	0	0	0	0	0	0	0	0	0
9.4 Net	0	0	0	0	0	0	0	0	0	0	0	0	0	0
10. Accrued medical incentive pools and bonuses, prior year	3,410,000	257,796	3,152,204	0	0	0	0	0	0	0	0	0	0	0
11. Amounts recoverable from reinsurers December 31, prior year	0	0	0	0	0	0	0	0	0	0	0	0	0	0
12. Incurred Benefits:														
12.1 Direct	2,352,146,571	67,501,920	1,177,380,723	416,747,302	1,005,464	31,651,312	321,059,854	0	0	0	0	0	336,799,996	0
12.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0	0	0	0	0
12.3 Reinsurance ceded	0	0	0	0	0	0	0	0	0	0	0	0	0	0
12.4 Net	2,352,146,571	67,501,920	1,177,380,723	416,747,302	1,005,464	31,651,312	321,059,854	0	0	0	0	0	336,799,996	0
13. Incurred medical incentive pools and bonuses	8,230,868	457,346	7,773,522	0	0	0	0	0	0	0	0	0	0	0

(a) Excludes \$ 0 loans or advances to providers not yet expensed.

ANNUAL STATEMENT FOR THE YEAR 2024 OF THE Wellmark, Inc.
UNDERWRITING AND INVESTMENT EXHIBIT

PART 2A - CLAIMS LIABILITY END OF CURRENT YEAR

	1	Comprehensive (Hospital & Medical)		4	5	6	7	8	9	10	11	12	13	14
	Total	2 Individual	3 Group	Medicare Supplement	Vision Only	Dental Only	Federal Employees Health Benefits Plan	Title XVIII Medicare	Title XIX Medicaid	Credit A&H	Disability Income	Long-Term Care	Other Health	Other Non-Health
1. Reported in Process of Adjustment:														
1.1 Direct	88,561,003	3,237,449	42,376,887	30,003,191	8,133	378,089	4,382,233	0	0	0	0	0	8,175,021	0
1.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1.3 Reinsurance ceded	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1.4 Net	88,561,003	3,237,449	42,376,887	30,003,191	8,133	378,089	4,382,233	0	0	0	0	0	8,175,021	0
2. Incurred but Unreported:														
2.1 Direct	167,114,057	4,975,551	83,101,865	36,911,809	32,532	1,512,354	21,005,767	0	0	0	0	0	19,574,179	0
2.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2.3 Reinsurance ceded	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2.4 Net	167,114,057	4,975,551	83,101,865	36,911,809	32,532	1,512,354	21,005,767	0	0	0	0	0	19,574,179	0
3. Amounts Withheld from Paid Claims and Capitations:														
3.1 Direct	0	0	0	0	0	0	0	0	0	0	0	0	0	0
3.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0	0	0	0	0
3.3 Reinsurance ceded	0	0	0	0	0	0	0	0	0	0	0	0	0	0
3.4 Net	0	0	0	0	0	0	0	0	0	0	0	0	0	0
4. TOTALS:														
4.1 Direct	255,675,060	8,213,000	125,478,752	66,915,000	40,665	1,890,443	25,388,000	0	0	0	0	0	27,749,200	0
4.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0	0	0	0	0
4.3 Reinsurance ceded	0	0	0	0	0	0	0	0	0	0	0	0	0	0
4.4 Net	255,675,060	8,213,000	125,478,752	66,915,000	40,665	1,890,443	25,388,000	0	0	0	0	0	27,749,200	0

ANNUAL STATEMENT FOR THE YEAR 2024 OF THE Wellmark, Inc.
UNDERWRITING AND INVESTMENT EXHIBIT
PART 2B - ANALYSIS OF CLAIMS UNPAID - PRIOR YEAR - NET OF REINSURANCE

Line of Business	Claims Paid During the Year		Claim Reserve and Claim Liability December 31 of Current Year		5 Claims Incurred In Prior Years (Columns 1 + 3)	6 Estimated Claim Reserve and Claim Liability December 31 of Prior Year
	1 On Claims Incurred Prior to January 1 of Current Year	2 On Claims Incurred During the Year	3 On Claims Unpaid December 31 of Prior Year	4 On Claims Incurred During the Year		
	1. Comprehensive (hospital and medical) individual	5,325,820	65,724,762	81,230	8,131,770	5,407,050
2. Comprehensive (hospital and medical) group	100,135,685	1,085,490,595	1,014,815	124,463,937	101,150,500	117,135,512
3. Medicare Supplement	54,985,895	355,440,906	288,380	66,626,620	55,274,275	59,170,000
4. Vision Only	28,215	966,085	1,286	39,379	29,501	29,501
5. Dental Only	1,521,072	29,810,170	59,770	1,830,673	1,580,842	1,570,373
6. Federal Employees Health Benefits Plan	21,670,688	297,981,237	1,008,912	24,379,088	22,679,600	24,046,000
7. Title XVIII - Medicare	0	0	0	0	0	0
8. Title XIX - Medicaid	0	0	0	0	0	0
9. Credit A&H	0	0	0	0	0	0
10. Disability Income	0	0	0	0	0	0
11. Long-Term Care	0	0	0	0	0	0
12. Other health	22,459,060	318,258,657	327,002	27,422,198	22,786,062	26,530,356
13. Health subtotal (Lines 1 to 12)	206,126,435	2,153,672,412	2,781,395	252,893,665	208,907,830	236,281,742
14. Health care receivables (a)	38,023,648	89,191,439	6,395	508,171	38,030,043	100,684,059
15. Other non-health	0	0	0	0	0	0
16. Medical incentive pools and bonus amounts	2,221,965	7,523,572	0	1,895,331	2,221,965	3,410,000
17. Totals (Lines 13 - 14 + 15 + 16)	170,324,752	2,072,004,545	2,775,000	254,280,825	173,099,752	139,007,683

(a) Excludes \$ 0 loans or advances to providers not yet expensed.

ANNUAL STATEMENT FOR THE YEAR 2024 OF THE Wellmark, Inc.

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS
 (\$000 Omitted)

Section A - Paid Health Claims - Comprehensive (Hospital & Medical)

Year in Which Losses Were Incurred		Cumulative Net Amounts Paid				
		1 2020	2 2021	3 2022	4 2023	5 2024
1.	Prior	216,854	216,202	216,202	216,202	216,202
2.	2020	1,057,547	1,254,477	1,254,112	1,254,112	1,254,112
3.	2021	XXX	1,072,179	1,293,725	1,295,107	1,295,107
4.	2022	XXX	XXX	1,133,410	1,248,243	1,250,709
5.	2023	XXX	XXX	XXX	1,111,815	1,217,032
6.	2024	XXX	XXX	XXX	XXX	1,158,739

Section B - Incurred Health Claims - Comprehensive (Hospital & Medical)

Year in Which Losses Were Incurred		Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Pool and Bonuses Outstanding at End of Year				
		1 2020	2 2021	3 2022	4 2023	5 2024
1.	Prior	218,376	216,202	216,202	216,202	216,202
2.	2020	1,274,806	1,255,114	1,254,112	1,254,112	1,254,112
3.	2021	XXX	1,307,427	1,294,225	1,295,151	1,295,107
4.	2022	XXX	XXX	1,266,030	1,249,094	1,250,765
5.	2023	XXX	XXX	XXX	1,239,264	1,218,072
6.	2024	XXX	XXX	XXX	XXX	1,293,230

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Comprehensive (Hospital & Medical)

Years in which Premiums were Earned and Claims were Incurred	1 Premiums Earned	2 Claims Payment	3 Claim Adjustment Expense Payments	4 (Col. 3/2) Percent	5 Claim and Claim Adjustment Expense Payments (Col. 2 + 3)	6 (Col. 5/1) Percent	7 Claims Unpaid	8 Unpaid Claims Adjustment Expenses	9 Total Claims and Claims Adjustment Expense Incurred (Col. 5+7+8)	10 (Col. 9/1) Percent
1. 2020	1,482,435	1,254,112	16,269	1.3	1,270,381	85.7	0	0	1,270,381	85.7
2. 2021	1,452,835	1,295,107	22,553	1.7	1,317,660	90.7	0	0	1,317,660	90.7
3. 2022	1,448,806	1,250,709	21,150	1.7	1,271,859	87.8	56	0	1,271,915	87.8
4. 2023	1,442,069	1,217,032	33,435	2.7	1,250,467	86.7	1,040	16	1,251,523	86.8
5. 2024	1,458,339	1,158,739	30,740	2.7	1,189,479	81.6	134,491	2,002	1,325,972	90.9

ANNUAL STATEMENT FOR THE YEAR 2024 OF THE Wellmark, Inc.

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS
 (\$000 Omitted)

Section A - Paid Health Claims - Medicare Supplement

Year in Which Losses Were Incurred		Cumulative Net Amounts Paid				
		1 2020	2 2021	3 2022	4 2023	5 2024
1.	Prior	68,911	69,020	69,020	69,020	69,020
2.	2020	280,791	345,076	345,247	345,247	345,247
3.	2021	XXX	300,240	374,948	375,128	375,128
4.	2022	XXX	XXX	330,862	381,951	382,221
5.	2023	XXX	XXX	XXX	341,935	396,651
6.	2024	XXX	XXX	XXX	XXX	355,441

Section B - Incurred Health Claims - Medicare Supplement

Year in Which Losses Were Incurred		Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Pool and Bonuses Outstanding at End of Year				
		1 2020	2 2021	3 2022	4 2023	5 2024
1.	Prior	68,975	69,020	69,020	69,020	69,020
2.	2020	357,704	345,213	345,247	345,247	345,247
3.	2021	XXX	386,010	375,019	375,129	375,128
4.	2022	XXX	XXX	393,216	382,025	382,231
5.	2023	XXX	XXX	XXX	401,030	396,929
6.	2024	XXX	XXX	XXX	XXX	422,068

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Medicare Supplement

Years in which Premiums were Earned and Claims were Incurred	1	2	3	4	5	6	7	8	9	10
	Premiums Earned	Claims Payment	Claim Adjustment Expense Payments	(Col. 3/2) Percent	Claim and Claim Adjustment Expense Payments (Col. 2 + 3)	(Col. 5/1) Percent	Claims Unpaid	Unpaid Claims Adjustment Expenses	Total Claims and Claims Adjustment Expense Incurred (Col. 5+7+8)	(Col. 9/1) Percent
1. 2020	425,168	345,247	15,224	4.4	360,471	84.8	0	0	360,471	84.8
2. 2021	447,801	375,128	14,530	3.9	389,658	87.0	0	0	389,658	87.0
3. 2022	458,152	382,221	12,614	3.3	394,835	86.2	10	0	394,845	86.2
4. 2023	461,665	396,651	12,679	3.2	409,330	88.7	278	4	409,612	88.7
5. 2024	478,442	355,441	13,866	3.9	369,307	77.2	66,627	992	436,926	91.3

12.MS

ANNUAL STATEMENT FOR THE YEAR 2024 OF THE Wellmark, Inc.

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS

(\$000 Omitted)

Section A - Paid Health Claims - Dental Only

Year in Which Losses Were Incurred		Cumulative Net Amounts Paid				
		1 2020	2 2021	3 2022	4 2023	5 2024
1.	Prior	1,207	1,219	1,219	1,219	1,219
2.	2020	19,748	21,192	21,246	21,246	21,246
3.	2021	XXX	24,943	26,328	26,356	26,356
4.	2022	XXX	XXX	25,939	27,338	27,378
5.	2023	XXX	XXX	XXX	27,437	28,918
6.	2024	XXX	XXX	XXX	XXX	29,810

Section B - Incurred Health Claims - Dental Only

Year in Which Losses Were Incurred		Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Pool and Bonuses Outstanding at End of Year				
		1 2020	2 2021	3 2022	4 2023	5 2024
1.	Prior	1,214	1,219	1,219	1,219	1,219
2.	2020	21,525	21,215	21,246	21,246	21,246
3.	2021	XXX	26,683	26,364	26,356	26,356
4.	2022	XXX	XXX	27,569	27,374	27,378
5.	2023	XXX	XXX	XXX	28,972	28,978
6.	2024	XXX	XXX	XXX	XXX	31,641

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Dental Only

Years in which Premiums were Earned and Claims were Incurred	1 Premiums Earned	2 Claims Payment	3 Claim Adjustment Expense Payments	4 (Col. 3/2) Percent	5 Claim and Claim Adjustment Expense Payments (Col. 2 + 3)	6 (Col. 5/1) Percent	7 Claims Unpaid	8 Unpaid Claims Adjustment Expenses	9 Total Claims and Claims Adjustment Expense Incurred (Col. 5+7+8)	10 (Col. 9/1) Percent
1. 2020	31,989	21,246	1,457	6.9	22,703	71.0	0	0	22,703	71.0
2. 2021	32,537	26,356	1,233	4.7	27,589	84.8	0	0	27,589	84.8
3. 2022	34,015	27,378	1,221	4.5	28,599	84.1	0	0	28,599	84.1
4. 2023	35,676	28,918	1,551	5.4	30,469	85.4	60	1	30,530	85.6
5. 2024	38,391	29,810	1,569	5.3	31,379	81.7	1,831	27	33,237	86.6

12.D0

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS
(\$000 Omitted)

Section A - Paid Health Claims - Vision Only

Year in Which Losses Were Incurred	Cumulative Net Amounts Paid				
	1 2020	2 2021	3 2022	4 2023	5 2024
1. Prior	22	22	22	22	22
2. 2020	658	683	684	684	684
3. 2021	XXX	793	818	819	819
4. 2022	XXX	XXX	849	882	883
5. 2023	XXX	XXX	XXX	907	934
6. 2024	XXX	XXX	XXX	XXX	966

Section B - Incurred Health Claims - Vision Only

Year in Which Losses Were Incurred	Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Pool and Bonuses Outstanding at End of Year				
	1 2020	2 2021	3 2022	4 2023	5 2024
1. Prior	22	22	22	22	22
2. 2020	683	683	684	684	684
3. 2021	XXX	819	819	819	819
4. 2022	XXX	XXX	883	883	883
5. 2023	XXX	XXX	XXX	936	935
6. 2024	XXX	XXX	XXX	XXX	1,005

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Vision Only

Years in which Premiums were Earned and Claims were Incurred	1 Premiums Earned	2 Claims Payment	3 Claim Adjustment Expense Payments	4 (Col. 3/2) Percent	5 Claim and Claim Adjustment Expense Payments (Col. 2 + 3)	6 (Col. 5/1) Percent	7 Claims Unpaid	8 Unpaid Claims Adjustment Expenses	9 Total Claims and Claims Adjustment Expense Incurred (Col. 5+7+8)	10 (Col. 9/1) Percent
1. 2020	1,017	684	122	17.8	806	79.3	0	0	806	79.3
2. 2021	1,092	819	95	11.6	914	83.7	0	0	914	83.7
3. 2022	1,131	883	115	13.0	998	88.2	0	0	998	88.2
4. 2023	1,195	934	150	16.1	1,084	90.7	1	0	1,085	90.8
5. 2024	1,250	966	116	12.0	1,082	86.6	39	1	1,122	89.8

ANNUAL STATEMENT FOR THE YEAR 2024 OF THE Wellmark, Inc.

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS

(\$000 Omitted)

Section A - Paid Health Claims - Federal Employees Health Benefits Plan Premium

Year in Which Losses Were Incurred		Cumulative Net Amounts Paid				
		1 2020	2 2021	3 2022	4 2023	5 2024
1.	Prior	37,557	37,829	37,829	37,829	37,829
2.	2020	215,143	247,113	247,267	247,267	247,267
3.	2021	XXX	231,942	274,478	275,118	275,118
4.	2022	XXX	XXX	247,128	269,314	270,303
5.	2023	XXX	XXX	XXX	278,151	298,833
6.	2024	XXX	XXX	XXX	XXX	297,981

Section B - Incurred Health Claims - Federal Employees Health Benefits Plan Premium

Year in Which Losses Were Incurred		Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Pool and Bonuses Outstanding at End of Year				
		1 2020	2 2021	3 2022	4 2023	5 2024
1.	Prior	38,202	37,829	37,829	37,829	37,829
2.	2020	251,503	247,532	247,267	247,267	247,267
3.	2021	XXX	274,530	274,701	275,138	275,118
4.	2022	XXX	XXX	271,014	269,946	270,330
5.	2023	XXX	XXX	XXX	301,545	299,815
6.	2024	XXX	XXX	XXX	XXX	322,360

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Federal Employees Health Benefits Plan Premium

Years in which Premiums were Earned and Claims were Incurred	1 Premiums Earned	2 Claims Payment	3 Claim Adjustment Expense Payments	4 (Col. 3/2) Percent	5 Claim and Claim Adjustment Expense Payments (Col. 2 + 3)	6 (Col. 5/1) Percent	7 Claims Unpaid	8 Unpaid Claims Adjustment Expenses	9 Total Claims and Claims Adjustment Expense Incurred (Col. 5+7+8)	10 (Col. 9/1) Percent
1. 2020	287,201	247,267	19,165	7.8	266,432	92.8	0	0	266,432	92.8
2. 2021	292,734	275,118	17,036	6.2	292,154	99.8	0	0	292,154	99.8
3. 2022	295,556	270,303	16,666	6.2	286,969	97.1	27	0	286,996	97.1
4. 2023	328,152	298,833	18,885	6.3	317,718	96.8	982	34	318,734	97.1
5. 2024	353,878	297,981	21,468	7.2	319,449	90.3	24,379	828	344,656	97.4

ANNUAL STATEMENT FOR THE YEAR 2024 OF THE Wellmark, Inc.

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS

(\$000 Omitted)

Section A - Paid Health Claims - Other

Year in Which Losses Were Incurred		Cumulative Net Amounts Paid				
		1 2020	2 2021	3 2022	4 2023	5 2024
1.	Prior	22,315	22,316	22,316	22,316	22,316
2.	2020	270,189	288,076	288,076	288,076	288,076
3.	2021	XXX	241,114	260,480	260,480	260,480
4.	2022	XXX	XXX	291,356	316,096	316,096
5.	2023	XXX	XXX	XXX	265,239	287,698
6.	2024	XXX	XXX	XXX	XXX	318,259

Section B - Incurred Health Claims - Other

Year in Which Losses Were Incurred		Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Pool and Bonuses Outstanding at End of Year				
		1 2020	2 2021	3 2022	4 2023	5 2024
1.	Prior	22,470	22,316	22,316	22,316	22,316
2.	2020	290,399	288,204	288,076	288,076	288,076
3.	2021	XXX	262,375	260,653	260,481	260,480
4.	2022	XXX	XXX	318,200	316,348	316,096
5.	2023	XXX	XXX	XXX	291,517	288,025
6.	2024	XXX	XXX	XXX	XXX	345,681

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Other

Years in which Premiums were Earned and Claims were Incurred	1 Premiums Earned	2 Claims Payment	3 Claim Adjustment Expense Payments	4 (Col. 3/2) Percent	5 Claim and Claim Adjustment Expense Payments (Col. 2 + 3)	6 (Col. 5/1) Percent	7 Claims Unpaid	8 Unpaid Claims Adjustment Expenses	9 Total Claims and Claims Adjustment Expense Incurred (Col. 5+7+8)	10 (Col. 9/1) Percent
1. 2020	306,322	288,076	16,803	5.8	304,879	99.5	0	0	304,879	99.5
2. 2021	324,897	260,480	12,892	4.9	273,372	84.1	0	0	273,372	84.1
3. 2022	332,915	316,096	7,987	2.5	324,083	97.3	0	0	324,083	97.3
4. 2023	353,073	287,698	10,472	3.6	298,170	84.4	327	5	298,502	84.5
5. 2024	392,106	318,259	9,419	3.0	327,678	83.6	27,422	408	355,508	90.7

12.01

ANNUAL STATEMENT FOR THE YEAR 2024 OF THE Wellmark, Inc.

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS
 (\$000 Omitted)

Section A - Paid Health Claims - Grand Total

Year in Which Losses Were Incurred		Cumulative Net Amounts Paid				
		1 2020	2 2021	3 2022	4 2023	5 2024
1.	Prior	346,866	346,608	346,608	346,608	346,608
2.	2020	1,844,076	2,156,617	2,156,632	2,156,632	2,156,632
3.	2021	XXX	1,871,211	2,230,777	2,233,008	2,233,008
4.	2022	XXX	XXX	2,029,544	2,243,824	2,247,590
5.	2023	XXX	XXX	XXX	2,025,484	2,230,066
6.	2024	XXX	XXX	XXX	XXX	2,161,196

Section B - Incurred Health Claims - Grand Total

Year in Which Losses Were Incurred		Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Pool and Bonuses Outstanding at End of Year				
		1 2020	2 2021	3 2022	4 2023	5 2024
1.	Prior	349,259	346,608	346,608	346,608	346,608
2.	2020	2,196,620	2,157,961	2,156,632	2,156,632	2,156,632
3.	2021	XXX	2,257,844	2,231,781	2,233,074	2,233,008
4.	2022	XXX	XXX	2,276,912	2,245,670	2,247,683
5.	2023	XXX	XXX	XXX	2,263,264	2,232,754
6.	2024	XXX	XXX	XXX	XXX	2,415,985

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Grand Total

Years in which Premiums were Earned and Claims were Incurred	1 Premiums Earned	2 Claims Payment	3 Claim Adjustment Expense Payments	4 (Col. 3/2) Percent	5 Claim and Claim Adjustment Expense Payments (Col. 2 + 3)	6 (Col. 5/1) Percent	7 Claims Unpaid	8 Unpaid Claims Adjustment Expenses	9 Total Claims and Claims Adjustment Expense Incurred (Col. 5+7+8)	10 (Col. 9/1) Percent
1. 2020	2,534,132	2,156,632	69,040	3.2	2,225,672	87.8	0	0	2,225,672	87.8
2. 2021	2,551,896	2,233,008	68,339	3.1	2,301,347	90.2	0	0	2,301,347	90.2
3. 2022	2,570,575	2,247,590	59,753	2.7	2,307,343	89.8	93	0	2,307,436	89.8
4. 2023	2,621,830	2,230,066	77,172	3.5	2,307,238	88.0	2,688	60	2,309,986	88.1
5. 2024	2,722,406	2,161,196	77,178	3.6	2,238,374	82.2	254,789	4,258	2,497,421	91.7

12.GT

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2D - AGGREGATE RESERVE FOR ACCIDENT AND HEALTH CONTRACTS ONLY

	1 Total	Comprehensive (Hospital & Medical)		4 Medicare Supplement	5 Vision Only	6 Dental Only	7 Federal Employees Health Benefits Plan	8 Title XVIII Medicare	9 Title XIX Medicaid	10 Credit A&H	11 Disability Income	12 Long-Term Care	13 Other
		2 Individual	3 Group										
1. Unearned premium reserves	(305,097)	(156,790)	(140,105)	(5,615)	0	(2,587)	0	0	0	0	0	0	0
2. Additional policy reserves (a)	0	0	0	0	0	0	0	0	0	0	0	0	0
3. Reserve for future contingent benefits	0	0	0	0	0	0	0	0	0	0	0	0	0
4. Reserve for rate credits or experience rating refunds (including \$0 for investment income) ..	45,315,288	0	29,019,863	0	0	0	16,295,425	0	0	0	0	0	0
5. Aggregate write-ins for other policy reserves	1,956,000	0	1,956,000	0	0	0	0	0	0	0	0	0	0
6. Totals (gross)	46,966,191	(156,790)	30,835,758	(5,615)	0	(2,587)	16,295,425	0	0	0	0	0	0
7. Reinsurance ceded	0	0	0	0	0	0	0	0	0	0	0	0	0
8. Totals (Net)(Page 3, Line 4)	46,966,191	(156,790)	30,835,758	(5,615)	0	(2,587)	16,295,425	0	0	0	0	0	0
9. Present value of amounts not yet due on claims	0	0	0	0	0	0	0	0	0	0	0	0	0
10. Reserve for future contingent benefits	0	0	0	0	0	0	0	0	0	0	0	0	0
11. Aggregate write-ins for other claim reserves	0	0	0	0	0	0	0	0	0	0	0	0	0
12. Totals (gross)	0	0	0	0	0	0	0	0	0	0	0	0	0
13. Reinsurance ceded	0	0	0	0	0	0	0	0	0	0	0	0	0
14. Totals (Net)(Page 3, Line 7)	0	0	0	0	0	0	0	0	0	0	0	0	0
DETAILS OF WRITE-INS													
0501. ACA Risk Adjustment Payable	1,956,000	0	1,956,000	0	0	0	0	0	0	0	0	0	0
0502.													
0503.													
0598. Summary of remaining write-ins for Line 5 from overflow page.....	0	0	0	0	0	0	0	0	0	0	0	0	0
0599. Totals (Lines 0501 through 0503 plus 0598) (Line 5 above)	1,956,000	0	1,956,000	0	0	0	0	0	0	0	0	0	0
1101.													
1102.													
1103.													
1198. Summary of remaining write-ins for Line 11 from overflow page	0	0	0	0	0	0	0	0	0	0	0	0	0
1199. Totals (Lines 1101 through 1103 plus 1198) (Line 11 above)	0	0	0	0	0	0	0	0	0	0	0	0	0

(a) Includes \$0 premium deficiency reserve.

ANNUAL STATEMENT FOR THE YEAR 2024 OF THE Wellmark, Inc.
UNDERWRITING AND INVESTMENT EXHIBIT

PART 3 - ANALYSIS OF EXPENSES

	Claim Adjustment Expenses		3 General Administrative Expenses	4 Investment Expenses	5 Total
	1 Cost Containment Expenses	2 Other Claim Adjustment Expenses			
1. Rent (\$ 13,475,025 for occupancy of own building)	226,241	519,772	15,004,819	0	15,750,832
2. Salary, wages and other benefits	16,175,382	35,434,073	136,689,327	158,904	188,457,686
3. Commissions (less \$ 0 ceded plus \$ 0 assumed)	0	0	48,725,514	0	48,725,514
4. Legal fees and expenses	0	0	2,230,374	0	2,230,374
5. Certifications and accreditation fees	0	0	1,336	0	1,336
6. Auditing, actuarial and other consulting services ...	0	54,822	381,396	0	436,218
7. Traveling expenses	62,096	113,110	1,345,188	0	1,520,394
8. Marketing and advertising	120,834	2,139	3,177,932	0	3,300,905
9. Postage, express and telephone	180,691	2,132,780	1,938,376	0	4,251,847
10. Printing and office supplies	257,119	584,617	797,335	14	1,639,085
11. Occupancy, depreciation and amortization	449,137	1,020,517	3,009,021	0	4,478,675
12. Equipment	6,733	14,845	393,738	0	415,316
13. Cost or depreciation of EDP equipment and software	3,441,341	1,323,529	29,165,544	0	33,930,414
14. Outsourced services including EDP, claims, and other services	6,697,682	35,401,100	33,965,621	0	76,064,403
15. Boards, bureaus and association fees	20,815	9,367	1,579,612	40,161	1,649,955
16. Insurance, except on real estate	147,923	325,196	1,923,286	0	2,396,405
17. Collection and bank service charges	0	0	0	372,988	372,988
18. Group service and administration fees	6,899,394	13,668,580	0	0	20,567,974
19. Reimbursements by uninsured plans	(23,454,413)	(29,929,955)	(77,511,779)	0	(130,896,147)
20. Reimbursements from fiscal intermediaries	0	0	0	0	0
21. Real estate expenses	47,825	107,399	312,196	0	467,420
22. Real estate taxes	277,563	610,375	1,720,827	0	2,608,765
23. Taxes, licenses and fees:					
23.1 State and local insurance taxes	0	0	0	0	0
23.2 State premium taxes	0	0	19,524,668	0	19,524,668
23.3 Regulatory authority licenses and fees	0	0	(81,655)	0	(81,655)
23.4 Payroll taxes	808,580	1,751,236	4,934,787	385	7,494,988
23.5 Other (excluding federal income and real estate taxes)	0	0	990,264	0	990,264
24. Investment expenses not included elsewhere	0	0	0	6,168,727	6,168,727
25. Aggregate write-ins for expenses	6,324,877	4,764,224	(453,692)	0	10,635,409
26. Total expenses incurred (Lines 1 to 25)	18,689,820	67,907,726	229,764,035	6,741,179	(a) 323,102,760
27. Less expenses unpaid December 31, current year	931,912	3,386,014	229,358,982	1,537,315	235,214,223
28. Add expenses unpaid December 31, prior year	972,420	3,086,340	197,134,147	1,585,738	202,778,645
29. Amounts receivable relating to uninsured plans, prior year	0	0	231,847,469	0	231,847,469
30. Amounts receivable relating to uninsured plans, current year	0	0	210,074,063	0	210,074,063
31. Total expenses paid (Lines 26 minus 27 plus 28 minus 29 plus 30)	18,730,328	67,608,052	175,765,794	6,789,602	268,893,776
DETAILS OF WRITE-INS					
2501. BlueCard Home Access Fees	6,286,197	4,190,798	0	0	10,476,995
2502. Miscellaneous Expenses and Reimbursements	38,680	573,426	(453,692)	0	158,414
2503.					
2598. Summary of remaining write-ins for Line 25 from overflow page	0	0	0	0	0
2599. Totals (Lines 2501 through 2503 plus 2598)(Line 25 above)	6,324,877	4,764,224	(453,692)	0	10,635,409

(a) Includes management fees of \$ 0 to affiliates and \$ 0 to non-affiliates.

ANNUAL STATEMENT FOR THE YEAR 2024 OF THE Wellmark, Inc.

EXHIBIT OF NET INVESTMENT INCOME

	1 Collected During Year	2 Earned During Year
1. U.S. government bonds	(a) 4,249,482	3,825,898
1.1 Bonds exempt from U.S. tax	(a) 0	0
1.2 Other bonds (unaffiliated)	(a) 50,238,520	51,417,950
1.3 Bonds of affiliates	(a) 0	0
2.1 Preferred stocks (unaffiliated)	(b) 34,141	34,025
2.11 Preferred stocks of affiliates	(b) 0	0
2.2 Common stocks (unaffiliated)	23,899,583	23,596,801
2.21 Common stocks of affiliates	90,000,000	90,000,000
3. Mortgage loans	(c) 0	0
4. Real estate	(d) 13,475,025	13,475,025
5. Contract Loans	0	0
6. Cash, cash equivalents and short-term investments	(e) 21,312,482	20,671,089
7. Derivative instruments	(f) 0	0
8. Other invested assets	12,769,073	12,769,073
9. Aggregate write-ins for investment income	1,326,967	1,326,967
10. Total gross investment income	217,305,273	217,116,828
11. Investment expenses		(g) 6,740,794
12. Investment taxes, licenses and fees, excluding federal income taxes		(g) 385
13. Interest expense		(h) 5,356,596
14. Depreciation on real estate and other invested assets		(i) 6,451,944
15. Aggregate write-ins for deductions from investment income		0
16. Total deductions (Lines 11 through 15)		18,549,719
17. Net investment income (Line 10 minus Line 16)		198,567,109
DETAILS OF WRITE-INS		
0901. Miscellaneous Investment Income	1,326,967	1,326,967
0902.		
0903.		
0998. Summary of remaining write-ins for Line 9 from overflow page	0	0
0999. Totals (Lines 0901 through 0903 plus 0998) (Line 9, above)	1,326,967	1,326,967
1501.		
1502.		
1503.		
1598. Summary of remaining write-ins for Line 15 from overflow page		0
1599. Totals (Lines 1501 through 1503 plus 1598) (Line 15, above)		0

- (a) Includes \$ 11,757,174 accrual of discount less \$ 13,595,269 amortization of premium and less \$ 1,616,778 paid for accrued interest on purchases.
- (b) Includes \$ 0 accrual of discount less \$ 0 amortization of premium and less \$ 0 paid for accrued dividends on purchases.
- (c) Includes \$ 0 accrual of discount less \$ 0 amortization of premium and less \$ 0 paid for accrued interest on purchases.
- (d) Includes \$ 13,475,025 for company's occupancy of its own buildings; and excludes \$ 0 interest on encumbrances.
- (e) Includes \$ 414,889 accrual of discount less \$ 0 amortization of premium and less \$ 0 paid for accrued interest on purchases.
- (f) Includes \$ 0 accrual of discount less \$ 0 amortization of premium.
- (g) Includes \$ 0 investment expenses and \$ 0 investment taxes, licenses and fees, excluding federal income taxes, attributable to segregated and Separate Accounts.
- (h) Includes \$ 0 interest on surplus notes and \$ 0 interest on capital notes.
- (i) Includes \$ 6,451,944 depreciation on real estate and \$ 0 depreciation on other invested assets.

EXHIBIT OF CAPITAL GAINS (LOSSES)

	1	2	3	4	5
	Realized Gain (Loss) On Sales or Maturity	Other Realized Adjustments	Total Realized Capital Gain (Loss) (Columns 1 + 2)	Change in Unrealized Capital Gain (Loss)	Change in Unrealized Foreign Exchange Capital Gain (Loss)
1. U.S. Government bonds	(75,886)	(19,118)	(95,004)	0	0
1.1 Bonds exempt from U.S. tax	0	0	0	0	0
1.2 Other bonds (unaffiliated)	(6,339,083)	(1,644,130)	(7,983,213)	2,247,255	0
1.3 Bonds of affiliates	0	0	0	0	0
2.1 Preferred stocks (unaffiliated)	0	0	0	51,789	(102,464)
2.11 Preferred stocks of affiliates	0	0	0	0	0
2.2 Common stocks (unaffiliated)	20,839,939	(1,999,362)	18,840,577	68,232,038	(6,846,451)
2.21 Common stocks of affiliates	0	0	0	23,378,225	0
3. Mortgage loans	0	0	0	0	0
4. Real estate	0	0	0	0	0
5. Contract loans	0	0	0	0	0
6. Cash, cash equivalents and short-term investments	1,099	(252,993)	(251,894)	0	0
7. Derivative instruments	0	0	0	0	0
8. Other invested assets	(237,325)	(1,171,591)	(1,408,916)	(15,396,382)	0
9. Aggregate write-ins for capital gains (losses)	0	0	0	0	0
10. Total capital gains (losses)	14,188,744	(5,087,194)	9,101,550	78,512,925	(6,948,915)
DETAILS OF WRITE-INS					
0901.					
0902.					
0903.					
0998. Summary of remaining write-ins for Line 9 from overflow page	0	0	0	0	0
0999. Totals (Lines 0901 through 0903 plus 0998) (Line 9, above)	0	0	0	0	0

ANNUAL STATEMENT FOR THE YEAR 2024 OF THE Wellmark, Inc.

EXHIBIT OF NON-ADMITTED ASSETS

	1	2	3
	Current Year Total Nonadmitted Assets	Prior Year Total Nonadmitted Assets	Change in Total Nonadmitted Assets (Col. 2 - Col. 1)
1. Bonds (Schedule D)	0	0	0
2. Stocks (Schedule D):			
2.1 Preferred stocks	552,485	552,485	0
2.2 Common stocks	50,274,178	56,690,394	6,416,216
3. Mortgage loans on real estate (Schedule B):			
3.1 First liens	0	0	0
3.2 Other than first liens.....	0	0	0
4. Real estate (Schedule A):			
4.1 Properties occupied by the company	23,608,054	27,424,760	3,816,706
4.2 Properties held for the production of income.....	0	0	0
4.3 Properties held for sale	0	0	0
5. Cash (Schedule E - Part 1), cash equivalents (Schedule E - Part 2) and short-term investments (Schedule DA)	0	0	0
6. Contract loans	0	0	0
7. Derivatives (Schedule DB)	0	0	0
8. Other invested assets (Schedule BA)	15,848,554	8,883,851	(6,964,703)
9. Receivables for securities	0	0	0
10. Securities lending reinvested collateral assets (Schedule DL)	0	0	0
11. Aggregate write-ins for invested assets	0	0	0
12. Subtotals, cash and invested assets (Lines 1 to 11)	90,283,271	93,551,490	3,268,219
13. Title plants (for Title insurers only)	0	0	0
14. Investment income due and accrued	0	0	0
15. Premiums and considerations:			
15.1 Uncollected premiums and agents' balances in the course of collection	0	0	0
15.2 Deferred premiums, agents' balances and installments booked but deferred and not yet due ..	0	0	0
15.3 Accrued retrospective premiums and contracts subject to redetermination	0	0	0
16. Reinsurance:			
16.1 Amounts recoverable from reinsurers	0	0	0
16.2 Funds held by or deposited with reinsured companies	0	0	0
16.3 Other amounts receivable under reinsurance contracts	0	0	0
17. Amounts receivable relating to uninsured plans	15,942,020	16,772,001	829,981
18.1 Current federal and foreign income tax recoverable and interest thereon	0	0	0
18.2 Net deferred tax asset	5,641,000	11,689,000	6,048,000
19. Guaranty funds receivable or on deposit	0	0	0
20. Electronic data processing equipment and software	4,702,778	6,163,290	1,460,512
21. Furniture and equipment, including health care delivery assets	30,009,210	16,974,334	(13,034,876)
22. Net adjustment in assets and liabilities due to foreign exchange rates	0	0	0
23. Receivable from parent, subsidiaries and affiliates	12,971,828	11,986,754	(985,074)
24. Health care and other amounts receivable	54,650,144	53,493,319	(1,156,825)
25. Aggregate write-ins for other-than-invested assets	48,654,617	64,519,923	15,865,306
26. Total assets excluding Separate Accounts, Segregated Accounts and Protected Cell Accounts (Lines 12 to 25)	262,854,868	275,150,111	12,295,243
27. From Separate Accounts, Segregated Accounts and Protected Cell Accounts	0	0	0
28. Total (Lines 26 and 27)	262,854,868	275,150,111	12,295,243
DETAILS OF WRITE-INS			
1101.			
1102.			
1103.			
1198. Summary of remaining write-ins for Line 11 from overflow page	0	0	0
1199. Totals (Lines 1101 through 1103 plus 1198)(Line 11 above)	0	0	0
2501. Prepaid Premium Tax Assets	12,298,421	13,891,586	1,593,165
2502. Prepaid Pension Costs	20,795,651	24,763,757	3,968,106
2503. Other Prepaid Expenses	14,231,963	24,438,685	10,206,722
2598. Summary of remaining write-ins for Line 25 from overflow page	1,328,582	1,425,895	97,313
2599. Totals (Lines 2501 through 2503 plus 2598)(Line 25 above)	48,654,617	64,519,923	15,865,306

EXHIBIT 1 - ENROLLMENT BY PRODUCT TYPE FOR HEALTH BUSINESS ONLY

Source of Enrollment	Total Members at End of					6 Current Year Member Months
	1 Prior Year	2 First Quarter	3 Second Quarter	4 Third Quarter	5 Current Year	
1. Health Maintenance Organizations	0	0	0	0	0	0
2. Provider Service Organizations	0	0	0	0	0	0
3. Preferred Provider Organizations	800,390	779,453	772,547	769,860	752,336	9,242,353
4. Point of Service	0	0	0	0	0	0
5. Indemnity Only	158,440	154,180	153,705	153,352	152,221	1,843,591
6. Aggregate write-ins for other lines of business.....	169,806	173,088	173,814	175,332	175,307	2,091,770
7. Total	1,128,636	1,106,721	1,100,066	1,098,544	1,079,864	13,177,714
DETAILS OF WRITE-INS						
0601. Dental	101,585	103,648	104,437	106,103	106,504	1,259,997
0602. Medicare Part D	55,522	55,869	55,673	55,461	55,049	667,497
0603. Vision	12,699	13,571	13,704	13,768	13,754	164,276
0698. Summary of remaining write-ins for Line 6 from overflow page	0	0	0	0	0	0
0699. Totals (Lines 0601 through 0603 plus 0698) (Line 6 above)	169,806	173,088	173,814	175,332	175,307	2,091,770

NOTES TO FINANCIAL STATEMENTS

NOTE 1 Summary of Significant Accounting Policies and Going Concern

A. Accounting Practices

The financial statements of Wellmark, Inc. (the Company) have been prepared in conformity with the accounting practices prescribed by the National Association of Insurance Commissioners (NAIC) and the State of Iowa.

The NAIC Accounting Practices and Procedures manual has been adopted as a component of prescribed or permitted practices by the State of Iowa. The Commissioner of Insurance has the right to permit specific practices that deviate from prescribed practices. The Company does not have any permitted practices.

	SSAP #	F/S Page	F/S Line #	2024	2023
NET INCOME					
(1) State basis (Page 4, Line 32, Columns 2 & 3)	XXX	XXX	XXX	\$ 181,019,246	\$ 216,533,140
(2) State Prescribed Practices that are an increase/(decrease) from NAIC SAP:					
(3) State Permitted Practices that are an increase/(decrease) from NAIC SAP:					
(4) NAIC SAP (1-2-3=4)	XXX	XXX	XXX	\$ 181,019,246	\$ 216,533,140
SURPLUS					
(5) State basis (Page 3, Line 33, Columns 3 & 4)	XXX	XXX	XXX	\$ 2,920,110,992	\$ 2,640,534,685
(6) State Prescribed Practices that are an increase/(decrease) from NAIC SAP:					
(7) State Permitted Practices that are an increase/(decrease) from NAIC SAP:					
(8) NAIC SAP (5-6-7=8)	XXX	XXX	XXX	\$ 2,920,110,992	\$ 2,640,534,685

B. Use of Estimates in the Preparation of the Financial Statements

The preparation of financial statements in conformity with Statutory Accounting Principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities. It also requires disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the period. Actual results could differ from those estimates.

C. Accounting Policy

Premiums on fully insured accident and health plans are billed in advance of their respective coverage periods. Receivables and income for such premiums are recorded at the effective date of the coverage period. Premiums received in advance and any unearned portion of premiums are recorded on the balance sheets as premiums received in advance and unearned premiums and reported as income when earned.

Expenses incurred in connection with acquiring new insurance business, including acquisition costs such as sales commissions, are charged to operations as incurred. Other costs, such as premium taxes and other underwriting expenses, are also charged to operations as incurred.

Real estate is carried at depreciated cost, less encumbrances. The fair value of real estate owned is determined by an external appraisal. To the extent the depreciated cost exceeds the fair value, this excess has been nonadmitted.

In addition, the Company uses the following accounting policies:

(1) Basis for Short-Term Investments

Short-term investments that are NAIC designation 1 or 2 are reported at cost adjusted for amortization of premiums and accretion of discounts using the effective interest method. Short-term investments that are NAIC designation 3 through 6 are stated at the lower of amortized cost or fair value.

(2) Basis for Bonds and Amortization Method

Bonds that are NAIC designation 1 or 2 are reported at cost adjusted for amortization of premiums and accretion of discounts using the effective interest method. Bonds that are NAIC designation 3 through 6 are stated at the lower of amortized cost or fair value. When a decline in the fair value of a bond has been determined to be other than temporary, the Company evaluates whether the decline is interest or credit related. For those credit-related declines in value that are considered to be other than temporary, the bond's carrying value is reduced and a loss is realized on the Statement of Revenues and Expenses. Surplus notes that are rated by an NAIC credit rating provider and have an NAIC designation of 1 are reported at cost, adjusted for amortization of premiums and accretion of discounts using the effective interest method.

The Company does not own any mandatory convertible securities or SVO-Identified Investments identified in SSAP No. 26.

(3) Basis for Common Stocks

Unaffiliated common stocks are reported at fair value. When a decline in the fair value of an unaffiliated common stock is considered to be other than temporary, the book value of the stock is reduced to fair value and a loss is realized on the Statement of Revenues and Expenses.

(4) Basis for Preferred Stocks

Preferred stock is reported based on the underlying characteristics of the security (redeemable or perpetual) and the quality rating of the security expressed as an NAIC designation. When a decline in the fair value of a preferred stock is considered other than temporary, the book value of the stock is reduced to fair value, and a loss is realized on the Statement of Revenues and Expenses.

(5) Basis for Mortgage Loans

Not applicable

(6) Basis for Loan-Backed Securities and Adjustment Methodology

Loan-backed securities that are NAIC designation 1 or 2 are reported at cost adjusted for amortization of premiums and accretion of discounts using the effective interest method. For all securities except for interest only securities or securities where the yield had become negative, the amortization of premiums and accretion of discounts on loan-backed securities is adjusted quarterly using current estimated future cash flows, including any new prepayment assumptions, using the retrospective adjustment method. Interest only securities and securities where the yield had become negative are valued using the prospective method. Loan-backed securities are stated at the lower of amortized cost or fair value if they are NAIC designation 3 through 6.

NOTES TO FINANCIAL STATEMENTS

(7) Accounting Policies for Investments in Subsidiaries, Controlled and Affiliated Entities

Common stock of the Company's insurance subsidiaries is carried based on the underlying statutory equity of the entities and is nonadmitted for those entities where statutory basis audited financial statements are not obtained. The ownership interest in the Company's non-insurance subsidiaries is carried based on the underlying GAAP equity of the investees and are nonadmitted for those investees where GAAP basis audited financial statements are not available. For any non-insurance subsidiaries in a retained deficit position, the carrying value is reported at \$0.

(8) Accounting Policies for Investments in Joint Ventures, Partnerships and Limited Liability Entities

The Company has ownership interest in an affiliated joint venture. This investment is in a downstream noninsurance holding company and the Company utilizes a look through approach to carry this investment at the underlying statutory equity of the insurance entity owned by the holding company. See Note #10 L.

The Company has minor ownership interests in three limited partnerships. The Company carries these interests based on the underlying audited GAAP equity of the investees.

The Company also has minor ownership interests in limited liability companies. These interests are carried based on the underlying GAAP equity of the investees and are nonadmitted for those investees where GAAP basis audited financial statements are not available. For any limited liability company investment in a retained deficit position, the carrying value is reported at \$0.

(9) Accounting Policies for Derivatives

Not applicable

(10) Anticipated Investment Income Used in Premium Deficiency Calculation

The Company anticipates investment income as a factor in the premium deficiency calculation, in accordance with Statement of Statutory Accounting Principles (SSAP) 54, Individual and Group Accident and Health Contracts.

(11) Management's Policies and Methodologies for Estimating Liabilities for Losses and Loss/Claim Adjustment Expenses

The Company provides a liability for unpaid and unreported benefits, which represents the estimated ultimate cost of benefits incurred through the balance sheet date. The liability is estimated on the basis of past experience and accumulated statistical data. Subsequent actual benefit experience may differ from the estimated liability due to variances in estimated and actual utilization of health care services, the amount of charges and other factors. These estimates are continuously reviewed and, as adjustments become necessary, such adjustments are reflected in current operations.

(12) Changes in the Capitalization Policy and Predefined Thresholds from Prior Period

The Company has not modified its capitalization policy from the prior period.

(13) Method Used to Estimate Pharmaceutical Rebate Receivables

The Company estimates pharmaceutical rebates utilizing past experience and accumulated statistical data. These estimates are continuously reviewed, and any adjustments are reflected in current operations.

D. Going Concern

Management has evaluated the Company's ability to continue as a going concern and has concluded that there are no events or circumstances that raise any doubt about the Company's ability to continue as a going concern.

NOTE 2 Accounting Changes and Corrections of Errors

Not applicable

NOTE 3 Business Combinations and Goodwill

Not applicable

NOTE 4 Discontinued Operations

Not applicable

NOTE 5 Investments

A. Mortgage Loans, including Mezzanine Real Estate Loans

Not applicable

B. Debt Restructuring

Not applicable

C. Reverse Mortgages

Not applicable

NOTES TO FINANCIAL STATEMENTS

D. Loan-Backed Securities

(1) Description of Sources Used to Determine Prepayment Assumptions

For fixed-rate agency mortgage-backed securities, prepayment speeds are calculated utilizing Mortgage Industry Advisory Corporation (MIAC) Mortgage Industry Medians (MIMs). MIMs are derived from a semi-monthly dealer-consensus survey of long-term prepayment projections. For other mortgage-backed, loan-backed, and structured securities, prepayment assumptions are utilized from Moody's Analytics. Moody's applies a flat economic credit model and utilizes a vector of multiple monthly speeds as opposed to a single speed for more robust projections. In instances where Moody's projections are not available, data from Refinitiv is used, which utilizes the median prepayment speed from contributors' models.

(2) Other-Than-Temporary Impairments

There were no loan-backed securities with a current period recognized other-than-temporary impairment (OTTI) classified on the basis for the OTTI as "Intent to sell" or "Inability or lack of intent to retain the investment in the security for a period of time sufficient to recover the amortized cost basis."

(3) Recognized OTTI Securities

Loan-backed securities with a current period recognized other-than-temporary impairment, currently held by the Company, as the present value of cash flows expected to be collected is less than the amortized cost basis of the securities follows as of December 31, 2024:

1 CUSIP	2 Book/Adjusted Carrying Value Amortized Cost Before Current Period OTTI	3 Present Value of Projected Cash Flows	4 Recognized Other-Than- Temporary Impairment	5 Amortized Cost After Other-Than- Temporary Impairment	6 Fair Value at time of OTTI	7 Date of Financial Statement Where Reported
45660L-F3-8	\$ 277,756	\$ 229,525	\$ 48,231	\$ 229,525	\$ 229,525	12/31/2024
86359L-RW-1	\$ 700,193	\$ 663,239	\$ 36,954	\$ 663,239	\$ 663,239	12/31/2024
45660L-RX-9	\$ 790,155	\$ 747,600	\$ 42,555	\$ 747,600	\$ 661,255	12/01/2024
12498N-AB-9	\$ 642,358	\$ 641,750	\$ 608	\$ 641,750	\$ 587,176	12/31/2024
362334-MF-8	\$ 2,949,518	\$ 2,578,026	\$ 371,492	\$ 2,578,026	\$ 2,520,740	12/31/2024
30247D-AD-3	\$ 1,001,503	\$ 961,037	\$ 40,466	\$ 961,037	\$ 925,493	12/01/2024
61748B-AC-8	\$ 836,108	\$ 730,247	\$ 105,861	\$ 730,247	\$ 730,247	12/01/2024
933631-AC-7	\$ 2,569,003	\$ 2,305,189	\$ 263,814	\$ 2,305,189	\$ 2,016,178	12/31/2024
86360U-AF-3	\$ 1,317,301	\$ 1,280,762	\$ 36,539	\$ 1,280,762	\$ 1,024,669	12/31/2024
86364R-AA-7	\$ 267,105	\$ 228,802	\$ 38,303	\$ 228,802	\$ 205,584	12/31/2024
12464Y-AB-5	\$ 1,355,409	\$ 1,266,802	\$ 88,607	\$ 1,266,802	\$ 1,158,388	12/01/2024
12593P-AX-0	\$ 131,293	\$ 99,074	\$ 32,219	\$ 99,074	\$ 57,708	12/31/2024
45661X-AB-8	\$ 1,018,853	\$ 959,193	\$ 59,660	\$ 959,193	\$ 878,478	12/01/2024
17311Y-AC-7	\$ 1,605,827	\$ 1,392,088	\$ 213,739	\$ 1,392,088	\$ 1,173,734	12/31/2024
3622MP-AV-0	\$ 1,550,845	\$ 1,401,967	\$ 148,878	\$ 1,401,967	\$ 1,189,237	12/01/2024
74922K-AH-8	\$ 1,580,954	\$ 1,464,750	\$ 116,204	\$ 1,464,750	\$ 1,360,321	12/31/2024
Total	XXX	XXX	\$ 1,644,130	XXX	XXX	XXX

(4) All impaired securities (fair value is less than cost or amortized cost) for which an other-than-temporary impairment has not been recognized in earnings as a realized loss (including securities with a recognized other-than-temporary impairment for non-interest related declines when a non-recognized interest related impairment remains):

a) The aggregate amount of unrealized losses:

1. Less than 12 Months	\$ 3,587,693
2. 12 Months or Longer	\$ 20,845,026

b) The aggregate related fair value of securities with unrealized losses:

1. Less than 12 Months	\$ 138,604,533
2. 12 Months or Longer	\$ 194,031,552

(5) Information Investor Considered in Reaching Conclusion that Impairments are Not Other-Than-Temporary

The unrealized losses on the Company's investments in loan-backed securities were due to temporary changes in interest rates and market conditions. The contractual cash flows of the agency mortgage-backed investments are guaranteed by an agency of the U.S. government and the non-agency mortgage-backed and asset-backed securities include collateral which reduce the risk of loss. Based on cash flow projections, the Company believes it will recover the carrying value of these investments. Because the Company does not have the intent to sell these securities, nor is it more likely than not the Company will be required to sell these securities until a recovery of carrying value, which may be maturity, the Company does not consider these investments to be other-than-temporarily impaired.

E. Dollar Repurchase Agreements and/or Securities Lending Transactions

Not applicable

F. Repurchase Agreements Transactions Accounted for as Secured Borrowing

(1) Company Policies or Strategies for Repo Programs

The Company participates in a repurchase agreement with Bankers Trust (the Bank). The repurchase agreement is an obligation of the Bank to repay the Company the principal amount invested by the Company with interest upon demand by the Company. To secure the obligations under the repurchase agreement, the Bank grants to the Company an undivided security interest in certain United States government securities having a market value equal to at least 102% of the principal amount invested. The United States government securities comprising the collateral are at all times owned by the Bank; therefore, this collateral was not recorded on the Company's statutory Balance Sheet. Since the repurchase agreement matures upon demand, there is no asset-liability mismatch.

(2) Type of Repo Trades Used

- a. Bilateral (YES/NO)
b. Tri-Party (YES/NO)

	FIRST QUARTER	SECOND QUARTER	THIRD QUARTER	FOURTH QUARTER
a. Bilateral (YES/NO)	Yes	Yes	Yes	Yes
b. Tri-Party (YES/NO)	No	No	No	No

NOTES TO FINANCIAL STATEMENTS

(3) Original (Flow) & Residual Maturity

	FIRST QUARTER	SECOND QUARTER	THIRD QUARTER	FOURTH QUARTER
a. Maximum Amount				
1. Open – No Maturity	\$ 56,589,828	\$ 42,071,123	\$ 19,416,529	\$ 46,175,828
2. Overnight	\$ -	\$ -	\$ -	\$ -
3. 2 Days to 1 Week	\$ -	\$ -	\$ -	\$ -
4. > 1 Week to 1 Month	\$ -	\$ -	\$ -	\$ -
5. > 1 Month to 3 Months	\$ -	\$ -	\$ -	\$ -
6. > 3 Months to 1 Year	\$ -	\$ -	\$ -	\$ -
7. > 1 Year	\$ -	\$ -	\$ -	\$ -
b. Ending Balance				
1. Open – No Maturity	\$ 5,921,965	\$ 5,866,144	\$ 5,023,271	\$ 3,347,035
2. Overnight	\$ -	\$ -	\$ -	\$ -
3. 2 Days to 1 Week	\$ -	\$ -	\$ -	\$ -
4. > 1 Week to 1 Month	\$ -	\$ -	\$ -	\$ -
5. > 1 Month to 3 Months	\$ -	\$ -	\$ -	\$ -
6. > 3 Months to 1 Year	\$ -	\$ -	\$ -	\$ -
7. > 1 Year	\$ -	\$ -	\$ -	\$ -

(4) Fair Value Securities Sold and/or Acquired that Resulted in Default

No securities were sold and/or acquired that resulted in default.

(5) Securities "Sold" Under Repo – Secured Borrowing

The Company deposits cash into an overnight sweep account. The Bank sweeps cash out of the Company's account and invests these funds into a Repurchase Agreement. The Company has not sold any securities as part of this agreement.

(6) Securities Sold Under Repo – Secured Borrowing by NAIC Designation

The Company deposits cash into an overnight sweep account. The Bank sweeps cash out of the Company's account and invests these funds into a Repurchase Agreement. The Company has not sold any securities as part of this agreement.

(7) Collateral Received – Secured Borrowing

	FIRST QUARTER	SECOND QUARTER	THIRD QUARTER	FOURTH QUARTER
a. Maximum Amount				
1. Cash	\$ -	\$ -	\$ -	\$ -
2. Securities (FV)	\$ 57,721,816	\$ 42,915,598	\$ 19,805,452	\$ 47,099,551
b. Ending Balance				
1. Cash	\$ -	\$ -	\$ -	\$ -
2. Securities (FV)	\$ 6,040,819	\$ 5,985,086	\$ 5,123,979	\$ 3,413,994

(8) Cash & Non-Cash Collateral Received – Secured Borrowing by NAIC Designation

ENDING BALANCE

	1 NONE	2 NAIC 1	3 NAIC 2	4 NAIC 3
a. Cash	\$ -	\$ -	\$ -	\$ -
b. Bonds - FV	\$ -	\$ 3,413,994	\$ -	\$ -
c. LB & SS - FV	\$ -	\$ -	\$ -	\$ -
d. Preferred Stock - FV	\$ -	\$ -	\$ -	\$ -
e. Common Stock	\$ -	\$ -	\$ -	\$ -
f. Mortgage Loans - FV	\$ -	\$ -	\$ -	\$ -
g. Real Estate - FV	\$ -	\$ -	\$ -	\$ -
h. Derivatives - FV	\$ -	\$ -	\$ -	\$ -
i. Other Invested Assets - FV	\$ -	\$ -	\$ -	\$ -
j. Total Collateral Assets - FV (Sum of a through i)	\$ -	\$ 3,413,994	\$ -	\$ -

ENDING BALANCE

	5 NAIC 4	6 NAIC 5	7 NAIC 6	8 DOES NOT QUALIFY AS ADMITTED
a. Cash	\$ -	\$ -	\$ -	\$ -
b. Bonds - FV	\$ -	\$ -	\$ -	\$ -
c. LB & SS - FV	\$ -	\$ -	\$ -	\$ -
d. Preferred Stock - FV	\$ -	\$ -	\$ -	\$ -
e. Common Stock	\$ -	\$ -	\$ -	\$ -
f. Mortgage Loans - FV	\$ -	\$ -	\$ -	\$ -
g. Real Estate - FV	\$ -	\$ -	\$ -	\$ -
h. Derivatives - FV	\$ -	\$ -	\$ -	\$ -
i. Other Invested Assets - FV	\$ -	\$ -	\$ -	\$ -
j. Total Collateral Assets - FV (Sum of a through i)	\$ -	\$ -	\$ -	\$ -

(9) Allocation of Aggregate Collateral by Remaining Contractual Maturity

- a. Overnight and Continuous
- b. 30 Days or Less
- c. 31 to 90 Days
- d. > 90 Days

FAIR VALUE
\$ 3,413,994
\$ -
\$ -
\$ -

NOTES TO FINANCIAL STATEMENTS

(10) Allocation of Aggregate Collateral Reinvested by Remaining Contractual Maturity

The Bank holds the collateral for the benefit of the Company during the term of the repurchase agreement. The Company does not have any authority to reinvest the collateral.

(11) Liability to Return Collateral – Secured Borrowing (Total)

The Bank holds the collateral for the benefit of the Company during the term of the repurchase agreement. The Bank retains all rights of ownership in the collateral unless or until a default under the repurchase agreement. As a result, no liability has been recognized on the Company's Balance Sheet.

G. Reverse Repurchase Agreements Transactions Accounted for as Secured Borrowing

Not applicable

H. Repurchase Agreements Transactions Accounted for as a Sale

Not applicable

I. Reverse Repurchase Agreements Transactions Accounted for as a Sale

Not applicable

J. Real Estate

Not applicable

K. Low Income Housing Tax Credits (LIHTC)

Not applicable

L. Restricted Assets

1. Restricted Assets (Including Pledged)

Restricted Asset Category	1 Total Gross (Admitted & Non- admitted) Restricted from Current Year	2 Total Gross (Admitted & Non- admitted) Restricted from Prior Year	3 Increase/ (Decrease) (1 minus 2)	4 Total Current Year Non- admitted Restricted	5 Total Current Year Admitted Restricted (1 minus 4)	6 Gross (Admitted & Non- admitted) Restricted to Total Assets (a)	7 Admitted Restricted to Total Admitted Assets (b)
a. Subject to contractual obligation for which liability is not shown	\$ -	\$ -	\$ -	\$ -	\$ -	0.000%	0.000%
b. Collateral held under security lending agreements	\$ -	\$ -	\$ -	\$ -	\$ -	0.000%	0.000%
c. Subject to repurchase agreements	\$ 3,347,035	\$ 7,589,867	\$ (4,242,832)	\$ -	\$ 3,347,035	0.079%	0.084%
d. Subject to reverse repurchase agreements	\$ -	\$ -	\$ -	\$ -	\$ -	0.000%	0.000%
e. Subject to dollar repurchase agreements	\$ -	\$ -	\$ -	\$ -	\$ -	0.000%	0.000%
f. Subject to dollar reverse repurchase agreements	\$ -	\$ -	\$ -	\$ -	\$ -	0.000%	0.000%
g. Placed under option contracts	\$ -	\$ -	\$ -	\$ -	\$ -	0.000%	0.000%
h. Letter stock or securities restricted as to sale - excluding FHLB capital stock	\$ -	\$ -	\$ -	\$ -	\$ -	0.000%	0.000%
i. FHLB capital stock	\$ 2,509,300	\$ 2,148,700	\$ 360,600	\$ -	\$ 2,509,300	0.059%	0.063%
j. On deposit with states	\$ -	\$ -	\$ -	\$ -	\$ -	0.000%	0.000%
k. On deposit with other regulatory bodies	\$ -	\$ -	\$ -	\$ -	\$ -	0.000%	0.000%
l. Pledged collateral to FHLB (including assets backing funding agreements)	\$ -	\$ -	\$ -	\$ -	\$ -	0.000%	0.000%
m. Pledged as collateral not captured in other categories	\$ -	\$ -	\$ -	\$ -	\$ -	0.000%	0.000%
n. Other restricted assets	\$ -	\$ -	\$ -	\$ -	\$ -	0.000%	0.000%
o. Total Restricted Assets (Sum of a through n)	\$ 5,856,335	\$ 9,738,567	\$ (3,882,232)	\$ -	\$ 5,856,335	0.137%	0.146%

(a) Column 1 divided by Asset Page, Column 1, Line 28

(b) Column 5 divided by Asset Page, Column 3, Line 28

2. Detail of Assets Pledged as Collateral Not Captured in Other Categories (Contracts That Share Similar Characteristics, Such as Reinsurance and Derivatives, Are Reported in the Aggregate)

Not applicable

3. Detail of Other Restricted Assets (Contracts That Share Similar Characteristics, Such as Reinsurance and Derivatives, Are Reported in the Aggregate)

Not applicable

4. Collateral Received and Reflected as Assets Within the Reporting Entity's Financial Statements

Not applicable

M. Working Capital Finance Investments

Not applicable

NOTES TO FINANCIAL STATEMENTS

N. Offsetting and Netting of Assets and Liabilities

Not applicable

O. 5GI Securities

Not applicable

P. Short Sales

Not applicable

Q. Prepayment Penalty and Acceleration Fees

	<u>General Account</u>
1. Number of CUSIPs	1
2. Aggregate Amount of Investment Income	\$ 14,500

R. Reporting Entity's Share of Cash Pool by Asset Type

Not applicable

S. Aggregate Collateral Loans by Qualifying Investment Collateral

Not applicable

NOTE 6 Joint Ventures, Partnerships and Limited Liability Companies

A. Investments in Joint Ventures, Partnerships and Limited Liability Companies that Exceed 10% of Ownership

As of December 31, 2024, the Company has no investments in Joint Ventures, Partnerships or Limited Liability Companies that exceed 10% of its admitted assets.

B. Investments in Impaired Joint Ventures, Partnerships and Limited Liability Companies

The Company did not recognize any impairment write down for its investments in Joint Ventures, Partnerships or Limited Liability Companies during 2024 or 2023.

NOTE 7 Investment Income

A. The basis, by category of investment income, for excluding (nonadmitting) any investment income due and accrued.

There was no amount of Investment Income due and accrued that was nonadmitted as of December 31, 2024.

B. The total amount excluded.

Not applicable

C. The gross, nonadmitted and admitted amounts for interest income due and accrued.

	<u>Amount</u>
Interest Income Due and Accrued	
1. Gross	\$ 9,161,773
2. Nonadmitted	\$ -
3. Admitted	\$ 9,161,773

D. The aggregate deferred interest.

Not applicable

E. The cumulative amounts of paid-in-kind (PIK) interest included in the current principal balance.

Not applicable

NOTE 8 Derivative Instruments

Not applicable

NOTES TO FINANCIAL STATEMENTS

NOTE 9 Income Taxes

A. Deferred Tax Assets/(Liabilities)

1. Components of Net Deferred Tax Asset/(Liability)

	12/31/2024			12/31/2023			Change		
	(1) Ordinary	(2) Capital	(3) (Col. 1 + 2) Total	(4) Ordinary	(5) Capital	(6) (Col. 4 + 5) Total	(7) (Col. 1 - 4) Ordinary	(8) (Col. 2 - 5) Capital	(9) (Col. 7 + 8) Total
(a) Gross Deferred Tax Assets	\$ 89,661,000	\$ 27,984,000	\$ 117,645,000	\$ 80,036,000	\$ 28,432,000	\$ 108,468,000	\$ 9,625,000	\$ (448,000)	\$ 9,177,000
(b) Statutory Valuation Allowance Adjustment	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
(c) Adjusted Gross Deferred Tax Assets (1a - 1b)	\$ 89,661,000	\$ 27,984,000	\$ 117,645,000	\$ 80,036,000	\$ 28,432,000	\$ 108,468,000	\$ 9,625,000	\$ (448,000)	\$ 9,177,000
(d) Deferred Tax Assets Nonadmitted	\$ 5,641,000	\$ -	\$ 5,641,000	\$ 11,689,000	\$ -	\$ 11,689,000	\$ (6,048,000)	\$ -	\$ (6,048,000)
(e) Subtotal Net Admitted Deferred Tax Asset (1c - 1d)	\$ 84,020,000	\$ 27,984,000	\$ 112,004,000	\$ 68,347,000	\$ 28,432,000	\$ 96,779,000	\$ 15,673,000	\$ (448,000)	\$ 15,225,000
(f) Deferred Tax Liabilities	\$ 904,000	\$ 50,448,000	\$ 51,352,000	\$ 444,000	\$ 40,405,000	\$ 40,849,000	\$ 460,000	\$ 10,043,000	\$ 10,503,000
(g) Net Admitted Deferred Tax Asset/(Net Deferred Tax Liability) (1e - 1f)	\$ 83,116,000	\$ (22,464,000)	\$ 60,652,000	\$ 67,903,000	\$ (11,973,000)	\$ 55,930,000	\$ 15,213,000	\$ (10,491,000)	\$ 4,722,000

2. Admission Calculation Components SSAP No. 101

	12/31/2024			12/31/2023			Change		
	(1) Ordinary	(2) Capital	(3) (Col. 1 + 2) Total	(4) Ordinary	(5) Capital	(6) (Col. 4 + 5) Total	(7) (Col. 1 - 4) Ordinary	(8) (Col. 2 - 5) Capital	(9) (Col. 7 + 8) Total
(a) Federal Income Taxes Paid In Prior Years Recoverable Through Loss Carrybacks	\$ 47,103,000	\$ 1,960,000	\$ 49,063,000	\$ 42,135,000	\$ 5,996,000	\$ 48,131,000	\$ 4,968,000	\$ (4,036,000)	\$ 932,000
(b) Adjusted Gross Deferred Tax Assets Expected To Be Realized (Excluding The Amount Of Deferred Tax Assets From 2(a) above) After Application of the Threshold Limitation (The Lesser of 2(b)1 and 2(b)2 Below)	\$ 8,407,000	\$ 3,182,000	\$ 11,589,000	\$ 7,799,000	\$ -	\$ 7,799,000	\$ 608,000	\$ 3,182,000	\$ 3,790,000
1. Adjusted Gross Deferred Tax Assets Expected to be Realized Following the Balance Sheet Date	\$ 8,407,000	\$ 3,182,000	\$ 11,589,000	\$ 7,799,000	\$ -	\$ 7,799,000	\$ 608,000	\$ 3,182,000	\$ 3,790,000
2. Adjusted Gross Deferred Tax Assets Allowed per Limitation Threshold	XXX	XXX	\$ 428,877,000	XXX	XXX	\$ 387,589,000	XXX	XXX	\$ 41,288,000
(c) Adjusted Gross Deferred Tax Assets (Excluding The Amount Of Deferred Tax Assets From 2(a) and 2(b) above) Offset by Gross Deferred Tax Liabilities	\$ 28,510,000	\$ 22,842,000	\$ 51,352,000	\$ 18,413,000	\$ 22,436,000	\$ 40,849,000	\$ 10,097,000	\$ 406,000	\$ 10,503,000
(d) Deferred Tax Assets Admitted as the result of application of SSAP No. 101. Total (2(a) + 2(b) + 2(c))	\$ 84,020,000	\$ 27,984,000	\$ 112,004,000	\$ 68,347,000	\$ 28,432,000	\$ 96,779,000	\$ 15,673,000	\$ (448,000)	\$ 15,225,000

3. Other Admissibility Criteria

	2024	2023
a. Ratio Percentage Used To Determine Recovery Period And Threshold Limitation Amount.	1061.834%	1118.230%
b. Amount Of Adjusted Capital And Surplus Used To Determine Recovery Period And Threshold Limitation In 2(b)2 Above.	\$ 2,864,251,401	\$ 2,594,436,255

4. Impact of Tax Planning Strategies

a. Determination of adjusted gross deferred tax assets and net admitted deferred tax assets, by tax character as a percentage.

	12/31/2024		12/31/2023		Change	
	(1) Ordinary	(2) Capital	(3) Ordinary	(4) Capital	(5) (Col. 1 - 3) Ordinary	(6) (Col. 2 - 4) Capital
(a) Determination of adjusted gross deferred tax assets and net admitted deferred tax assets, by tax character as a percentage.						
1. Adjusted Gross DTAs amount from Note 9A1 (c)	\$ 89,661,000	\$ 27,984,000	\$ 80,036,000	\$ 28,432,000	\$ 9,625,000	\$ (448,000)
2. Percentage of adjusted gross DTAs by tax character attributable to the impact of tax planning strategies	0.000%	0.000%	0.000%	0.000%	0.000%	0.000%
3. Net Admitted Adjusted Gross DTAs amount from Note 9A1(e)	\$ 84,020,000	\$ 27,984,000	\$ 68,347,000	\$ 28,432,000	\$ 15,673,000	\$ (448,000)
4. Percentage of net admitted adjusted gross DTAs by tax character admitted because of the impact of tax planning strategies	0.000%	0.000%	0.000%	0.000%	0.000%	0.000%

b. Does the Company's tax-planning strategies include the use of reinsurance? Yes No

B. Deferred Tax Liabilities Are Not Recognized For the Following Amounts:

None

NOTES TO FINANCIAL STATEMENTS

C. Current and Deferred Income Taxes

	(1)	(2)	(3)
	12/31/2024	12/31/2023	(Col. 1 - 2) Change
1. Current Income Tax			
(a) Federal	\$ 51,821,000	\$ 66,836,000	\$ (15,015,000)
(b) Foreign	\$ -	\$ -	\$ -
(c) Subtotal (1a+1b)	\$ 51,821,000	\$ 66,836,000	\$ (15,015,000)
(d) Federal income tax on net capital gains	\$ 1,353,000	\$ 128,000	\$ 1,225,000
(e) Utilization of capital loss carry-forwards	\$ -	\$ -	\$ -
(f) Other	\$ -	\$ -	\$ -
(g) Federal and foreign income taxes incurred (1c+1d+1e+1f)	\$ 53,174,000	\$ 66,964,000	\$ (13,790,000)
2. Deferred Tax Assets:			
(a) Ordinary:			
(1) Discounting of unpaid losses	\$ 2,920,000	\$ 2,073,000	\$ 847,000
(2) Unearned premium reserve	\$ -	\$ -	\$ -
(3) Policyholder reserves	\$ -	\$ -	\$ -
(4) Investments	\$ -	\$ -	\$ -
(5) Deferred acquisition costs	\$ -	\$ -	\$ -
(6) Policyholder dividends accrual	\$ -	\$ -	\$ -
(7) Fixed assets	\$ 3,078,000	\$ 2,572,000	\$ 506,000
(8) Compensation and benefits accrual	\$ 16,577,000	\$ 17,213,000	\$ (636,000)
(9) Pension accrual	\$ -	\$ -	\$ -
(10) Receivables - nonadmitted	\$ 17,565,000	\$ 17,290,000	\$ 275,000
(11) Net operating loss carry-forward	\$ -	\$ -	\$ -
(12) Tax credit carry-forward	\$ -	\$ -	\$ -
(13) Other	\$ 49,521,000	\$ 40,888,000	\$ 8,633,000
(99) Subtotal (sum of 2a1 through 2a13)	\$ 89,661,000	\$ 80,036,000	\$ 9,625,000
(b) Statutory valuation allowance adjustment	\$ -	\$ -	\$ -
(c) Nonadmitted	\$ 5,641,000	\$ 11,689,000	\$ (6,048,000)
(d) Admitted ordinary deferred tax assets (2a99 - 2b - 2c)	\$ 84,020,000	\$ 68,347,000	\$ 15,673,000
(e) Capital:			
(1) Investments	\$ 21,894,000	\$ 22,478,000	\$ (584,000)
(2) Net capital loss carry-forward	\$ -	\$ -	\$ -
(3) Real estate	\$ 6,090,000	\$ 5,954,000	\$ 136,000
(4) Other	\$ -	\$ -	\$ -
(99) Subtotal (2e1+2e2+2e3+2e4)	\$ 27,984,000	\$ 28,432,000	\$ (448,000)
(f) Statutory valuation allowance adjustment	\$ -	\$ -	\$ -
(g) Nonadmitted	\$ -	\$ -	\$ -
(h) Admitted capital deferred tax assets (2e99 - 2f - 2g)	\$ 27,984,000	\$ 28,432,000	\$ (448,000)
(i) Admitted deferred tax assets (2d + 2h)	\$ 112,004,000	\$ 96,779,000	\$ 15,225,000
3. Deferred Tax Liabilities:			
(a) Ordinary:			
(1) Investments	\$ 651,000	\$ 444,000	\$ 207,000
(2) Fixed assets	\$ 253,000	\$ -	\$ 253,000
(3) Deferred and uncollected premium	\$ -	\$ -	\$ -
(4) Policyholder reserves	\$ -	\$ -	\$ -
(5) Other	\$ -	\$ -	\$ -
(99) Subtotal (3a1+3a2+3a3+3a4+3a5)	\$ 904,000	\$ 444,000	\$ 460,000
(b) Capital:			
(1) Investments	\$ 50,448,000	\$ 40,405,000	\$ 10,043,000
(2) Real estate	\$ -	\$ -	\$ -
(3) Other	\$ -	\$ -	\$ -
(99) Subtotal (3b1+3b2+3b3)	\$ 50,448,000	\$ 40,405,000	\$ 10,043,000
(c) Deferred tax liabilities (3a99 + 3b99)	\$ 51,352,000	\$ 40,849,000	\$ 10,503,000
4. Net Deferred Tax Assets/Liabilities (2i - 3c)	\$ 60,652,000	\$ 55,930,000	\$ 4,722,000

5. The change in net deferred income taxes is comprised of the following (this analysis is exclusive of nonadmitted assets as the change in nonadmitted assets is reported separately from the change in net deferred income taxes in unassigned surplus):

	12/31/2024			12/31/2023			Change		
	(1) Ordinary	(2) Capital	(3) (Col. 1 + 2) Total	(4) Ordinary	(5) Capital	(6) (Col. 4 + 5) Total	(7) (Col. 1 - 4) Ordinary	(8) (Col. 2 - 5) Capital	(9) (Col. 7 + 8) Total
Total adjusted gross deferred tax assets	\$ 89,661,000	\$ 27,984,000	\$ 117,645,000	\$ 80,036,000	\$ 28,432,000	\$ 108,468,000	\$ 9,625,000	\$ (448,000)	\$ 9,177,000
Total deferred tax liabilities	\$ (904,000)	\$ (50,448,000)	\$ (51,352,000)	\$ (444,000)	\$ (40,405,000)	\$ (40,849,000)	\$ (460,000)	\$ (10,043,000)	\$ (10,503,000)
Net deferred tax asset (liability)	\$ 88,757,000	\$ (22,464,000)	\$ 66,293,000	\$ 79,592,000	\$ (11,973,000)	\$ 67,619,000	\$ 9,165,000	\$ (10,491,000)	\$ (1,326,000)
Tax effect of unrealized gains									\$ 10,043,000
Tax effect of SSAP 92/SSAP 102									\$ 3,365,000
Change in net deferred income tax									\$ 12,082,000

NOTES TO FINANCIAL STATEMENTS

D. Reconciliation of Federal Income Tax Rate to Actual Effective Rate

Among the more significant book to tax adjustments were the following:

	12/31/2024
Provision computed at statutory rate	\$ 49,181,000
Change in nonadmitted assets	\$ 2,022,000
Tax exempt interest deduction	\$ (98,000)
100% dividend received from affiliate	\$ (18,742,000)
Dividends received deduction, net	\$ (361,000)
Nondeductible lobbying expenses	\$ 47,000
§162(m)(6) limitation	\$ 8,554,000
Other permanent differences	\$ 442,000
Credits generated in current year	\$ (580,000)
Adjustment of prior year's tax	\$ 627,000
Total	\$ 41,092,000
Federal and foreign income taxes incurred	\$ 51,821,000
Realized capital gains (losses) tax	\$ 1,353,000
Change in net deferred income taxes	\$ (12,082,000)
Total statutory income taxes	\$ 41,092,000

E. Operating Loss and Tax Credit Carryforwards and Protective Tax Deposits

- At December 31, 2024, the Company did not have any unused operating loss carryforwards available to offset against future taxable income.
- The following are income taxes in the current and prior years that will be available for recoupment in the event of future net losses:

Year	Ordinary	Capital	Total
12/31/2024	\$ 55,138,000	\$ 1,353,000	\$ 56,491,000
12/31/2023	\$ 55,809,000	\$ 607,000	\$ 56,416,000
12/31/2022	N/A	\$ -	\$ -
Total	\$ 110,947,000	\$ 1,960,000	\$ 112,907,000

- The Company did not have any protective tax deposits under Section 6603 of the Internal Revenue Code.

F. Consolidated Federal Income Tax Return

- The Company's federal income tax return is consolidated with the following entities:

Wellmark of South Dakota, Inc.
Wellmark Health Plan of Iowa, Inc.
Wellmark Synergy Health, Inc.
Wellmark Value Health Plan, Inc.
First Administrators, LLC
Midwest Benefit Consultants, LLC
Wellmark Holdings, LLC

- The manner in which the Board of Directors sets forth for allocating the consolidated federal income tax:

The method of allocation between the companies is subject to a written agreement, approved by the Board of Directors and the Iowa Insurance Division. Allocation is based upon separate return calculations with current credit for net losses.

At December 31, 2024, the Company's tax related balance due from subsidiaries was \$26,528,093.

G. Federal and Foreign Income Tax Loss Contingencies

At December 31, 2024, it is not reasonably possible to determine the Company's amount of tax loss contingencies that will significantly increase or decrease within twelve months of the reporting date.

H. Repatriation Transition Tax (RTT)

Not applicable

I. Alternative Minimum Tax (AMT) Credit

The Inflation Reduction Act was enacted on August 16, 2022, and included a new corporate alternative minimum tax (CAMT). The CAMT is effective for tax years beginning after December 31, 2022. The Company is not an "applicable corporation" for purposes of the CAMT and therefore does not expect to be liable for CAMT in 2024.

NOTE 10 Information Concerning Parent, Subsidiaries, Affiliates and Other Related Parties

A. Nature of the Relationship Involved

The Company and Wellmark Health Plan of Iowa, Inc. (WHPI), a wholly owned subsidiary, have a management agreement whereby WHPI agrees to pay the Company for costs related to services outlined in the agreement. These costs are computed on a monthly basis. For 2024 and 2023, these costs were \$166,198,164 and \$133,481,763, respectively. The Company and WHPI also have an intercompany tax sharing arrangement (See Note 9). For 2024 and 2023, the tax related balance due from WHPI under this tax sharing arrangement was \$21,174,193 and \$23,728,990, respectively. The Company received dividends of \$89,000,000 and \$89,500,000 from WHPI in 2024 and 2023, respectively. The dividends reduced the intercompany payable to WHPI and were recorded in net investment income.

The Company and Wellmark of South Dakota, Inc. (WSD), a wholly owned subsidiary, have an intercorporate service agreement whereby WSD agrees to pay the Company for costs related to services outlined in the agreement. These costs are computed on a monthly basis. For 2024 and 2023, these costs were \$91,437,212 and \$82,552,782, respectively. The Company and WSD also have an intercompany tax sharing arrangement (See Note 9). For 2024 and 2023, the tax related balance due from WSD under this tax sharing arrangement was \$5,164,575 and \$3,684,952, respectively.

In February 2024, the Company sold 40,000 shares of Wellmark Value Health Plan, Inc. (WVHP) stock back to WVHP at \$100 per share, for a total cash receipt of \$4,000,000. As of March 31, 2024, the Company owns 10,000 shares of WVHP stock. The Company also received a cash dividend of \$1,000,000 from WVHP in February 2024. The dividend was recorded in net investment income.

NOTES TO FINANCIAL STATEMENTS

Through a joint venture agreement, the Company holds a 49% ownership interest in Wellmark Advantage Holdings, LLC. Wellmark Advantage Holdings, LLC owns 100% of the capital stock of Wellmark Advantage Health Plan, Inc. (WAHP). WAHP is an insurance entity domiciled in Iowa and licensed to sell products in Iowa and South Dakota. The Company contributed capital totaling \$49,490,000 and \$40,180,000 to WAHP in 2024 and 2023, respectively.

On January 1, 2024, the Company's subsidiaries First Administrators, LLC, Midwest Benefit Consultants, LLC, and Wellmark Holdings, LLC each converted their business structure from a corporation to limited liability company. The carrying value associated with these three subsidiaries continues to be fully nonadmitted.

B. Description of Transactions

See Note 10 A

C. Transactions with Related Parties Who Are Not Reported on Schedule Y

None

D. Amounts Due From or To Related Parties

At December 31, 2024, the Company reported \$14,526,841 as amounts due to subsidiaries and affiliates and \$24,616,579 as admitted amounts due from subsidiaries and affiliates. At December 31, 2023, the Company reported \$114,722,610 as amounts due to subsidiaries and affiliates and \$12,310,568 as admitted amounts due from subsidiaries and affiliates.

E. Material Management or Service Contracts and Cost-Sharing Arrangements

See Note 10 A

F. Guarantees or Undertakings

See Note 14

G. Nature of the Control Relationship

Not applicable

H. Amount Deducted from the Value of Upstream Intermediate Entity or Ultimate Parent Owned

Not applicable

I. Investments in SCA that Exceed 10% of Admitted Assets

The Company had no investments in SCA entities that exceeded 10% of the Company's admitted assets in 2024 or 2023.

J. Investments in Impaired SCAs

Not applicable

K. Investment in Foreign Insurance Subsidiary

Not applicable

L. Investment in Downstream Noninsurance Holding Company

The Company utilizes the look-through approach in valuing its investment in Wellmark Advantage Holdings, LLC (WAH) at \$26,748,286 and \$15,359,341 as of December 31, 2024 and 2023, respectively. WAH's financial statements are not audited and the Company has limited the value of its investment in WAH to the audited statutory equity of Wellmark Advantage Health Plan, Inc., a wholly owned insurance subsidiary of WAH. The Company considers all liabilities, commitments, contingencies, guarantees, or obligations of WAH in the determination of the carrying value of its investment in WAH.

M. All SCA Investments

(1) Balance Sheet Value (Admitted and Nonadmitted) All SCAs (Except 8bi Entities)

SCA Entity	Percentage of SCA Ownership	Gross Amount	Admitted Amount	Nonadmitted Amount
a. SSAP No. 97 8a Entities				
Total SSAP No. 97 8a Entities	XXX	\$ -	\$ -	\$ -
b. SSAP No. 97 8b(ii) Entities				
Total SSAP No. 97 8b(ii) Entities	XXX	\$ -	\$ -	\$ -
c. SSAP No. 97 8b(iii) Entities				
Wellmark Holdings, LLC	100.0%	\$ -	\$ -	\$ -
First Administrators, LLC	100.0%	\$ 3,602,886	\$ -	\$ 3,602,886
Midwest Benefit Consultants, LLC	100.0%	\$ 6,193,812	\$ -	\$ 6,193,812
Total SSAP No. 97 8b(iii) Entities	XXX	\$ 9,796,698	\$ -	\$ 9,796,698
d. SSAP No. 97 8b(iv) Entities				
Total SSAP No. 97 8b(iv) Entities	XXX	\$ -	\$ -	\$ -
e. Total SSAP No. 97 8b Entities (except 8bi entities) (b+c+d)	XXX	\$ 9,796,698	\$ -	\$ 9,796,698
f. Aggregate Total (a+ e)	XXX	\$ 9,796,698	\$ -	\$ 9,796,698

NOTES TO FINANCIAL STATEMENTS

(2) NAIC Filing Response Information

SCA Entity (Should be same entities as shown in M(1) above.)	Type of NAIC Filing *	Date of Filing to the NAIC	NAIC Valuation Amount	NAIC Response Received Yes/No	NAIC Disallowed Entities Valuation Method, Resubmission Required Yes/No	Code **
a. SSAP No. 97 8a Entities						
Total SSAP No. 97 8a Entities	XXX	XXX	\$ -	XXX	XXX	XXX
b. SSAP No. 97 8b(ii) Entities						
Total SSAP No. 97 8b(ii) Entities	XXX	XXX	\$ -	XXX	XXX	XXX
c. SSAP No. 97 8b(iii) Entities						
Wellmark Holdings, LLC	S1	10/25/2016	\$ -	Yes	No	
First Administrators, LLC	S1	10/25/2016	\$ -	Yes	No	
Midwest Benefit Consultants, LLC	S1	10/25/2016	\$ -	Yes	No	
Total SSAP No. 97 8b(iii) Entities	XXX	XXX	\$ -	XXX	XXX	XXX
d. SSAP No. 97 8b(iv) Entities						
Total SSAP No. 97 8b(iv) Entities	XXX	XXX	\$ -	XXX	XXX	XXX
e. Total SSAP No. 97 8b Entities (except 8bi entities) (b+c+d)						
	XXX	XXX	\$ -	XXX	XXX	XXX
f. Aggregate Total (a+e)						
	XXX	XXX	\$ -	XXX	XXX	XXX

* S1 - Sub-1, S2 - Sub-2 or RDF - Resubmission of Disallowed Filing
 ** I - Immaterial or M - Material

The Company is exempt from a Sub-2 filing for its SSAP 97 8b(iii) subsidiaries because they are fully nonadmitted.

N. Investment in Insurance SCAs

Not applicable

O. SCA or SSAP 48 Entity Loss Tracking

1 Entity	2 Reporting Entity's Share of Net Income (Loss)	3 Accumulated Share of Net Income (Losses)	4 Reporting Entity's Share of Equity, Including Negative Equity	5 Guaranteed Obligation / Commitment for Financial Support (Yes/No)	6 Amount of the Recognized Guarantee Under SSAP No. 5R
Wellmark Holdings, LLC	\$ (80,100)	\$ (2,239,477)	\$ (2,182,443)	No	\$ -

The losses in Wellmark Holdings, LLC have not impacted other investments.

NOTE 11 Debt

A. Debt Including Capital Notes

The Company has a total amount of \$80,000,000 available under two lines of credit. The Company has not drawn on its lines of credit in 2024 and had no outstanding draws as of December 31, 2024.

B. FHLB (Federal Home Loan Bank) Agreements

(1) Nature of the Agreement

The Company is a member of the Federal Home Loan Bank (FHLB) of Des Moines. The Company has determined the estimated current maximum borrowing capacity as approximately \$82,000,000. The Company calculated this amount in accordance with FHLB Des Moines credit and collateral guidelines. When borrowings occur, it is anticipated that the Company's strategy will be to utilize these funds to meet daily liquidity needs. As of year-end, the Company has no outstanding advances with FHLB Des Moines.

(2) FHLB Capital Stock

a. Aggregate Totals

	Total
1. Current Year	
(a) Membership Stock - Class A	\$ -
(b) Membership Stock - Class B	\$ 2,509,300
(c) Activity Stock	\$ -
(d) Excess Stock	\$ -
(e) Aggregate Total (a+b+c+d)	\$ 2,509,300
(f) Actual or estimated Borrowing Capacity as Determined by the Insurer	\$ 82,000,000
2. Prior Year-end	
(a) Membership Stock - Class A	\$ -
(b) Membership Stock - Class B	\$ 2,148,700
(c) Activity Stock	\$ -
(d) Excess Stock	\$ -
(e) Aggregate Total (a+b+c+d)	\$ 2,148,700
(f) Actual or estimated Borrowing Capacity as Determined by the Insurer	\$ 68,000,000

11B(2)a1(f) should be equal to or greater than 11B(4)a1(d)
 11B(2)a2(f) should be equal to or greater than 11B(4)a2(d)

NOTES TO FINANCIAL STATEMENTS

b. Membership Stock (Class A and B) Eligible and Not Eligible for Redemption

	1	2	Eligible for Redemption			
			3	4	5	6
	Current Year Total (2+3+4+5+6)	Not Eligible for Redemption	Less Than 6 Months	6 Months to Less Than 1 Year	1 to Less Than 3 Years	3 to 5 Years
Membership Stock						
1. Class A	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
2. Class B	\$ 2,509,300	\$ 2,509,300	\$ -	\$ -	\$ -	\$ -

11B(2)b1 Current Year Total (Column 1) should equal 11B(2)a1(a) Total (Column 1)

11B(2)b2 Current Year Total (Column 1) should equal 11B(2)a1(b) Total (Column 1)

(3) Collateral Pledged to FHLB

No amounts were pledged during the reporting period and no amounts were pledged as of December 31, 2024.

(4) Borrowing from FHLB

No amounts were borrowed during the reporting period and no amounts were outstanding as of December 31, 2024.

NOTE 12 Retirement Plans, Deferred Compensation, Postemployment Benefits and Compensated Absences and Other Postretirement Benefit Plans

A. Defined Benefit Plan

The Company sponsors a pension program (the program) covering substantially all employees. The pension program contains both a defined benefit and cash balance plan available to eligible employees depending on the date of hire. The defined benefit pension plan benefits are based on years of service and the employee's highest five consecutive years' compensation in the last ten years of service. Under the cash balance plan, employees earn annual credits based on a percentage of salary that are accumulated in an account that earns interest annually. Effective January 1, 2022, the program was amended to close participation to new entrants after December 31, 2021 and to provide for the cessation of all benefit accruals under all plan formulas under the program effective December 31, 2029.

The administration and recordkeeping services for the program are performed by Principal Life Insurance Company (collectively with Principal Financial Group as Principal). Pension plan assets are held in the Non-Contributory Retirement Program for Certain Employees of Wellmark, Inc. Trust (Trust) with Principal Trust Company as the trustee of the program.

The funding policy of the program is to contribute amounts sufficient to meet the minimum funding requirements set forth in the Employee Retirement Income Security Act of 1974 and the Pension Protection Act of 1996, plus additional amounts as determined to be appropriate from time to time. No voluntary contributions were made to the pension plan in 2024 or 2023. There are no current plans for the Company to make voluntary contributions to the pension plan in 2025.

The Company also sponsors a postretirement health care benefit plan. The plan has two separate benefit calculations available to employees depending on the date of hire. One plan contributes toward the cost of health care premiums based on years of service and is available to employees who retire from the Company who have at least ten years of service and have attained age 65 while in service to the Company. This plan also includes a life insurance benefit based on the employee's annual salary at retirement and is available to employees who retire from the Company who have at least five years of service and have attained age 55 while in service to the Company. The second plan option allows employees to accumulate annual credits in an account that earns interest annually and can be used to pay for health care premiums when the employee becomes Medicare eligible. Effective January 1, 2022, the postretirement health care benefit plan was amended to close the plan to additional participants and to freeze accruals of annual credits under the plan for all participants under age 62. The Company has not funded either the postretirement health care or life insurance plans but intends to meet the obligations of the plans through general assets of the Company.

A summary of assets, obligations and assumptions of the Pension and Other Postretirement Benefit Plans are as follows at December 31, 2024 and 2023:

(1) Change in Benefit Obligation

	Overfunded		Underfunded	
	2024	2023	2024	2023
a. Pension Benefits				
1. Benefit obligation at beginning of year	\$ 271,402,949	\$ 274,754,991	\$ -	\$ -
2. Service cost	\$ 8,584,897	\$ 8,728,306	\$ -	\$ -
3. Interest cost	\$ 13,076,647	\$ 14,003,395	\$ -	\$ -
4. Contribution by plan participants	\$ -	\$ -	\$ -	\$ -
5. Actuarial gain/loss	\$ (13,349,664)	\$ (7,436,656)	\$ -	\$ -
6. Foreign currency exchange rate changes	\$ -	\$ -	\$ -	\$ -
7. Benefits paid	\$ (4,421,373)	\$ (18,647,087)	\$ -	\$ -
8. Plan amendments	\$ -	\$ -	\$ -	\$ -
9. Business combinations, divestitures, curtailments, settlements and special termination benefits	\$ (61,999,990)	\$ -	\$ -	\$ -
10. Benefit obligation at end of year	\$ 213,293,466	\$ 271,402,949	\$ -	\$ -
b. Postretirement Benefits				
1. Benefit obligation at beginning of year	\$ -	\$ -	\$ 27,633,653	\$ 27,718,747
2. Service cost	\$ -	\$ -	\$ 20,345	\$ 42,051
3. Interest cost	\$ -	\$ -	\$ 1,315,933	\$ 1,392,235
4. Contribution by plan participants	\$ -	\$ -	\$ -	\$ -
5. Actuarial gain/loss	\$ -	\$ -	\$ (1,037,156)	\$ (123,366)
6. Foreign currency exchange rate changes	\$ -	\$ -	\$ -	\$ -
7. Benefits paid	\$ -	\$ -	\$ (1,428,701)	\$ (1,396,014)
8. Plan amendments	\$ -	\$ -	\$ -	\$ -
9. Business combinations, divestitures, curtailments, settlements and special termination benefits	\$ -	\$ -	\$ (1,733,069)	\$ -
10. Benefit obligation at end of year	\$ -	\$ -	\$ 24,771,005	\$ 27,633,653

NOTES TO FINANCIAL STATEMENTS

	Overfunded		Underfunded	
	2024	2023	2024	2023
c. Special or Contractual Benefits Per SSAP No. 11				
1. Benefit obligation at beginning of year	\$ -	\$ -	\$ 12,681,906	\$ 12,333,481
2. Service cost	\$ -	\$ -	\$ 27,985,082	\$ 25,747,843
3. Interest cost	\$ -	\$ -	\$ -	\$ -
4. Contribution by plan participants	\$ -	\$ -	\$ -	\$ -
5. Actuarial gain/loss	\$ -	\$ -	\$ -	\$ -
6. Foreign currency exchange rate changes	\$ -	\$ -	\$ -	\$ -
7. Benefits paid	\$ -	\$ -	\$ (26,357,027)	\$ (25,399,418)
8. Plan amendments	\$ -	\$ -	\$ -	\$ -
9. Business combinations, divestitures, curtailments, settlements and special termination benefits	\$ -	\$ -	\$ -	\$ -
10. Benefit obligation at end of year	\$ -	\$ -	\$ 14,309,961	\$ 12,681,906

(2) Change in Plan Assets

	Pension Benefits		Postretirement Benefits		Special or Contractual Benefits Per SSAP No. 11	
	2024	2023	2024	2023	2024	2023
a. Fair value of plan assets at beginning of year	\$ 296,166,706	\$ 287,220,882	\$ -	\$ -	\$ -	\$ -
b. Actual return on plan assets	\$ 4,343,774	\$ 27,592,911	\$ -	\$ -	\$ -	\$ -
c. Foreign currency exchange rate changes	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
d. Reporting entity contribution	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
e. Plan participants' contributions	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
f. Benefits paid	\$ (4,421,373)	\$ (18,647,087)	\$ -	\$ -	\$ -	\$ -
g. Business combinations, divestitures and settlements	\$ (61,999,990)	\$ -	\$ -	\$ -	\$ -	\$ -
h. Fair value of plan assets at end of year	\$ 234,089,117	\$ 296,166,706	\$ -	\$ -	\$ -	\$ -

(3) Funded Status

	Pension Benefits		Postretirement Benefits	
	2024	2023	2024	2023
a. Components:				
1. Prepaid benefit costs	\$ 59,760,162	\$ 78,204,976	\$ -	\$ -
2. Overfunded plan assets	\$ (38,964,511)	\$ (53,441,219)	\$ -	\$ -
3. Accrued benefit costs	\$ -	\$ -	\$ 39,013,245	\$ 40,328,793
4. Liability for pension benefits	\$ -	\$ -	\$ (14,242,240)	\$ (12,695,140)
b. Assets and liabilities recognized:				
1. Assets (nonadmitted)	\$ 20,795,651	\$ 24,763,757	\$ -	\$ -
2. Liabilities recognized	\$ -	\$ -	\$ 24,771,005	\$ 27,633,653
c. Unrecognized liabilities	\$ -	\$ -	\$ -	\$ -

(4) Components of Net Periodic Benefit Cost

	Pension Benefits		Postretirement Benefits		Special or Contractual Benefits Per SSAP No. 11	
	2024	2023	2024	2023	2024	2023
a. Service cost	\$ 8,584,897	\$ 8,728,306	\$ 20,345	\$ 42,051	\$ 27,985,082	\$ 25,747,843
b. Interest cost	\$ 13,076,647	\$ 14,003,395	\$ 1,315,933	\$ 1,392,235	\$ -	\$ -
c. Expected return on plan assets	\$ (17,109,286)	\$ (16,709,257)	\$ -	\$ -	\$ -	\$ -
d. Transition asset or obligation	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
e. Gains and losses	\$ 2,567,300	\$ 5,173,010	\$ (1,223,125)	\$ (1,299,721)	\$ -	\$ -
f. Prior service cost or credit	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
g. Gain or loss recognized due to a settlement or curtailment	\$ 11,325,256	\$ -	\$ -	\$ -	\$ -	\$ -
h. Total net periodic benefit cost	\$ 18,444,814	\$ 11,195,454	\$ 113,153	\$ 134,565	\$ 27,985,082	\$ 25,747,843

(5) Amounts in Unassigned Funds (Surplus) Recognized as Components of Net Periodic Benefit Cost

	Pension Benefits		Postretirement Benefits	
	2024	2023	2024	2023
a. Items not yet recognized as a component of net periodic cost - prior year	\$ 53,441,219	\$ 76,934,539	\$ (12,695,140)	\$ (13,871,495)
b. Net transition asset or obligation recognized	\$ -	\$ -	\$ -	\$ -
c. Net prior service cost or credit arising during the period	\$ -	\$ -	\$ (1,733,069)	\$ -
d. Net prior service cost or credit recognized	\$ -	\$ -	\$ -	\$ -
e. Net gain and loss arising during the period	\$ (584,152)	\$ (18,320,310)	\$ (1,037,156)	\$ (123,366)
f. Net gain and loss recognized	\$ (13,892,556)	\$ (5,173,010)	\$ 1,223,125	\$ 1,299,721
g. Items not yet recognized as a component of net periodic cost - current year	\$ 38,964,511	\$ 53,441,219	\$ (14,242,240)	\$ (12,695,140)

(6) Amounts in Unassigned Funds (Surplus) That Have Not Yet Been Recognized as Components of Net Periodic Benefit Cost

	Pension Benefits		Postretirement Benefits	
	2024	2023	2024	2023
a. Net transition asset or obligation	\$ -	\$ -	\$ -	\$ -
b. Net prior service cost or credit	\$ -	\$ -	\$ (1,733,069)	\$ -
c. Net recognized gains and losses	\$ 38,964,511	\$ 53,441,219	\$ (12,509,171)	\$ (12,695,140)

NOTES TO FINANCIAL STATEMENTS

(7) Weighted-Average Assumptions Used to Determine Net Periodic Benefit Cost as of December 31:

	Pension Benefits	
	2024	2023
a. Weighted average discount rate	5.00%	5.30%
b. Expected long-term rate of return on plan assets	6.50%	6.50%
c. Rate of compensation increase	3.00 - 8.00%	3.00 - 8.00%
d. Interest crediting rates (for cash balance plans and other plans with promised interest crediting rates)	4.00%	3.50%

Weighted-Average Assumptions Used to Determine Projected Benefit Obligations as of December 31:

	Pension Benefits	
	2024	2023
e. Weighted average discount rate	5.55%	5.00%
f. Rate of compensation increase	3.00 - 8.00%	3.00 - 8.00%
g. Interest crediting rates (for cash balance plans and other plans with promised interest crediting rates)	4.00%	4.00%

Weighted-Average Assumptions Used to Determine Net Periodic Benefit Costs as of December 31:

	Postretirement Benefits	
	2024	2023
a. Weighted average discount rate	5.00%	5.20%
b. Expected long-term rate of return on plan assets	N/A	N/A
c. Rate of compensation increase	3.00 - 8.00%	3.00 - 8.00%
d. Interest crediting rates (for cash balance plans and other plans with promised interest crediting rates)	N/A	N/A

Weighted-Average Assumptions Used to Determine Projected Benefit Obligations as of December 31:

	Postretirement Benefits	
	2024	2023
e. Weighted average discount rate	5.50%	5.00%
f. Rate of compensation increase	3.00 - 8.00%	3.00 - 8.00%
g. Interest crediting rates (for cash balance plans and other plans with promised interest crediting rates)	N/A	N/A

(8) Accumulated Benefit Obligation for Defined Benefit Pension Plans

The amount of the accumulated benefit obligation for the defined benefit pension plan was \$195,484,052 for the current year and \$248,992,369 for the prior year.

(9) Assumed Health Care Cost Trend Rate(s) For Postretirement Benefits Other than Pensions

For postretirement benefits other than pensions, for measurement purposes, 8.5% (pre-65) and 6.25% (post-65) annual rates of increase in the per capita cost of covered health care benefits were assumed for 2024. These rates grade down annually to 4.5% for 2034 and beyond.

(10) The following estimated future payments, which reflect expected future service, as appropriate, are expected to be paid in the years indicated:

Pension Benefits	Amount
a. 2025	\$ 14,990,000
b. 2026	\$ 16,040,000
c. 2027	\$ 16,400,000
d. 2028	\$ 16,330,000
e. 2029	\$ 17,640,000
f. 2030 through 2034	\$ 90,180,000
Postretirement Benefits	Amount
a. 2025	\$ 2,940,000
b. 2026	\$ 2,110,000
c. 2027	\$ 2,060,000
d. 2028	\$ 2,070,000
e. 2029	\$ 2,160,000
f. 2030 through 2034	\$ 9,140,000

(11) Estimate of Contributions Expected to be Paid to the Plan

The Company does not have any regulatory contribution requirements for 2025. In addition, there are no current plans for the Company to make voluntary contributions to the defined benefit pension plan in 2025.

(12) Amounts and Types of Securities Included in Plan Assets

Not applicable

(13) Alternative Method Used to Amortize Prior Service Amounts or Net Gains and Losses

Not applicable

(14) Substantive Comment Used to Account for Benefit Obligation

Not applicable

(15) Cost of Providing Special or Contractual Termination Benefits Recognized

Not applicable

(16) Reasons for Significant Gains/Losses Related to Changes in Defined Benefit Obligation and any Other Significant Change in the Benefit Obligations or Plan Assets Not Otherwise Apparent

During the year ended December 31, 2024, the pension benefit obligation generated a gain due to an increase in the discount rate, an active participant experience loss due to higher than expected compensation during 2023, a participant experience gain due to the purchase of an annuity to fund future retiree pension payments, and a loss due to lower than expected return on plan assets. During the year ended December 31, 2024, the other postretirement benefit obligation experienced a gain due to an increase in the discount rate and due to a life insurance program change.

NOTES TO FINANCIAL STATEMENTS

(17) Accumulated Postretirement and Pension Benefit Obligation and Fair Value of Plan Assets for Defined Postretirement and Pension Benefit Plans

The pension plan was in an overfunded status at December 31, 2024 and 2023. As required by SSAP 102, overfunded plan assets are nonadmitted. The Company has not funded either the postretirement health care or life insurance plans. The impact to surplus to recognize the unfunded status of the Other Postretirement Benefit Plans was (\$14,242,240) and (\$12,695,140) at December 31, 2024 and 2023, respectively.

(18) Full Transition Surplus Impact of SSAP 102

Not applicable

B. Investment Policies and Strategies

The Company's pension plan assets are invested in the Trust. The investment program for the Trust is based on the precepts of capital market theory that are generally accepted and followed by institutional investors, who by definition are long-term oriented investors. This philosophy holds that:

1. Increasing risk is rewarded with compensating returns over time and therefore, prudent risk taking is justifiable for long term investors.
2. Risk can be controlled through diversification of asset classes and investment approaches as well as diversification of individual securities.
3. Risk is reduced by time, and over time the relative performance of different asset classes is reasonably consistent. Over the long-term, equity investments have provided and should continue to provide superior returns over other security types. Fixed-income securities can dampen volatility and provide liquidity in periods of depressed economic activity. Lengthening duration of fixed income securities may reduce surplus volatility.
4. The strategic or long-term allocation of assets among various asset classes is an important driver of long term returns.
5. Relative performance of various asset classes is unpredictable in the short-term and attempts to shift tactically between asset classes are unlikely to be rewarded.

Investments will be made for the sole interest of the participants of the pension plan participating in the Trust. Accordingly, the assets of the Trust shall be invested in accordance with these objectives:

1. To seek and maintain an adequate funded status with regard to current liabilities within a targeted range.
2. To manage overall costs of running the pension plan at levels favorable to industry benchmarks.
3. To ensure assets are available to meet current and future benefit and expense obligations when due.

C. Fair Value of Plan Assets

(1) Fair Value Measurements of Plan Assets at Reporting Date

Description For Each Class of Plan Assets	(Level 1)	(Level 2)	(Level 3)	Total
Cash Equivalents	\$ 3,040,667	\$ -	\$ -	\$ 3,040,667
U.S. Government Securities	\$ -	\$ 13,637,905	\$ -	\$ 13,637,905
Common/Collective Trusts: Equity Accounts	\$ -	\$ 23,964,026	\$ -	\$ 23,964,026
Common/Collective Trusts: Fixed Accounts	\$ -	\$ 113,993,841	\$ -	\$ 113,993,841
Mutual Funds: Fixed Funds	\$ 6,426,427	\$ -	\$ -	\$ 6,426,427
Total Plan Assets	\$ 9,467,094	\$ 151,595,772	\$ -	\$ 161,062,866

Pension plan assets also include \$73,026,251 of limited partnerships which are accounted for using NAV as a practical expedient.

(2) Valuation Technique(s) and Inputs Used to Measure Fair Value

Generally, Level 1 financial instruments consist of mutual funds that are actively traded and have quoted prices available. Mutual funds are valued at NAV of shares held based on the latest quoted market price. Financial instruments included in Level 2 consist of U.S. government securities and common/collective trusts that have direct or indirect price inputs that are observable in active markets or are measured at NAV. The fair value of the Company's limited partnership investments is estimated using NAV as a practical expedient. This practical expedient is not used when it is determined to be probable that the investments will be sold for an amount different than the reported NAV. It is not practicable to estimate the fair value of the Company's limited partnership investments due to the private and, in certain instances, confidential nature of the underlying investments in the partnerships and the specialized knowledge of specific industries and transactions required.

The Company obtains prices and/or relevant inputs to fair value calculations from external investment managers or from the custodian of the pension assets, which uses a third party pricing service. For securities not actively traded, the investment manager and/or pricing service may use quoted market prices of comparable instruments or discounted cash flow analyses, incorporating inputs that are currently observable in the markets for similar securities. Inputs that are often used in the valuation methodologies include, but are not limited to, benchmark yields, credit spreads, default rates, prepayment conditions, and nonbinding broker quotes. Additionally, for investments that do not have quoted market prices whereby fair value is measured using NAV per share as a practical expedient, inputs used in the valuation methodologies also include redemption frequency and redemption notice periods, to give consideration to liquidity constraints, if applicable.

D. Basis Used to Determine Expected Long-Term Rate-of-Return

The basis of the overall expected long-term rate of return on assets assumption is a forward-looking approach based on the current long-term capital market outlook assumptions of the asset categories the Trust invests in and the Trust's target asset allocation.

The assumed target asset allocation for the program is as follows: 58.5% liability matching fixed income, 20% private equity, 15% publicly-traded equity, 5% growth fixed income, and 1.5% cash and cash equivalents. Portfolio expectations were estimated through a combination of underlying asset assumptions including geometric returns, distributions, and correlations. Using these assumptions, the Company selected the expected return on asset assumption of 6.50% for 2024. This rate is net of both investment and other administrative expenses charged to the Trust.

E. Defined Contribution Plan

The Company also sponsors a defined contribution plan (the plan) which is qualified under Section 401(k) of the Internal Revenue Code. The plan covers substantially all employees of the Company and subsidiaries. Employees can contribute a maximum of 80% of their annual salary to the plan (up to the elective deferral limits set by the Commissioner of Internal Revenue). The Company will contribute an amount equal to 100% of the first 4% of salary contributed by the employee. The plan also provides for additional employer contributions at the discretion of the Board of Directors.

Effective January 1, 2022, the plan was amended to provide different employer contributions to employees hired or rehired effective January 1, 2022 or after. For participants hired or rehired on or after January 1, 2022, the Company will contribute an amount equal to 100% of the first 6% of salary contributed by the employee. The Company will also make an annual contribution for these participants of 2%, 3% or 4% based on their age and years of service. To be eligible for the annual contribution, a participant is required to be an active employee on the last day of the plan year. Participants hired on or before December 31, 2021 will continue to receive a Company contribution in an amount equal to 100% of the first 4% of salary contributed by the employee.

Recordkeeping responsibilities for the plan are performed by Principal. The Company's contribution for this plan was \$5,694,511 and \$4,507,372 for 2024 and 2023, respectively.

NOTES TO FINANCIAL STATEMENTS

F. Multiemployer Plans

Not applicable

G. Consolidated/Holding Company Plans

The Company is the plan sponsor of a pension program and a postretirement health and life benefit program which cover substantially all employees of the consolidated group.

H. Postemployment Benefits and Compensated Absences

Not applicable

I. Impact of Medicare Modernization Act on Postretirement Benefits (INT 04-17)

Not applicable

NOTE 13 Capital and Surplus, Dividend Restrictions and Quasi-Reorganizations

A. Number of Shares and Par or Stated Value of Each Class

Not applicable

B. Dividend Rate, Liquidation Value and Redemption Schedule of Preferred Stock Issues

Not applicable

C. Dividend Restrictions

Not applicable

D. Dates and Amounts of Dividends Paid

Not applicable

E. Profits that may be Paid as Ordinary Dividends to Stockholders

Not applicable

F. Restrictions Placed on Unassigned Funds (Surplus)

Not applicable

G. Amount of Advances to Surplus not Repaid

Not applicable

H. Amount of Stock Held for Special Purposes

Not applicable

I. Reasons for Changes in Balance of Special Surplus Funds from Prior Period

Not applicable

J. The Portion of Unassigned Funds (Surplus) Represented or Reduced by Cumulative Unrealized Gains and Losses is \$ 864,993,233

K. The Reporting Entity Issued the Following Surplus Debentures or Similar Obligations

Not applicable

L. The Impact of any Restatement Due to Prior Quasi-Reorganizations

Not applicable

M. Effective Date of Quasi-Reorganization for a Period of Ten Years Following Reorganization

Not applicable

NOTE 14 Liabilities, Contingencies and Assessments

A. Contingent Commitments

(1) The Company is required by licensure requirements of the Blue Cross Blue Shield Association (BCBSA) to execute parental guarantees for its licensed controlled affiliates, pursuant to which the Company guarantees to the full extent of its assets all contractual and financial obligations of WHPI, WSD, FAI, WSH and WVHP to their respective customers. Through parental guarantees executed between the Company and WSH and WVHP, the Company guarantees that WSH and WVHP are in compliance with the Iowa statutory minimum for HMO capital and surplus of \$1,000,000 or the statutory minimum for risk-based capital for health organizations, whichever is greater. Also, the Company, as the parent of WHPI is required by the Iowa Insurance Division to guarantee the obligations of WHPI to pay for services to enrollees up to \$1,100,000.

The Company is also required by licensure requirements of the BCBSA to execute a parental guarantee for WAHP, pursuant to which the Company guarantees to the full extent of its assets all contractual and financial obligations to members proportionate to the Company's subsidiary holding company's ownership interest in WAHP.

(2) Detail of Other Contingent Commitments

Not applicable

NOTES TO FINANCIAL STATEMENTS

(3) Guarantee Obligations

Not applicable

B. Assessments

(1) Assessments Where Amount is Known or Unknown

The Company is subject to health related assessments by the Iowa Comprehensive Health Association and the Iowa Individual Health Benefit Reinsurance Association for high risk insurance pools. The Company accrued a net admitted receivable of \$932,500 and a liability of \$6,940,000 for estimated health related assessments as of December 31, 2024.

(2) Assessments

Not applicable

(3) Guaranty Fund Liabilities and Assets Related to Assessments from Insolvencies for Long-Term Care Contracts

Not applicable

C. Gain Contingencies

Not applicable

D. Claims Related Extra Contractual Obligations and Bad Faith Losses Stemming From Lawsuits

Not applicable

E. Joint and Several Liabilities

Not applicable

F. All Other Contingencies

The Company, along with the BCBSA and Blue Cross and/or Blue Shield licensees, or Blue Plans across the country, is a defendant in a single multi-district consolidated lawsuit *In re Blue Cross Blue Shield Antitrust Litigation* that is pending in the United States District Court for the Northern District of Alabama. Generally, the litigation alleges that the BCBSA and Blue Plans have engaged in activities in violation of the Sherman Act and related state laws through license agreements, best efforts rules that limit the percentage of non-Blue revenue of each plan, restrictions on acquisitions and other arrangements. The cases were brought by two putative nationwide classes of plaintiffs, health plan subscribers and providers. The Company, the BCBSA and all other Blue Cross and/or Blue Shield licensees, have reached a settlement with the health plan subscriber class plaintiffs. This settlement was approved by the United States District Court for the Northern District of Alabama, and the appeal process concluded with the Petition for Certiorari being denied by the United States Supreme Court on June 24, 2024. The court currently is supervising the final class settlement process. There have been several additional individual lawsuits filed by groups and members who opted out of the subscriber class. The Company has made adequate provision for its proportional share of the settlement and any damages that may result from the opt-out suits. The Company, the BCBSA and all other Blue Cross and/or Blue Shield licensees, have reached a settlement with the provider class. The settlement was preliminarily approved by the United States District Court for the Northern District of Alabama on December 4, 2024. The Opt Out/Objection Deadline is March 4, 2025. There may be additional individual lawsuits filed by providers who opt out of the provider class.

In the ordinary course of business, the Company is involved in and subject to claims, contractual disputes and other uncertainties, which the Company defends vigorously. While the ultimate outcome of any other claims cannot be presently determined, in the opinion of management, adequate provision has been made for any potential losses which may result from these actions and the Company expects any liability that could result will not materially affect its financial position.

NOTE 15 Leases

A. Lessee Operating Lease

(1) Lessee's Leasing Arrangements

a. Rental Expense

The Company leases facilities under various noncancelable operating lease agreements that expire through December 2034. Rental expense associated with these lease arrangements was approximately \$1,040,593 and \$1,332,881 for 2024 and 2023, respectively.

b. Basis on Which Contingent Rental Payments are Determined

Not applicable

c. Existence and Terms of Renewal or Purchase Options and Escalation Clauses

Certain rental commitments have renewal options extending through the year 2044. Some of these renewals are subject to adjustments in future periods.

d. Restrictions Imposed by Lease Agreements

Not applicable

e. Identification of Lease Agreements That Have Been Terminated Early

Not applicable

NOTES TO FINANCIAL STATEMENTS

(2) Leases with Initial or Remaining Noncancelable Lease Terms in Excess of One Year

a. At December 31, 2024, the minimum aggregate rental commitments are as follows:

	Operating Leases
1. 2025	\$ 948,559
2. 2026	\$ 513,738
3. 2027	\$ 518,512
4. 2028	\$ 523,429
5. 2029	\$ 488,111
6. Thereafter	\$ 1,977,800
7. Total (sum of 1 through 6)	\$ 4,970,149

b. Total of Minimum Rentals to be Received in the Future Under Noncancelable Subleases

Not applicable

(3) For Sale-Leaseback Transactions

Not applicable

B. Lessor Leases

Not applicable

NOTE 16 Information About Financial Instruments With Off-Balance Sheet Risk and Financial Instruments With Concentrations of Credit Risk

Not applicable

NOTE 17 Sale, Transfer and Servicing of Financial Assets and Extinguishments of Liabilities

A. Transfers of Receivables Reported as Sales

Not applicable

B. Transfer and Servicing of Financial Assets

Not applicable

C. Wash Sales

(1) During the year, the Company's investment managers entered into one transaction that met wash sale criteria. The transaction occurred as a result of reallocation of funds.

(2) The details by NAIC designation 3 or below, or unrated of securities sold during the year ended December 31, 2024 and reacquired within 30 days of the sale date are:

Description	NAIC Designation	Number of Transactions	Book Value of Securities Sold	Cost of Securities Repurchased	Gain/(Loss)
Common Stocks		1	\$ 109,130	\$ 109,385	\$ (27,461)

NOTE 18 Gain or Loss to the Reporting Entity from Uninsured Plans and the Uninsured Portion of Partially Insured Plans

A. ASO Plans

Not applicable

B. ASC Plans

The gain (loss) from operations from Administrative Services Contract (ASC) uninsured plans and the uninsured portion of partially insured plans was as follows during 2024:

	ASC Uninsured Plans	Uninsured Portion of Partially Insured Plans	Total ASC
a. Gross reimbursement for medical cost incurred	\$ 1,762,520,227	\$ 1,683,597,997	\$ 3,446,118,224
b. Gross administrative fees accrued	\$ 49,248,964	\$ 104,637,859	\$ 153,886,823
c. Other income or expenses (including interest paid to or received from plans)	\$ -	\$ -	\$ -
d. Gross expenses incurred (claims and administrative) (a+b+c)	\$ 1,811,769,191	\$ 1,788,235,856	\$ 3,600,005,047
e. Total net gain or loss from operations	\$ (11,404,745)	\$ (33,040,621)	\$ (44,445,366)

C. Medicare or Similarly Structured Cost Based Reimbursement Contract

Reimbursements from Centers for Medicare and Medicaid Services (CMS) for the Company's participation in the Medicare Part D program for the year ended December 31, 2024 were \$59,476,268. This amount represents pharmacy benefit cost reimbursements for the Reinsurance Subsidy and Low-Income Cost Sharing Subsidy elements of the Medicare Part D program.

At December 31, 2024, the Company has a receivable of \$25,613,988 from CMS for these reimbursements.

NOTES TO FINANCIAL STATEMENTS

NOTE 19 Direct Premium Written/Produced by Managing General Agents/Third Party Administrators

Not applicable

NOTE 20 Fair Value Measurements

A. Fair Value Measurements

(1) Fair Value Measurements at Reporting Date

Description for Each Class of Asset or Liability	(Level 1)	(Level 2)	(Level 3)	Net Asset Value (NAV)	Total
a. Assets at fair value					
Cash Equivalents: Exempt Money Market Mutual Funds	\$ 25,573,444	\$ -	\$ -	\$ -	\$ 25,573,444
Cash Equivalents: Other Money Market Mutual Funds	\$ 179,914	\$ -	\$ -	\$ -	\$ 179,914
Cash Equivalents: Sweep Account	\$ -	\$ 3,347,035	\$ -	\$ -	\$ 3,347,035
Bonds: Industrial & Miscellaneous	\$ -	\$ 36,391,791	\$ -	\$ -	\$ 36,391,791
Bonds: Bank Loans	\$ -	\$ 3,284,799	\$ -	\$ -	\$ 3,284,799
Preferred Stock: Industrial & Miscellaneous	\$ 2,040,256	\$ -	\$ -	\$ -	\$ 2,040,256
Common Stock: Industrial & Miscellaneous	\$ 589,918,750	\$ 2,509,300	\$ 8,294,972	\$ -	\$ 600,723,022
Common Stock: Mutual Funds	\$ 235,030,411	\$ -	\$ -	\$ -	\$ 235,030,411
Other Invested Assets: Residual Tranches	\$ -	\$ 598,180	\$ -	\$ -	\$ 598,180
Total Assets at Fair Value/NAV	\$ 852,742,775	\$ 46,131,105	\$ 8,294,972	\$ -	\$ 907,168,852

(2) Fair Value Measurements in Level 3 of the Fair Value Hierarchy

Description	Beginning Balance at 01/01/2024	Transfers Into Level 3	Transfers Out of Level 3	Total Gains and (Losses) Included In Net Income	Total Gains and (Losses) Included In Surplus	Purchases	Issuances	Sales	Settlements	Ending Balance at 12/31/2024
a. Assets										
Common Stock - Industrial & Miscellaneous	\$ 2,787,112	\$ -	\$ -	\$ -	\$ 507,860	\$ 5,000,000	\$ -	\$ -	\$ -	\$ 8,294,972
Total Assets	\$ 2,787,112	\$ -	\$ -	\$ -	\$ 507,860	\$ 5,000,000	\$ -	\$ -	\$ -	\$ 8,294,972

(3) Policies When Transfers Between Levels Are Recognized

The Company recognizes transfers between fair value hierarchy levels at the end of the reporting period.

(4) Description of Valuation Techniques and Inputs Used in Fair Value Measurement

Bonds, structured securities, and surplus notes (other invested assets) are reported within Level 2 of the fair value hierarchy; all of these securities have direct or indirect price inputs that are observable in active markets. Fair values of these fixed income instruments are based on quoted market prices where available. The Company obtains at least one price from a third party pricing service or its custodian, which also uses a pricing service. In most instances, the Company obtains more than one price and evaluates between the pricing sources for any outliers or stale prices. Assuming prices are not stale and are reasonable between sources, the Company follows a pre-established hierarchy to conclude on which pricing source to utilize.

The pricing services normally derive security prices through recently reported trades for identical or similar securities, making adjustments through the reporting date based upon available observable market information. For securities not actively traded, the pricing service may use quoted market prices of comparable instruments or discounted cash flow analyses, incorporating inputs that are currently observable in the market for similar securities. Inputs that are often used in the valuation methodologies include, but are not limited to, benchmark yields, credit spreads, default rates, prepayment conditions, and nonbinding broker quotes.

Common stock reported within Level 2 of the fair value hierarchy is FHLB Class B Membership stock. This stock is non-redeemable and is reported at par, which is considered a proxy for fair value.

The Level 3 financial instruments are privately held stock whose fair values are determined based on the unaudited GAAP equity per outstanding common shares on a quarterly basis and on the audited GAAP equity per outstanding common shares at calendar year end.

(5) Fair Value Disclosures for Derivative Assets and Liabilities

Not applicable

B. Fair Value Reporting under SSAP 100 and Other Accounting Pronouncements

Statutory guidance requires the disclosure of fair values for certain other financial instruments for which it is practicable to estimate fair value, whether or not such values are recognized in the statements of assets, liabilities, capital and surplus. The carrying amounts for cash, receivable for securities, accrued investment income, premium receivables, other receivables, amounts due to/from affiliates, unearned premiums, accounts payable and accrued expenses, and certain other liabilities approximate fair value because of the short-term nature of these items.

C. Aggregate Fair Value For All Financial Instruments and the Level Within the Fair Value Hierarchy in Which the Fair Value Measurements in Their Entirety Fall

Type of Financial Instrument	Aggregate Fair Value	Admitted Assets	(Level 1)	(Level 2)	(Level 3)	Net Asset Value (NAV)	Not Practicable (Carrying Value)
Cash Equivalents	\$ 29,100,393	\$ 29,100,393	\$ 25,753,358	\$ 3,347,035	\$ -	\$ -	\$ -
Bonds	\$ 1,038,855,641	\$ 1,065,432,620	\$ -	\$ 1,038,855,641	\$ -	\$ -	\$ -
Preferred Stock	\$ 2,040,256	\$ 2,040,256	\$ 2,040,256	\$ -	\$ -	\$ -	\$ -
Common Stock	\$ 835,753,433	\$ 835,753,433	\$ 824,949,161	\$ 2,509,300	\$ 8,294,972	\$ -	\$ -
Other Invested Assets	\$ 1,284,103	\$ 1,218,509	\$ -	\$ 1,284,103	\$ -	\$ -	\$ -

D. Not Practicable to Estimate Fair Value

Not applicable

E. NAV Practical Expedient Investments

Not applicable

NOTES TO FINANCIAL STATEMENTS

NOTE 21 Other Items

A. Unusual or Infrequent Items

Not applicable

B. Troubled Debt Restructuring

Not applicable

C. Other Disclosures

Not applicable

D. Business Interruption Insurance Recoveries

Not applicable

E. State Transferable and Non-transferable Tax Credits

Not applicable

F. Subprime Mortgage Related Risk Exposure

(1) Description of the Subprime-Mortgage-Related Risk Exposure and Related Risk Management Practices

The Company's investment policy, approved by the Board of Directors, requires the use of high quality fixed income investments to cover its contractual liabilities. The investment policy requires that the Company's fixed income portfolio, excluding non-agency mortgage-backed securities, have a minimum average quality rating of BBB+ and the total of below investment grade securities, excluding non-agency mortgage-backed securities, is limited to 10% of the total portfolio. Further, no single issue, with the exception of US Government and Agency securities, can exceed 5% of an external investment manager's portfolio at time of purchase. The Company allows certain external investment managers to purchase non-agency mortgage-backed securities, and credit quality of those securities is at manager discretion with NAIC designation 1 or 2 preferred. The Company utilizes its strategic and tactical asset allocation to manage risk exposure, through allocations to various external investment managers with varying mandates.

The Company's exposure to subprime mortgages at December 31, 2024 is 1.6% of its total portfolio. The Company is receiving principal and interest payments on the subprime mortgage securities, and the Company does not require sale of these types of assets to meet future cash flow requirements. These securities are in gross unrealized gain and loss positions of \$740,811 and \$2,699,646, respectively, as of December 31, 2024. While no single definition exists for subprime, these securities are considered higher risk and carry higher than prime rates of interest. In addition to the interest rates, the Company considers the FICO scores below 660, level of documentation, evidence of delinquency, foreclosure, judgments or bankruptcy and other factors that limit the borrower's ability to service the debt when determining if a security should be classified as subprime.

(2) Direct Exposure Through Investments in Subprime Mortgage Loans

Not applicable

(3) Direct Exposure Through Other Investments

	Actual Cost	Book/Adjusted Carrying Value (excluding interest)	Fair Value	Other-Than-Temporary Impairment Losses Recognized
a. Residential mortgage backed securities	\$ 33,573,191	\$ 34,160,631	\$ 33,255,661	\$ 713,094
b. Commercial mortgage backed securities	\$ -	\$ -	\$ -	\$ -
c. Collateralized debt obligations	\$ -	\$ -	\$ -	\$ -
d. Structured securities	\$ 24,518,424	\$ 23,519,346	\$ 22,992,990	\$ -
e. Equity investment in SCAs *	\$ -	\$ -	\$ -	\$ -
f. Other assets	\$ -	\$ -	\$ -	\$ -
g. Total (a+b+c+d+e+f)	\$ 58,091,615	\$ 57,679,977	\$ 56,248,651	\$ 713,094

* These investments comprise 0.000% of the companies invested assets.

(4) Underwriting Exposure to Subprime Mortgage Risk Through Mortgage Guaranty or Financial Guaranty Insurance Coverage

Not applicable

G. Retained Assets

Not applicable

H. Insurance-Linked Securities (ILS) Contracts

Not applicable

I. The Amount That Could Be Realized on Life Insurance Where the Reporting Entity is Owner and Beneficiary or Has Otherwise Obtained Rights to Control the Policy

Not applicable

NOTE 22 Events Subsequent

Type I – Recognized Subsequent Events:

Subsequent events have been considered through February 25, 2025 for the statutory statement issued on March 1, 2025.

Type II – Nonrecognized Subsequent Events:

Subsequent events have been considered through February 25, 2025 for the statutory statement issued on March 1, 2025.

NOTES TO FINANCIAL STATEMENTS

NOTE 23 Reinsurance

Not applicable

NOTE 24 Retrospectively Rated Contracts & Contracts Subject to Redetermination

A. Method Used to Estimate Accrued Retrospective Premium Adjustments

The Company's participation in the Medicare Part D program includes a risk sharing provision with CMS. The Company estimates accrued retrospective premium adjustments for its Medicare Part D products through a prescribed formula approach. CMS adjusts its payments to the Company based on how actual benefit costs varied from the costs anticipated in the Company's bid for the Medicare Part D products.

The Company estimates accrued retrospective premium adjustments for individuals, small groups and large groups according to retrospective rating features pursuant to the medical loss ratio rebate requirements subject to the Public Health Service Act.

B. Retrospective Premiums Recorded Through Written Premium or Adjustment to Earned Premium

The Company records accrued retrospective premium as an adjustment to earned premium.

C. Amount and Percentage of Net Premiums Written Subject to Retrospective Rating Features

The amount of net premiums written by the Company at December 31, 2024 that are subject to retrospective rating features was \$1,834,358,455, which represented 67.8% of the total net premiums written by the Company. No other net premiums written by the Company are subject to retrospective rating features.

D. Medical Loss Ratio Rebates Required Pursuant to the Public Health Service Act

The Company estimates no medical loss ratio rebates required pursuant to the Public Health Service Act at December 31, 2024.

E. Risk Sharing Provisions of the Affordable Care Act

(1) Did the reporting entity write accident and health insurance premium which is subject to the Affordable Care Act risk sharing provisions (YES/NO)? Yes [X] No []

(2) Impact of risk sharing provisions of the Affordable Care Act on admitted assets, liabilities and revenue for the current year: Amount

a. Permanent ACA Risk Adjustment Program

Assets

1. Premium adjustments receivable due to ACA Risk Adjustment (including high risk pool payments) \$ 26,522,000

Liabilities

2. Risk adjustment user fees payable for ACA Risk Adjustment \$ 108,259

3. Premium adjustments payable due to ACA Risk Adjustment (including high risk pool premium) \$ 1,956,000

Operations (Revenue & Expense)

4. Reported as revenue in premium for accident and health contracts (written/collected) due to ACA Risk Adjustment \$ 30,090,406

5. Reported in expenses as ACA risk adjustment user fees (incurred/paid) \$ 107,685

(3) Roll forward of prior year ACA risk sharing provisions for the following asset (gross of any nonadmission) and liability balances along with the reasons for adjustments to prior year balance:

	Accrued During the Prior Year on Business Written Before December 31 of the Prior Year		Received or Paid as of the Current Year on Business Written Before December 31 of the Prior Year		Differences		Adjustments		Unsettled Balances as of the Reporting Date		
	1	2	3	4	Prior Year Accrued Less Payments (Col 1 - 3)	Prior Year Accrued Less Payments (Col 2 - 4)	To Prior Year Balances	To Prior Year Balances	Cumulative Balance from Prior Years (Col 1-3+7)	Cumulative Balance from Prior Years (Col 2-4+8)	
					5	6	7	8			
	Receivable	Payable	Receivable	Payable	Receivable	Payable	Receivable	Payable	Ref	Receivable	Payable
a. Permanent ACA Risk Adjustment Program											
1. Premium adjustments receivable (including high risk pool payments)	\$21,070,000	\$ -	\$26,489,613	\$ -	\$(5,419,613)	\$ -	\$ 5,419,613	\$ -	A	\$ -	\$ -
2. Premium adjustments (payable) (including high risk pool premium)	\$ -	\$(1,715,000)	\$ -	\$(1,610,207)	\$ -	\$(104,793)	\$ -	\$ 104,793	B	\$ -	\$ -
3. Total ACA Permanent Risk Adjustment Program	\$21,070,000	\$(1,715,000)	\$26,489,613	\$(1,610,207)	\$(5,419,613)	\$(104,793)	\$ 5,419,613	\$ 104,793		\$ -	\$ -

Explanations of Adjustments:

A. Revised data received

B. Revised data received

NOTE 25 Change in Incurred Claims and Claim Adjustment Expenses

A. Change in Incurred Claims and Claim Adjustment Expenses

The Company's reserves for incurred claims and claim adjustment expenses attributable to insured events of prior years have decreased by \$27,398,292 from \$240,340,502 in 2023. Because unpaid losses are estimated based on past experience and accumulated statistical data, the Company's actual benefit payments have varied from the original estimates.

B. Information About Significant Changes in Methodologies and Assumptions

There have been no significant changes in methodologies and assumptions used in calculating the liability for unpaid losses and loss adjustment expenses.

NOTE 26 Intercompany Pooling Arrangements

Not applicable

NOTES TO FINANCIAL STATEMENTS

NOTE 27 Structured Settlements

Not applicable

NOTE 28 Health Care Receivables

A. Pharmaceutical Rebate Receivables

Date	Estimated Pharmacy Rebates as Reported on Financial Statements	Pharmacy Rebates as Billed or Otherwise Confirmed	Actual Rebates Received Within 90 Days of Billing	Actual Rebates Received Within 91 to 180 Days of Billing	Actual Rebates Received More Than 180 Days After Billing
12/31/2024	\$ 83,850,952	\$ -	\$ -	\$ -	\$ -
09/30/2024	\$ 87,894,279	\$ 90,580,013	\$ 73,509,989	\$ -	\$ -
06/30/2024	\$ 88,277,550	\$ 89,892,202	\$ 70,868,672	\$ 16,884,406	\$ -
03/31/2024	\$ 86,298,784	\$ 88,599,602	\$ 66,618,084	\$ 16,172,221	\$ 6,236,217
12/31/2023	\$ 80,197,209	\$ 85,671,114	\$ 72,200,571	\$ 13,624,527	\$ 1,578,320
09/30/2023	\$ 80,836,045	\$ 85,682,190	\$ 72,868,862	\$ 13,644,307	\$ (57,328)
06/30/2023	\$ 82,821,705	\$ 83,973,516	\$ 73,459,589	\$ 12,343,882	\$ (61,823)
03/31/2023	\$ 77,735,929	\$ 80,312,359	\$ 68,991,085	\$ 9,208,957	\$ 1,114,377
12/31/2022	\$ 67,721,445	\$ 68,805,342	\$ -	\$ 67,197,050	\$ 1,559,073
09/30/2022	\$ 62,199,516	\$ 67,266,734	\$ -	\$ 64,864,514	\$ 2,425,159
06/30/2022	\$ 57,451,833	\$ 65,678,142	\$ -	\$ 62,981,179	\$ 2,845,519
03/31/2022	\$ 56,161,168	\$ 64,580,589	\$ -	\$ 62,351,687	\$ 2,216,316

B. Risk-Sharing Receivables

Not applicable

NOTE 29 Participating Policies

Not applicable

NOTE 30 Premium Deficiency Reserves

1. Liability carried for premium deficiency reserves	\$ -
2. Date of the most recent evaluation of this liability	12/31/2024
3. Was anticipated investment income utilized in the calculation?	Yes [X] No []

NOTE 31 Anticipated Salvage and Subrogation

Not applicable

GENERAL INTERROGATORIES

PART 1 - COMMON INTERROGATORIES GENERAL

- 1.1 Is the reporting entity a member of an Insurance Holding Company System consisting of two or more affiliated persons, one or more of which is an insurer? Yes [X] No []
If yes, complete Schedule Y, Parts 1, 1A, 2 and 3.
- 1.2 If yes, did the reporting entity register and file with its domiciliary State Insurance Commissioner, Director or Superintendent or with such regulatory official of the state of domicile of the principal insurer in the Holding Company System, a registration statement providing disclosure substantially similar to the standards adopted by the National Association of Insurance Commissioners (NAIC) in its Model Insurance Holding Company System Regulatory Act and model regulations pertaining thereto, or is the reporting entity subject to standards and disclosure requirements substantially similar to those required by such Act and regulations? Yes [X] No [] N/A []
- 1.3 State Regulating? Iowa
- 1.4 Is the reporting entity publicly traded or a member of a publicly traded group? Yes [] No [X]
- 1.5 If the response to 1.4 is yes, provide the CIK (Central Index Key) code issued by the SEC for the entity/group.
- 2.1 Has any change been made during the year of this statement in the charter, by-laws, articles of incorporation, or deed of settlement of the reporting entity? Yes [] No [X]
- 2.2 If yes, date of change:
- 3.1 State as of what date the latest financial examination of the reporting entity was made or is being made. 12/31/2021
- 3.2 State the as of date that the latest financial examination report became available from either the state of domicile or the reporting entity. This date should be the date of the examined balance sheet and not the date the report was completed or released. 12/31/2021
- 3.3 State as of what date the latest financial examination report became available to other states or the public from either the state of domicile or the reporting entity. This is the release date or completion date of the examination report and not the date of the examination (balance sheet date). 03/20/2023
- 3.4 By what department or departments?
Iowa Insurance Division and South Dakota Division of Insurance
- 3.5 Have all financial statement adjustments within the latest financial examination report been accounted for in a subsequent financial statement filed with Departments? Yes [] No [] N/A [X]
- 3.6 Have all of the recommendations within the latest financial examination report been complied with? Yes [] No [] N/A [X]
- 4.1 During the period covered by this statement, did any agent, broker, sales representative, non-affiliated sales/service organization or any combination thereof under common control (other than salaried employees of the reporting entity) receive credit or commissions for or control a substantial part (more than 20 percent of any major line of business measured on direct premiums) of:
4.11 sales of new business? Yes [] No [X]
4.12 renewals? Yes [] No [X]
- 4.2 During the period covered by this statement, did any sales/service organization owned in whole or in part by the reporting entity or an affiliate, receive credit or commissions for or control a substantial part (more than 20 percent of any major line of business measured on direct premiums) of:
4.21 sales of new business? Yes [] No [X]
4.22 renewals? Yes [] No [X]
- 5.1 Has the reporting entity been a party to a merger or consolidation during the period covered by this statement? Yes [] No [X]
If yes, complete and file the merger history data file with the NAIC.
- 5.2 If yes, provide the name of the entity, NAIC company code, and state of domicile (use two letter state abbreviation) for any entity that has ceased to exist as a result of the merger or consolidation.

1 Name of Entity	2 NAIC Company Code	3 State of Domicile

- 6.1 Has the reporting entity had any Certificates of Authority, licenses or registrations (including corporate registration, if applicable) suspended or revoked by any governmental entity during the reporting period? Yes [] No [X]
- 6.2 If yes, give full information
.....
- 7.1 Does any foreign (non-United States) person or entity directly or indirectly control 10% or more of the reporting entity? Yes [] No [X]
- 7.2 If yes,
7.21 State the percentage of foreign control 0.0 %
7.22 State the nationality(s) of the foreign person(s) or entity(s); or if the entity is a mutual or reciprocal, the nationality of its manager or attorney-in-fact and identify the type of entity(s) (e.g., individual, corporation, government, manager or attorney-in-fact).

1 Nationality	2 Type of Entity

GENERAL INTERROGATORIES

- 8.1 Is the company a subsidiary of a depository institution holding company (DIHC) or a DIHC itself, regulated by the Federal Reserve Board? Yes [] No [X]
- 8.2 If the response to 8.1 is yes, please identify the name of the DIHC.
.....
- 8.3 Is the company affiliated with one or more banks, thrifts or securities firms? Yes [] No [X]
- 8.4 If response to 8.3 is yes, please provide below the names and locations (city and state of the main office) of any affiliates regulated by a federal financial regulatory services agency [i.e. the Federal Reserve Board (FRB), the Office of the Comptroller of the Currency (OCC), the Federal Deposit Insurance Corporation (FDIC) and the Securities Exchange Commission (SEC)] and identify the affiliate's primary federal regulator.

1 Affiliate Name	2 Location (City, State)	3 FRB	4 OCC	5 FDIC	6 SEC

- 8.5 Is the reporting entity a depository institution holding company with significant insurance operations as defined by the Board of Governors of Federal Reserve System or a subsidiary of the depository institution holding company? Yes [] No [X]
- 8.6 If response to 8.5 is no, is the reporting entity a company or subsidiary of a company that has otherwise been made subject to the Federal Reserve Board's capital rule? Yes [] No [X] N/A []
- 9. What is the name and address of the independent certified public accountant or accounting firm retained to conduct the annual audit?
KPMG, 666 Grand Avenue, #2500, Des Moines, IA 50309
- 10.1 Has the insurer been granted any exemptions to the prohibited non-audit services provided by the certified independent public accountant requirements as allowed in Section 7H of the Annual Financial Reporting Model Regulation (Model Audit Rule), or substantially similar state law or regulation? Yes [] No [X]
- 10.2 If the response to 10.1 is yes, provide information related to this exemption:
.....
- 10.3 Has the insurer been granted any exemptions related to the other requirements of the Annual Financial Reporting Model Regulation as allowed for in Section 18A of the Model Regulation, or substantially similar state law or regulation? Yes [] No [X]
- 10.4 If the response to 10.3 is yes, provide information related to this exemption:
.....
- 10.5 Has the reporting entity established an Audit Committee in compliance with the domiciliary state insurance laws? Yes [X] No [] N/A []
- 10.6 If the response to 10.5 is no or n/a, please explain.
.....
- 11. What is the name, address and affiliation (officer/employee of the reporting entity or actuary/consultant associated with an actuarial consulting firm) of the individual providing the statement of actuarial opinion/certification?
Daniel J. Callahan, Senior Actuary, FSA, MAAA (employee), 1331 Grand Avenue, Des Moines, IA 50309-2901
- 12.1 Does the reporting entity own any securities of a real estate holding company or otherwise hold real estate indirectly? Yes [] No [X]
 - 12.11 Name of real estate holding company ...
 - 12.12 Number of parcels involved 0
 - 12.13 Total book/adjusted carrying value \$ 0
- 12.2 If yes, provide explanation
.....
- 13. **FOR UNITED STATES BRANCHES OF ALIEN REPORTING ENTITIES ONLY:**
- 13.1 What changes have been made during the year in the United States manager or the United States trustees of the reporting entity?
.....
- 13.2 Does this statement contain all business transacted for the reporting entity through its United States Branch on risks wherever located? Yes [] No []
- 13.3 Have there been any changes made to any of the trust indentures during the year? Yes [] No []
- 13.4 If answer to (13.3) is yes, has the domiciliary or entry state approved the changes? Yes [] No [] N/A []
- 14.1 Are the senior officers (principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions) of the reporting entity subject to a code of ethics, which includes the following standards? Yes [X] No []
 - a. Honest and ethical conduct, including the ethical handling of actual or apparent conflicts of interest between personal and professional relationships;
 - b. Full, fair, accurate, timely and understandable disclosure in the periodic reports required to be filed by the reporting entity;
 - c. Compliance with applicable governmental laws, rules and regulations;
 - d. The prompt internal reporting of violations to an appropriate person or persons identified in the code; and
 - e. Accountability for adherence to the code.
- 14.11 If the response to 14.1 is No, please explain:
.....
- 14.2 Has the code of ethics for senior managers been amended? Yes [] No [X]
- 14.21 If the response to 14.2 is yes, provide information related to amendment(s).
.....
- 14.3 Have any provisions of the code of ethics been waived for any of the specified officers? Yes [] No [X]
- 14.31 If the response to 14.3 is yes, provide the nature of any waiver(s).
.....

GENERAL INTERROGATORIES

- 15.1 Is the reporting entity the beneficiary of a Letter of Credit that is unrelated to reinsurance where the issuing or confirming bank is not on the SVO Bank List? Yes [] No [X]
- 15.2 If the response to 15.1 is yes, indicate the American Bankers Association (ABA) Routing Number and the name of the issuing or confirming bank of the Letter of Credit and describe the circumstances in which the Letter of Credit is triggered.

1 American Bankers Association (ABA) Routing Number	2 Issuing or Confirming Bank Name	3 Circumstances That Can Trigger the Letter of Credit	4 Amount

BOARD OF DIRECTORS

16. Is the purchase or sale of all investments of the reporting entity passed upon either by the board of directors or a subordinate committee thereof? Yes [X] No []
17. Does the reporting entity keep a complete permanent record of the proceedings of its board of directors and all subordinate committees thereof? Yes [X] No []
18. Has the reporting entity an established procedure for disclosure to its board of directors or trustees of any material interest or affiliation on the part of any of its officers, directors, trustees or responsible employees that is in conflict or is likely to conflict with the official duties of such person? Yes [X] No []

FINANCIAL

19. Has this statement been prepared using a basis of accounting other than Statutory Accounting Principles (e.g., Generally Accepted Accounting Principles)? Yes [] No [X]
- 20.1 Total amount loaned during the year (inclusive of Separate Accounts, exclusive of policy loans):
- 20.11 To directors or other officers.....\$0
 - 20.12 To stockholders not officers.....\$0
 - 20.13 Trustees, supreme or grand (Fraternal Only)\$0
- 20.2 Total amount of loans outstanding at the end of year (inclusive of Separate Accounts, exclusive of policy loans):
- 20.21 To directors or other officers.....\$0
 - 20.22 To stockholders not officers.....\$0
 - 20.23 Trustees, supreme or grand (Fraternal Only)\$0
- 21.1 Were any assets reported in this statement subject to a contractual obligation to transfer to another party without the liability for such obligation being reported in the statement? Yes [] No [X]
- 21.2 If yes, state the amount thereof at December 31 of the current year:
- 21.21 Rented from others.....\$0
 - 21.22 Borrowed from others.....\$0
 - 21.23 Leased from others\$0
 - 21.24 Other\$0
- 22.1 Does this statement include payments for assessments as described in the Annual Statement Instructions other than guaranty fund or guaranty association assessments? Yes [X] No []
- 22.2 If answer is yes:
- 22.21 Amount paid as losses or risk adjustment \$ 5,713,479
 - 22.22 Amount paid as expenses\$0
 - 22.23 Other amounts paid\$0
- 23.1 Does the reporting entity report any amounts due from parent, subsidiaries or affiliates on Page 2 of this statement? Yes [X] No []
- 23.2 If yes, indicate any amounts receivable from parent included in the Page 2 amount:\$0
- 24.1 Does the insurer utilize third parties to pay agent commissions in which the amounts advanced by the third parties are not settled in full within 90 days? Yes [] No [X]
- 24.2 If the response to 24.1 is yes, identify the third-party that pays the agents and whether they are a related party.

Name of Third-Party	Is the Third-Party Agent a Related Party (Yes/No)

INVESTMENT

- 25.01 Were all the stocks, bonds and other securities owned December 31 of current year, over which the reporting entity has exclusive control, in the actual possession of the reporting entity on said date? (other than securities lending programs addressed in 25.03)..... Yes [X] No []

GENERAL INTERROGATORIES

- 25.02 If no, give full and complete information, relating thereto
.....
- 25.03 For securities lending programs, provide a description of the program including value for collateral and amount of loaned securities, and whether collateral is carried on or off-balance sheet. (an alternative is to reference Note 17 where this information is also provided)
.....
- 25.04 For the reporting entity's securities lending program, report amount of collateral for conforming programs as outlined in the Risk-Based Capital Instructions. \$ 0
- 25.05 For the reporting entity's securities lending program, report amount of collateral for other programs. \$ 0
- 25.06 Does your securities lending program require 102% (domestic securities) and 105% (foreign securities) from the counterparty at the outset of the contract? Yes [] No [] N/A [X]
- 25.07 Does the reporting entity non-admit when the collateral received from the counterparty falls below 100%? Yes [] No [] N/A [X]
- 25.08 Does the reporting entity or the reporting entity's securities lending agent utilize the Master Securities lending Agreement (MSLA) to conduct securities lending? Yes [] No [] N/A [X]
- 25.09 For the reporting entity's securities lending program state the amount of the following as of December 31 of the current year:
- 25.091 Total fair value of reinvested collateral assets reported on Schedule DL, Parts 1 and 2 \$ 0
- 25.092 Total book/adjusted carrying value of reinvested collateral assets reported on Schedule DL, Parts 1 and 2 \$ 0
- 25.093 Total payable for securities lending reported on the liability page \$ 0

- 26.1 Were any of the stocks, bonds or other assets of the reporting entity owned at December 31 of the current year not exclusively under the control of the reporting entity or has the reporting entity sold or transferred any assets subject to a put option contract that is currently in force? (Exclude securities subject to Interrogatory 21.1 and 25.03). Yes [X] No []
- 26.2 If yes, state the amount thereof at December 31 of the current year:
- 26.21 Subject to repurchase agreements \$ 3,347,035
- 26.22 Subject to reverse repurchase agreements \$ 0
- 26.23 Subject to dollar repurchase agreements \$ 0
- 26.24 Subject to reverse dollar repurchase agreements \$ 0
- 26.25 Placed under option agreements \$ 0
- 26.26 Letter stock or securities restricted as to sale - excluding FHLB Capital Stock \$ 0
- 26.27 FHLB Capital Stock \$ 2,509,300
- 26.28 On deposit with states \$ 0
- 26.29 On deposit with other regulatory bodies \$ 0
- 26.30 Pledged as collateral - excluding collateral pledged to an FHLB \$ 0
- 26.31 Pledged as collateral to FHLB - including assets backing funding agreements \$ 0
- 26.32 Other \$ 0

26.3 For category (26.26) provide the following:

1 Nature of Restriction	2 Description	3 Amount
.....

- 27.1 Does the reporting entity have any hedging transactions reported on Schedule DB? Yes [] No [X]
- 27.2 If yes, has a comprehensive description of the hedging program been made available to the domiciliary state? Yes [] No [] N/A [X]
If no, attach a description with this statement.

LINES 27.3 through 27.5: FOR LIFE/FRATERNAL REPORTING ENTITIES ONLY:

- 27.3 Does the reporting entity utilize derivatives to hedge variable annuity guarantees subject to fluctuations as a result of interest rate sensitivity? Yes [] No []
- 27.4 If the response to 27.3 is YES, does the reporting entity utilize:
- 27.41 Special accounting provision of SSAP No. 108 Yes [] No []
- 27.42 Permitted accounting practice Yes [] No []
- 27.43 Other accounting guidance Yes [] No []
- 27.5 By responding YES to 27.41 regarding utilizing the special accounting provisions of SSAP No. 108, the reporting entity attests to the following: Yes [] No []
- The reporting entity has obtained explicit approval from the domiciliary state.
 - Hedging strategy subject to the special accounting provisions is consistent with the requirements of VM-21.
 - Actuarial certification has been obtained which indicates that the hedging strategy is incorporated within the establishment of VM-21 reserves and provides the impact of the hedging strategy within the Actuarial Guideline Conditional Tail Expectation Amount.
 - Financial Officer Certification has been obtained which indicates that the hedging strategy meets the definition of a Clearly Defined Hedging Strategy within VM-21 and that the Clearly Defined Hedging Strategy is the hedging strategy being used by the company in its actual day-to-day risk mitigation efforts.
- 28.1 Were any preferred stocks or bonds owned as of December 31 of the current year mandatorily convertible into equity, or, at the option of the issuer, convertible into equity? Yes [] No [X]
- 28.2 If yes, state the amount thereof at December 31 of the current year. \$ 0
29. Excluding items in Schedule E, Part 3 - Special Deposits, real estate, mortgage loans and investments held physically in the reporting entity's offices, vaults or safety deposit boxes, were all stocks, bonds and other securities, owned throughout the current year held pursuant to a custodial agreement with a qualified bank or trust company in accordance with Section 1, III - General Examination Considerations, F. Outsourcing of Critical Functions, Custodial or Safekeeping Agreements of the NAIC Financial Condition Examiners Handbook? Yes [X] No []

29.01 For agreements that comply with the requirements of the NAIC Financial Condition Examiners Handbook, complete the following:

1 Name of Custodian(s)	2 Custodian's Address
BNY	BNY Mellon Center, 500 Grant Street, Pittsburgh, PA 15258
Bankers Trust Company	453 7th Street, Des Moines, IA 50309

ANNUAL STATEMENT FOR THE YEAR 2024 OF THE Wellmark, Inc.

GENERAL INTERROGATORIES

29.02 For all agreements that do not comply with the requirements of the NAIC Financial Condition Examiners Handbook, provide the name, location and a complete explanation:

1 Name(s)	2 Location(s)	3 Complete Explanation(s)

29.03 Have there been any changes, including name changes, in the custodian(s) identified in 29.01 during the current year?..... Yes [] No [X]

29.04 If yes, give full and complete information relating thereto:

1 Old Custodian	2 New Custodian	3 Date of Change	4 Reason

29.05 Investment management – Identify all investment advisors, investment managers, broker/dealers, including individuals that have the authority to make investment decisions on behalf of the reporting entity. This includes both primary and sub-advisors. For assets that are managed internally by employees of the reporting entity, note as such. ["...that have access to the investment accounts"; "...handle securities"]

1 Name of Firm or Individual	2 Affiliation
NISA Investment Advisors, LLC	U.....
Wellington Management Company LLP	U.....
William Blair Investment Management, LLC	U.....
BlackRock Financial Management, Inc.	U.....
Metropolitan West Asset Management, LLC	U.....
Pyrford International, Ltd.	U.....
Broadridge Business Process Outsourcing, LLC	U.....
Cardinal Investment Advisors, LLC	U.....
Mercer Investments LLC	U.....
Wellmark, Inc.	I.....

29.0597 For those firms/individuals listed in the table for Question 29.05, do any firms/individuals unaffiliated with the reporting entity (i.e., designated with a "U") manage more than 10% of the reporting entity's invested assets?..... Yes [X] No []

29.0598 For firms/individuals unaffiliated with the reporting entity (i.e., designated with a "U") listed in the table for Question 29.05, does the total assets under management aggregate to more than 50% of the reporting entity's invested assets?..... Yes [X] No []

29.06 For those firms or individuals listed in the table for 29.05 with an affiliation code of "A" (affiliated) or "U" (unaffiliated), provide the information for the table below.

1 Central Registration Depository Number	2 Name of Firm or Individual	3 Legal Entity Identifier (LEI)	4 Registered With	5 Investment Management Agreement (IMA) Filed
107313	NISA Investment Advisors, LLC	549300L11G2J0W7XNY28	SEC	NO.....
106595	Wellington Management Company LLP	549300VHP12TEZNLX41	SEC	NO.....
173961	William Blair Investment Management, LLC	549300VQX7UK060A7X27	SEC	NO.....
107105	BlackRock Financial Management, Inc.	549300LVXY1VJKE13M84	SEC	NO.....
104571	Metropolitan West Asset Management, LLC	5493004MDKGC001Y283	SEC	NO.....
105646	Pyrford International, Ltd.	549300N5W87B21SAUG48	SEC	NO.....
114212	Broadridge Business Process Outsourcing, LLC	213800WWTABZ1G0JHH37	SEC	NO.....
116418	Cardinal Investment Advisors, LLC		SEC	NO.....
133449	Mercer Investments LLC	549300EH2E3BUCC07W92	SEC	NO.....

30.1 Does the reporting entity have any diversified mutual funds reported in Schedule D - Part 2 (diversified according to the Securities and Exchange Commission (SEC) in the Investment Company Act of 1940 [Section 5(b)(1)])? Yes [X] No []

30.2 If yes, complete the following schedule:

1 CUSIP #	2 Name of Mutual Fund	3 Book/Adjusted Carrying Value
72201F-49-0	PIMCO Income Instl	183,101,264
969251-50-3	William Blair Emerging Markets	51,929,148
30.2999 - Total		235,030,412

30.3 For each mutual fund listed in the table above, complete the following schedule:

1 Name of Mutual Fund (from above table)	2 Name of Significant Holding of the Mutual Fund	3 Amount of Mutual Fund's Book/Adjusted Carrying Value Attributable to the Holding	4 Date of Valuation
PIMCO Income Instl	Uniform Mortgage-Backed Security TBA 6.000% due 10/01/2054 - 12/01/2054	17,927,306	09/30/2024 ..
PIMCO Income Instl	Uniform Mortgage-Backed Security TBA 6.500% due 10/01/2054 - 11/01/2054	15,102,895	09/30/2024 ..
PIMCO Income Instl	Uniform Mortgage-Backed Security TBA 5.500% due 10/01/2054 - 11/01/2054	11,767,291	09/30/2024 ..
PIMCO Income Instl	Uniform Mortgage-Backed Security TBA 5.000% due 10/01/2054 - 11/01/2054	10,301,947	09/30/2024 ..
PIMCO Income Instl	PIMCO Short-Term Floating NAV Portfolio III	3,520,737	09/30/2024 ..
William Blair Emerging Markets	Taiwan Semiconductor Manufacturing Co. Ltd.	4,777,482	09/30/2024 ..
William Blair Emerging Markets	Tencent Holdings Ltd.	2,700,316	09/30/2024 ..
William Blair Emerging Markets	Samsung Electronics Co.	2,648,387	09/30/2024 ..
William Blair Emerging Markets	Trip.com Group Ltd.	1,609,804	09/30/2024 ..
William Blair Emerging Markets	Meituan	1,505,945	09/30/2024 ..

GENERAL INTERROGATORIES

31. Provide the following information for all short-term and long-term bonds and all preferred stocks. Do not substitute amortized value or statement value for fair value.

	1	2	3
	Statement (Admitted) Value	Fair Value	Excess of Statement over Fair Value (-), or Fair Value over Statement (+)
31.1 Bonds	1,065,432,620	1,038,855,641	(26,576,979)
31.2 Preferred stocks	2,040,256	2,040,256	0
31.3 Totals	1,067,472,876	1,040,895,897	(26,576,979)

31.4 Describe the sources or methods utilized in determining the fair values:

The Company obtains at least one price from a third party pricing service or its custodian, which also uses a pricing service. In most instances, the Company obtains more than one price and evaluates between the pricing sources for any outliers or stale prices. Assuming prices are not stale and are reasonable between sources, the Company follows a pre-established hierarchy to determine which pricing source to utilize.

32.1 Was the rate used to calculate fair value determined by a broker or custodian for any of the securities in Schedule D? Yes [X] No []

32.2 If the answer to 32.1 is yes, does the reporting entity have a copy of the broker's or custodian's pricing policy (hard copy or electronic copy) for all brokers or custodians used as a pricing source? Yes [X] No []

32.3 If the answer to 32.2 is no, describe the reporting entity's process for determining a reliable pricing source for purposes of disclosure of fair value for Schedule D:

33.1 Have all the filing requirements of the Purposes and Procedures Manual of the NAIC Investment Analysis Office been followed? Yes [X] No []

33.2 If no, list exceptions:

34. By self-designating 5GI securities, the reporting entity is certifying the following elements of each self-designated 5GI security:

- a. Documentation necessary to permit a full credit analysis of the security does not exist or an NAIC CRP credit rating for an FE or PL security is not available.
- b. Issuer or obligor is current on all contracted interest and principal payments.
- c. The insurer has an actual expectation of ultimate payment of all contracted interest and principal.

Has the reporting entity self-designated 5GI securities? Yes [] No [X]

35. By self-designating PLGI securities, the reporting entity is certifying its compliance with the requirements as specified in the Purposes and Procedures Manual of the NAIC Investment Analysis Office (P&P Manual) for private letter rating (PLR) securities and the following elements of each self-designated PLGI security:

- a. The security was either:
 - i. issued prior to January 1, 2018 (which is exempt from PLR filing requirements pursuant to the P&P Manual), or
 - ii. issued from January 1, 2018 to December 31, 2021 and subject to a confidentiality agreement executed prior to January 1, 2022 which confidentiality agreement remains in force, for which an insurance company cannot provide a copy of a private letter rating rationale report to the SVO due to confidentiality or other contractual reasons ("waived submission PLR securities").
- b. The reporting entity is holding capital commensurate with the NAIC Designation and NAIC Designation Category reported for the security.
- c. The NAIC Designation and NAIC Designation Category were derived from the credit rating assigned by an NAIC CRP in its legal capacity as a NRSRO which is shown on a current private letter rating, dated during the financial statement year, held by the insurer and available for examination by state insurance regulators.
- d. Other than for waived submission PLR securities, defined above, on or after January 1, 2024 for any PLR securities issued on or after January 1, 2022, if the reporting entity is not permitted to share this private credit rating or the private rating letter rationale report of the PL security with the SVO, it certifies that it is reporting it as an NAIC 5.B GI and may not assign any other self-designation.

Has the reporting entity self-designated PLGI to securities, all of which meet the above requirement and as specified in the P&P Manual? Yes [] No [X]

36. By assigning FE to a Schedule BA non-registered private fund, the reporting entity is certifying the following elements of each self-designated FE fund:

- a. The shares were purchased prior to January 1, 2019.
- b. The reporting entity is holding capital commensurate with the NAIC Designation reported for the security.
- c. The security had a public credit rating(s) with annual surveillance assigned by an NAIC CRP in its legal capacity as an NRSRO prior to January 1, 2019.
- d. The fund only or predominantly holds bonds in its portfolio.
- e. The current reported NAIC Designation was derived from the public credit rating(s) with annual surveillance assigned by an NAIC CRP in its legal capacity as an NRSRO.
- f. The public credit rating(s) with annual surveillance assigned by an NAIC CRP has not lapsed.

Has the reporting entity assigned FE to Schedule BA non-registered private funds that complied with the above criteria? Yes [] No [X]

37. By rolling/renewing short-term or cash equivalent investments with continued reporting on Schedule DA, Part 1 or Schedule E Part 2 (identified through a code (%) in those investment schedules), the reporting entity is certifying to the following:

- a. The investment is a liquid asset that can be terminated by the reporting entity on the current maturity date.
- b. If the investment is with a nonrelated party or nonaffiliate, then it reflects an arms-length transaction with renewal completed at the discretion of all involved parties.
- c. If the investment is with a related party or affiliate, then the reporting entity has completed robust re-underwriting of the transaction for which documentation is available for regulator review.
- d. Short-term and cash equivalent investments that have been renewed/rolled from the prior period that do not meet the criteria in 37.a - 37.c are reported as long-term investments.

Has the reporting entity rolled/renewed short-term or cash equivalent investments in accordance with these criteria? Yes [] No [] N/A [X]

GENERAL INTERROGATORIES

38.1 Does the reporting entity directly hold cryptocurrencies? Yes [] No [X]

38.2 If the response to 38.1 is yes, on what schedule are they reported?

39.1 Does the reporting entity directly or indirectly accept cryptocurrencies as payments for premiums on policies? Yes [] No [X]

39.2 If the response to 39.1 is yes, are the cryptocurrencies held directly or are they immediately converted to U.S. dollars?
 39.21 Held directly Yes [] No []
 39.22 Immediately converted to U.S. dollars Yes [] No []

39.3 If the response to 38.1 or 39.1 is yes, list all cryptocurrencies accepted for payments of premiums or that are held directly.

1 Name of Cryptocurrency	2 Immediately Converted to USD, Directly Held, or Both	3 Accepted for Payment of Premiums

OTHER

40.1 Amount of payments to trade associations, service organizations and statistical or rating bureaus, if any? \$ 1,485,739

40.2 List the name of the organization and the amount paid if any such payment represented 25% or more of the total payments to trade associations, service organizations, and statistical or rating bureaus during the period covered by this statement.

1 Name	2 Amount Paid
Blue Cross and Blue Shield Association	1,162,444

41.1 Amount of payments for legal expenses, if any? \$ 2,230,374

41.2 List the name of the firm and the amount paid if any such payment represented 25% or more of the total payments for legal expenses during the period covered by this statement.

1 Name	2 Amount Paid
Nyemaster Goode	687,446
Mintz Levin Cohn Ferris Glovsky and Popeo PC	1,300,902

42.1 Amount of payments for expenditures in connection with matters before legislative bodies, officers, or departments of government, if any? \$ 107,037

42.2 List the name of the firm and the amount paid if any such payment represented 25% or more of the total payment expenditures in connection with matters before legislative bodies, officers, or departments of government during the period covered by this statement.

1 Name	2 Amount Paid

GENERAL INTERROGATORIES

PART 2 - HEALTH INTERROGATORIES

1.1 Does the reporting entity have any direct Medicare Supplement Insurance in force? Yes [] No []

1.2 If yes, indicate premium earned on U.S. business only. \$ 478,442,018

1.3 What portion of Item (1.2) is not reported on the Medicare Supplement Insurance Experience Exhibit? \$ 0

1.31 Reason for excluding
.....

1.4 Indicate amount of earned premium attributable to Canadian and/or Other Alien not included in Item (1.2) above \$ 0

1.5 Indicate total incurred claims on all Medicare Supplement Insurance. \$ 416,747,302

1.6 Individual policies: Most current three years:

1.61 Total premium earned \$ 39,381,207

1.62 Total incurred claims \$ 38,413,294

1.63 Number of covered lives 21,121

All years prior to most current three years:

1.64 Total premium earned \$ 439,060,811

1.65 Total incurred claims \$ 378,334,008

1.66 Number of covered lives 127,155

1.7 Group policies: Most current three years:

1.71 Total premium earned \$ 0

1.72 Total incurred claims \$ 0

1.73 Number of covered lives 0

All years prior to most current three years:

1.74 Total premium earned \$ 0

1.75 Total incurred claims \$ 0

1.76 Number of covered lives 0

2. Health Test:

	1 Current Year	2 Prior Year
2.1 Premium Numerator	2,722,405,677	2,621,830,096
2.2 Premium Denominator	2,722,405,677	2,621,830,096
2.3 Premium Ratio (2.1/2.2)	1.000	1.000
2.4 Reserve Numerator	304,536,582	304,201,720
2.5 Reserve Denominator	304,536,582	304,201,720
2.6 Reserve Ratio (2.4/2.5)	1.000	1.000

3.1 Has the reporting entity received any endowment or gift from contracting hospitals, physicians, dentists, or others that is agreed will be returned when, as and if the earnings of the reporting entity permits? Yes [] No []

3.2 If yes, give particulars:
.....

4.1 Have copies of all agreements stating the period and nature of hospitals', physicians', and dentists' care offered to subscribers and dependents been filed with the appropriate regulatory agency? Yes [] No []

4.2 If not previously filed, furnish herewith a copy(ies) of such agreement(s). Do these agreements include additional benefits offered? Yes [] No []

5.1 Does the reporting entity have stop-loss reinsurance? Yes [] No []

5.2 If no, explain:
The Company retains all risk.

5.3 Maximum retained risk (see instructions)

5.31 Comprehensive Medical \$ 9,999,999

5.32 Medical Only \$ 0

5.33 Medicare Supplement \$ 9,999,999

5.34 Dental & Vision \$ 9,999,999

5.35 Other Limited Benefit Plan \$ 0

5.36 Other \$ 0

6. Describe arrangement which the reporting entity may have to protect subscribers and their dependents against the risk of insolvency including hold harmless provisions, conversion privileges with other carriers, agreements with providers to continue rendering services, and any other agreements:
Reserves exceed all regulatory requirements. Member of Iowa Life & Health Insurance Guaranty Association under Iowa Code 508C.

7.1 Does the reporting entity set up its claim liability for provider services on a service date basis?..... Yes [] No []

7.2 If no, give details
.....

8. Provide the following information regarding participating providers: 8.1 Number of providers at start of reporting year9,606

8.2 Number of providers at end of reporting year9,605

9.1 Does the reporting entity have business subject to premium rate guarantees? Yes [] No []

9.2 If yes, direct premium earned: 9.21 Business with rate guarantees between 15-36 months.. \$.....0

9.22 Business with rate guarantees over 36 months \$.....0

GENERAL INTERROGATORIES

- 10.1 Does the reporting entity have Incentive Pool, Withhold or Bonus Arrangements in its provider contracts? Yes No
- 10.2 If yes:
- | | | |
|----------------------------------------------------|----|------------|
| 10.21 Maximum amount payable bonuses..... | \$ | 13,204,466 |
| 10.22 Amount actually paid for year bonuses..... | \$ | 9,127,658 |
| 10.23 Maximum amount payable withholds..... | \$ | 0 |
| 10.24 Amount actually paid for year withholds..... | \$ | 0 |

- 11.1 Is the reporting entity organized as:
- | | | |
|-----------------------------------------------------------|------------------------------|----------------------------------------|
| 11.12 A Medical Group/Staff Model, | Yes <input type="checkbox"/> | No <input checked="" type="checkbox"/> |
| 11.13 An Individual Practice Association (IPA), or, | Yes <input type="checkbox"/> | No <input checked="" type="checkbox"/> |
| 11.14 A Mixed Model (combination of above)? | Yes <input type="checkbox"/> | No <input checked="" type="checkbox"/> |
- 11.2 Is the reporting entity subject to Statutory Minimum Capital and Surplus Requirements? Yes No
- 11.3 If yes, show the name of the state requiring such minimum capital and surplus. IOWA
- 11.4 If yes, show the amount required. \$ 5,000,000
- 11.5 Is this amount included as part of a contingency reserve in stockholder's equity? Yes No
- 11.6 If the amount is calculated, show the calculation
-

12. List service areas in which reporting entity is licensed to operate:

1 Name of Service Area
Iowa
South Dakota
.....

- 13.1 Do you act as a custodian for health savings accounts? Yes No
- 13.2 If yes, please provide the amount of custodial funds held as of the reporting date. \$ 0
- 13.3 Do you act as an administrator for health savings accounts? Yes No
- 13.4 If yes, please provide the balance of funds administered as of the reporting date. \$ 0
- 14.1 Are any of the captive affiliates reported on Schedule S, Part 3, authorized reinsurers? Yes No N/A
- 14.2 If the answer to 14.1 is yes, please provide the following:

1 Company Name	2 NAIC Company Code	3 Domiciliary Jurisdiction	4 Reserve Credit	Assets Supporting Reserve Credit		
				5 Letters of Credit	6 Trust Agreements	7 Other
.....

15. Provide the following for individual ordinary life insurance* policies (U.S. business only) for the current year (prior to reinsurance assumed or ceded):
- | | | |
|------------------------------------|----|---|
| 15.1 Direct Premium Written | \$ | 0 |
| 15.2 Total Incurred Claims | \$ | 0 |
| 15.3 Number of Covered Lives | | 0 |

*Ordinary Life Insurance Includes
Term(whether full underwriting, limited underwriting, jet issue, "short form app")
Whole Life (whether full underwriting, limited underwriting, jet issue, "short form app")
Variable Life (with or without secondary gurarantee)
Universal Life (with or without secondary gurarantee)
Variable Universal Life (with or without secondary gurarantee)

16. Is the reporting entity licensed or chartered, registered, qualified, eligible or writing business in at least two states? Yes No
- 16.1 If no, does the reporting entity assume reinsurance business that covers risks residing in at least one state other than the state of domicile of the reporting entity? Yes No

ANNUAL STATEMENT FOR THE YEAR 2024 OF THE Wellmark, Inc.

FIVE-YEAR HISTORICAL DATA

	1 2024	2 2023	3 2022	4 2021	5 2020
Balance Sheet (Pages 2 and 3)					
1. Total admitted assets (Page 2, Line 28)	3,997,692,857	3,907,004,071	3,308,799,411	3,289,273,666	2,954,103,558
2. Total liabilities (Page 3, Line 24)	1,077,581,865	1,266,469,386	1,028,017,615	971,500,067	928,738,915
3. Statutory minimum capital and surplus requirement	5,000,000	5,000,000	5,000,000	5,000,000	5,000,000
4. Total capital and surplus (Page 3, Line 33)	2,920,110,992	2,640,534,685	2,280,781,796	2,317,773,599	2,025,364,643
Income Statement (Page 4)					
5. Total revenues (Line 8)	2,722,405,677	2,621,830,096	2,570,574,724	2,551,895,501	2,534,234,453
6. Total medical and hospital expenses (Line 18)	2,360,377,439	2,248,771,981	2,238,058,571	2,212,780,421	2,161,873,674
7. Claims adjustment expenses (Line 20)	86,597,546	86,294,705	80,403,314	89,136,809	96,791,030
8. Total administrative expenses (Line 21)	229,764,035	200,118,325	200,614,192	205,083,068	274,239,742
9. Net underwriting gain (loss) (Line 24)	45,666,657	86,645,085	51,498,647	44,895,203	1,330,007
10. Net investment gain (loss) (Line 27)	206,315,659	198,704,598	58,001,861	129,980,008	180,045,837
11. Total other income (Lines 28 plus 29)	(19,142,070)	(1,980,543)	(3,722,487)	127,803	(4,921,594)
12. Net income or (loss) (Line 32)	181,019,246	216,533,140	82,368,021	143,344,014	136,322,250
Cash Flow (Page 6)					
13. Net cash from operations (Line 11)	156,532,334	72,632,013	(73,587,981)	76,524,564	21,942,504
Risk-Based Capital Analysis					
14. Total adjusted capital	2,924,903,401	2,650,366,255	2,280,781,796	2,317,773,599	2,025,364,643
15. Authorized control level risk-based capital	269,745,657	232,012,849	213,806,298	210,601,587	180,444,825
Enrollment (Exhibit 1)					
16. Total members at end of period (Column 5, Line 7)	1,079,864	1,128,636	1,132,334	1,150,378	1,180,058
17. Total members months (Column 6, Line 7)	13,177,714	13,565,905	13,661,152	13,864,371	14,324,116
Operating Percentage (Page 4) (Item divided by Page 4, sum of Lines 2, 3 and 5) x 100.0					
18. Premiums earned plus risk revenue (Line 2 plus Lines 3 and 5)	100.0	100.0	100.0	100.0	100.0
19. Total hospital and medical plus other non-health (Lines 18 plus Line 19)	86.7	85.8	87.1	86.7	85.3
20. Cost containment expenses	0.7	0.8	0.7	0.8	0.8
21. Other claims adjustment expenses	2.5	2.5	2.4	2.7	3.1
22. Total underwriting deductions (Line 23)	98.3	96.7	98.0	98.2	100.0
23. Total underwriting gain (loss) (Line 24)	1.7	3.3	2.0	1.8	0.1
Unpaid Claims Analysis (U&I Exhibit, Part 2B)					
24. Total claims incurred for prior years (Line 17, Col. 5)	173,099,752	185,513,762	332,241,815	295,110,958	339,023,075
25. Estimated liability of unpaid claims-[prior year (Line 17, Col. 6)]	139,007,683	132,229,382	283,296,128	254,009,736	283,079,231
Investments In Parent, Subsidiaries and Affiliates					
26. Affiliated bonds (Sch. D Summary, Line 12, Col. 1)	0	0	0	0	0
27. Affiliated preferred stocks (Sch. D Summary, Line 18, Col. 1)	0	0	0	0	0
28. Affiliated common stocks (Sch. D Summary, Line 24, Col. 1)	702,496,084	692,549,659	656,143,966	606,738,262	545,909,177
29. Affiliated short-term investments (subtotal included in Schedule DA Verification, Col. 5, Line 10)	0	0	0	0	0
30. Affiliated mortgage loans on real estate	0	0	0	0	0
31. All other affiliated	39,603,946	0	0	0	0
32. Total of above Lines 26 to 31	742,100,030	692,549,659	656,143,966	606,738,262	545,909,177
33. Total investment in parent included in Lines 26 to 31 above.	0	0	0	0	0

NOTE: If a party to a merger, have the two most recent years of this exhibit been restated due to a merger in compliance with the disclosure requirements of SSAP No. 3, Accounting Changes and Correction of Errors? Yes [] No []
 If no, please explain:

SCHEDULE T PREMIUMS AND OTHER CONSIDERATIONS

Allocated by States and Territories

States, etc.	1 Active Status (a)	Direct Business Only									
		2 Accident and Health Premiums	3 Medicare Title XVIII	4 Medicaid Title XIX	5 CHIP Title XXI	6 Federal Employees Health Benefits Program Premiums	7 Life and Annuity Premiums & Other Considerations	8 Property/Casualty Premiums	9 Total Columns 2 Through 8	10 Deposit-Type Contracts	
1. Alabama	AL	.N	0	0	0	0	0	0	0	0	0
2. Alaska	AK	.N	0	0	0	0	0	0	0	0	0
3. Arizona	AZ	.N	0	0	0	0	0	0	0	0	0
4. Arkansas	AR	.N	0	0	0	0	0	0	0	0	0
5. California	CA	.N	0	0	0	0	0	0	0	0	0
6. Colorado	CO	.N	0	0	0	0	0	0	0	0	0
7. Connecticut	CT	.N	0	0	0	0	0	0	0	0	0
8. Delaware	DE	.N	0	0	0	0	0	0	0	0	0
9. District of Columbia	DC	.N	0	0	0	0	0	0	0	0	0
10. Florida	FL	.N	0	0	0	0	0	0	0	0	0
11. Georgia	GA	.N	0	0	0	0	0	0	0	0	0
12. Hawaii	HI	.N	0	0	0	0	0	0	0	0	0
13. Idaho	ID	.N	0	0	0	0	0	0	0	0	0
14. Illinois	IL	.N	0	0	0	0	0	0	0	0	0
15. Indiana	IN	.N	0	0	0	0	0	0	0	0	0
16. Iowa	IA	L	2,301,379,400	0	0	0	336,728,549	0	0	2,638,107,949	0
17. Kansas	KS	.N	0	0	0	0	0	0	0	0	0
18. Kentucky	KY	.N	0	0	0	0	0	0	0	0	0
19. Louisiana	LA	.N	0	0	0	0	0	0	0	0	0
20. Maine	ME	.N	0	0	0	0	0	0	0	0	0
21. Maryland	MD	.N	0	0	0	0	0	0	0	0	0
22. Massachusetts	MA	.N	0	0	0	0	0	0	0	0	0
23. Michigan	MI	.N	0	0	0	0	0	0	0	0	0
24. Minnesota	MN	.N	0	0	0	0	0	0	0	0	0
25. Mississippi	MS	.N	0	0	0	0	0	0	0	0	0
26. Missouri	MO	.N	0	0	0	0	0	0	0	0	0
27. Montana	MT	.N	0	0	0	0	0	0	0	0	0
28. Nebraska	NE	.N	0	0	0	0	0	0	0	0	0
29. Nevada	NV	.N	0	0	0	0	0	0	0	0	0
30. New Hampshire	NH	.N	0	0	0	0	0	0	0	0	0
31. New Jersey	NJ	.N	0	0	0	0	0	0	0	0	0
32. New Mexico	NM	.N	0	0	0	0	0	0	0	0	0
33. New York	NY	.N	0	0	0	0	0	0	0	0	0
34. North Carolina	NC	.N	0	0	0	0	0	0	0	0	0
35. North Dakota	ND	.N	0	0	0	0	0	0	0	0	0
36. Ohio	OH	.N	0	0	0	0	0	0	0	0	0
37. Oklahoma	OK	.N	0	0	0	0	0	0	0	0	0
38. Oregon	OR	.N	0	0	0	0	0	0	0	0	0
39. Pennsylvania	PA	.N	0	0	0	0	0	0	0	0	0
40. Rhode Island	RI	.N	0	0	0	0	0	0	0	0	0
41. South Carolina	SC	.N	0	0	0	0	0	0	0	0	0
42. South Dakota	SD	L	66,512,940	0	0	0	0	0	0	66,512,940	0
43. Tennessee	TN	.N	0	0	0	0	0	0	0	0	0
44. Texas	TX	.N	0	0	0	0	0	0	0	0	0
45. Utah	UT	.N	0	0	0	0	0	0	0	0	0
46. Vermont	VT	.N	0	0	0	0	0	0	0	0	0
47. Virginia	VA	.N	0	0	0	0	0	0	0	0	0
48. Washington	WA	.N	0	0	0	0	0	0	0	0	0
49. West Virginia	WV	.N	0	0	0	0	0	0	0	0	0
50. Wisconsin	WI	.N	0	0	0	0	0	0	0	0	0
51. Wyoming	WY	.N	0	0	0	0	0	0	0	0	0
52. American Samoa	AS	.N	0	0	0	0	0	0	0	0	0
53. Guam	GU	.N	0	0	0	0	0	0	0	0	0
54. Puerto Rico	PR	.N	0	0	0	0	0	0	0	0	0
55. U.S. Virgin Islands	VI	.N	0	0	0	0	0	0	0	0	0
56. Northern Mariana Islands	MP	.N	0	0	0	0	0	0	0	0	0
57. Canada	CAN	.N	0	0	0	0	0	0	0	0	0
58. Aggregate Other Aliens	OT	XXX	0	0	0	0	0	0	0	0	0
59. Subtotal	XXX	2,367,892,340	0	0	0	336,728,549	0	0	2,704,620,889	0	0
60. Reporting Entity Contributions for Employee Benefit Plans	XXX	0	0	0	0	0	0	0	0	0	0
61. Totals (Direct Business)	XXX	2,367,892,340	0	0	0	336,728,549	0	0	2,704,620,889	0	0
DETAILS OF WRITE-INS											
58001.	XXX										
58002.	XXX										
58003.	XXX										
58998. Summary of remaining write-ins for Line 58 from overflow page	XXX	0	0	0	0	0	0	0	0	0	0
58999. Totals (Lines 58001 through 58003 plus 58998)(Line 58 above)	XXX	0	0	0	0	0	0	0	0	0	0


(a) Active Status Counts:

- 1. L - Licensed or Chartered - Licensed insurance carrier or domiciled RRG..... 2
- 2. R - Registered - Non-domiciled RRGs..... 0
- 3. E - Eligible - Reporting entities eligible or approved to write surplus lines in the state. 0
- 4. Q - Qualified - Qualified or accredited reinsurer..... 0
- 5. N - None of the above - Not allowed to write business in the state..... 55

(b) Explanation of basis of allocation by states, premiums by state, etc.

Accident and Health premiums are allocated according to the location of the group or individual purchaser at the point of issue.

SCHEDULE Y – INFORMATION CONCERNING ACTIVITIES OF INSURER MEMBERS OF A HOLDING COMPANY GROUP
PART 1 – ORGANIZATIONAL CHART



40

Non-Contributory Retirement Program for Certain Employees of Wellmark, Inc. Trust FEIN 35-2772844

Wellmark, Inc. Savings and Investment Plan Trust FEIN 42-0318333

OVERFLOW PAGE FOR WRITE-INS

Additional Write-ins for Assets Line 25

	Current Year			Prior Year
	1 Assets	2 Nonadmitted Assets	3 Net Admitted Assets (Cols. 1 - 2)	4 Net Admitted Assets
2504. Miscellaneous Assets	1,798,821	1,328,582	470,239	512,270
2597. Summary of remaining write-ins for Line 25 from overflow page	1,798,821	1,328,582	470,239	512,270

Additional Write-ins for Liabilities Line 23

	Current Year			Prior Year
	1 Covered	2 Uncovered	3 Total	4 Total
2304. Escheat Liability	2,805,206	0	2,805,206	3,018,294
2397. Summary of remaining write-ins for Line 23 from overflow page	2,805,206	0	2,805,206	3,018,294

Additional Write-ins for Exhibit of Nonadmitted Assets Line 25

	1 Current Year Total Nonadmitted Assets	2 Prior Year Total Nonadmitted Assets	3 Change in Total Nonadmitted Assets (Col. 2 - Col. 1)
2504. Miscellaneous Assets	1,328,582	1,425,895	97,313
2597. Summary of remaining write-ins for Line 25 from overflow page	1,328,582	1,425,895	97,313